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Introduction and outline of the thesis
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Introduction and outline 11
This thesis focuses on the diagnostic and therapeutic role of endoscopic retrograde 
cholangiopancreaticography (ERCP) and endoscopic ultrasonography (EUS) in benign 
and malignant pancreaticobiliary disease. Since the first practical applications of ERCP 
and EUS were developed in the first half of the nineteen-seventies and nineteen-eighties, 
respectively, both techniques have evolved in concurrence with the general trend in 
endoscopy from being merely diagnostic tools to full-fledged therapeutic procedures 
during which complex diseases can be treated and invasive surgical procedures can be 
avoided.
In a way the pancreas and, to a lesser extent, the biliary system are orphan organs. 
Due to their relative inaccessibility both for physicians and surgeons and the poor prog-
nosis of malignant pancreaticobiliary disease, the quantity and quality of research in this 
field traditionally has not been up to par compared with standards in some other areas 
of research in the medical field. Fortunately times have changed and the pancreas, bile 
ducts and its associated diseases are now one of the most actively researched topics in 
basic, translational and clinical research.
The aim of this thesis is to investigate the role of EUS in the diagnosis of benign, 
premalignant and malignant pancreatic disease, to evaluate a novel method of tissue 
acquisition through EUS and summarize the latest developments of therapeutic endo-
sonography. Furthermore the role of the endoscopic treatment of chronic pancreatitis 
and benign biliary strictures are evaluated.
This thesis is divided in three sections. In section one, EUS in screening and diagnosis 
of pancreatic disease, the value of EUS as a screening tool for individuals with a mark-
edly increased risk for the development of pancreatic cancer is investigated in chapter 
2. In these high-risk individuals, cystic lesions are identified at a much higher frequency 
as compared to the general population. It is often thought that fine needle aspiration 
(FNA) of these cysts is helpful in establishing a definite diagnosis. In chapter 3 we dem-
onstrate that the usefulness of EUS FNA is limited both with regard to biochemical and 
pathological analysis.
Despite the huge developments in accuracy of modern helical multi-slice CT scan-
ning machines, the cause of obstructive jaundice sometimes cannot readily be identi-
fied on CT scan. The value of EUS in this particular clinical setting in which patients are 
suspected to have pancreatic cancer is investigated in chapter 4.
In section 2, EUS: from diagnosis to intervention, both improvements in the di-
agnostic and therapeutic capabilities of EUS are covered. In chapter 5 the results of an 
international multi-center study are described in which a novel EUS needle is tested in 
a variety of patients. This needle was developed to routinely acquire histological speci-
mens through EUS (EUS-guided fine needle biopsy or FNB), thereby possibly improving 
diagnostic accuracy of EUS. Although the acquisition of the specimen is very important, 
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the ability of pathologists to accurately assess the material and to be able to perform for 
example additional immunostainings is as important. To investigate the concurrence of 
opinions, a study was performed in which experienced and dedicated gastrointestinal 
pathologists independently graded specimens acquired through EUS-guided FNB in 
chapter 6. The latest developments and techniques of interventional endosonography 
are discussed in chapter 7.
Although chronic pancreatitis is a benign disease, its clinical course is highly variable 
and may be complicated by a variety of conditions. Not infrequently, the quality of life 
of patients with chronic pancreatitis is severely impaired by pain, pseudocyst formation 
or benign biliary strictures. In section 3, Novel developments in the endoscopic treat-
ment of benign biliary and pancreatic disease, the endoscopic treatment of chronic 
pancreatitis but also other causes of benign biliary strictures (BBS) are discussed. In 
chapter 8 an extensive review is given of the endoscopic treatment of chronic pancre-
atitis.
Although chronic pancreatitis is one of the most common causes of benign biliary 
strictures, other conditions may also give rise to BBS. One very important cause is ortho-
topic liver transplantation with the creation of a duct-to-duct biliary anastomosis. In the 
past these patients were usually treated with a progressive stenting protocol requiring 
multiple ERCP’s with cumulative side by side insertion of plastic stents. Another pos-
sible strategy is the temporary placement of fully covered self expandable metal stents 
(fcSEMS). Since no randomized comparative trials comparing both methods are avail-
able, we sought to evaluate the outcome of liver transplant patients with anastomotic 
strictures whom were treated according a progressive stenting protocol. These results 
are described in chapter 9. In chapter 10 both strategies are compared with regards to 
cost-effectiveness.
When fcSEMS are used for the treatment of benign conditions safety and remov-
ability are of paramount importance. In chapter 11 the results of a group sequential 
study on the safety and efficacy of a novel type of fcSEMS are described in a cohort of 
patients with BBS due to chronic pancreatitis, orthotopic liver transplantation and lapa-
roscopic cholecystectomy. A special category of BBS are those extending into the liver 
hilum. Initially it was thought that these strictures were not amenable for treatment with 
fcSEMS due to blockage of secondary and tertiary ducts when fcSEMS are placed above 
the hilum. In chapter 12 however we show that use of a fcSEMS in such conditions is 
technically feasible, safe and effective when its placement is combined with a protective 
plastic contralateral stent.
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Objectives
Approximately 10–15% of all pancreatic cancers (PCs) may be hereditary in origin. We 
investigated the use of endoscopic ultrasonography (EUS) for the screening of individu-
als at high risk for developing PC. In this paper the results of first-time screening with 
EUS are presented.
methods
Those eligible for screening in this study were first-degree family members of affected 
individuals from familial pancreatic cancer (FPC) families, mutation carriers of PC-prone 
hereditary syndromes, individuals with Peutz–Jeghers syndrome, and mutation carriers 
of other PC-prone hereditary syndromes with clustering (≥2 cases per family) of PC. All 
individuals were asymptomatic and had not undergone EUS before.
Results
Forty-four individuals (M/F 18/26), aged 32–75 years underwent screening with EUS. 
Thirteen were from families with familial atypical multiple-mole melanoma (FAMMM), 21 
with FPC, 3 individuals were diagnosed with hereditary pancreatitis, 2 were Peutz–Jegh-
ers patients, 3 were BRCA1 and 2 were BRCA2 mutation carriers with familial clustering 
of PC, and 1 individual had a p53 mutation. Three (6.8%) patients had an asymptomatic 
mass lesion (12, 27, and 50 mm) in the body (n = 2) or tail of the pancreas. All lesions were 
completely resected. Pathology showed moderately differentiated adenocarcinomas 
with N1 disease in the two patients with the largest lesions. EUS showed branch-type 
intraductal papillary mucinous neoplasia (IPMN) in seven individuals.
Conclusions
Screening of individuals at a high risk for PC with EUS is feasible and safe. The incidence 
of clinically relevant findings at first screening is high with asymptomatic cancer in 7% 
and premalignant IPMN-like lesions in 16% in our series. Whether screening improves 
survival remains to be determined, as does the optimal screening interval with EUS.
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2
INTRODUCTION
Pancreatic cancer is one of the most lethal cancers with mortality rates that almost equal 
incidence and a 5 year survival rate of maximally 5%1,2. One of the reasons for the dismal 
prognosis of this disease is that only approximately 20% of patients have a resectable 
tumour at the time of diagnosis. However, even after radical resection, the 5 year survival 
rate is at best no more than 24% and in most series between 7 and 17%.3-5. Survival of 
pancreatic cancer is strongly dependent on stage6. Five-year survival in patients with 
stage IA after curative surgery is 31%. Survival rates drop dramatically in more advanced 
stages of the disease. Especially lymph node status is a strong predictor of survival7. 
At present one of the hopes for improving survival lies in identifying those individuals 
with asymptomatic disease or precursor lesions through a screening programme. Due 
to the overall low incidence of the disease, screening of the general population is not 
feasible at present. However, screening may be appropriate in selected populations with 
an increased risk.
For many years anecdotal case reports have suggested that pancreatic cancer may 
aggregate in families8-10. Several case-control studies have shown that patients with 
pancreatic cancer are more likely to have a family history of pancreatic cancer than con-
trols11-13. Although the majority of pancreatic cancer cases are believed to be sporadic, 
about 10 to 15% of cases are thought to be caused by inherited genetic factors14. Other 
authors suggest a much lower incidence of no more than 2.7% when stricter criteria 
are used15,16. Based on clinical criteria these individuals can be divided into two groups. 
At present, the largest group consists of individuals from families in which pancreatic 
cancer accumulates with at least two affected first-degree relatives without a known un-
derlying gene defect. This condition is most commonly referred to as familial pancreatic 
cancer (FPC).
The second group of patients with hereditary pancreatic cancer consists of kindreds 
with various hereditary syndromes or diseases that predisposes them to the develop-
ment of pancreatic cancer. Although these syndromes inherit in an autosomal dominant 
fashion the penetrance for PC is highly variable. In most of these syndromes the risk 
of developing other types of cancer is higher than the risk of PC. Therefore familial 
clustering of pancreatic cancer can be less obvious or indeed completely absent. An 
overview of the syndromes known at present that are accompanied by an increased risk 
of pancreatic cancer are listed in table 1. The estimated life-time risk of individuals can 
be as high as 50% in smoking men with hereditary pancreatitis and up to 36% in one 
series of patients with Peutz-Jeghers syndrome17,18.
An ideal technique or method to screen high-risk individuals should not only detect 
(small) asymptomatic pancreatic cancer lesions, but also, and more preferable, known 
and recognizable, benign precursor lesions. In recent years it has become clear that 
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three types of lesions can be detected when screening asymptomatic individuals with 
familial or hereditary pancreatic cancer. First, small, usually asymptomatic malignant 
mass lesions can be detected by various imaging methods and are associated with bet-
ter survival rates than symptomatic pancreatic cancer19. Second, it has become clear that 
intraductal papillary mucinous neoplasms (IPMN) of both main pancreatic duct (main 
branch IPMN) and its branches (branch type IPMN) can be precursor lesions of pancre-
atic cancer in high-risk individuals and are also associated with other malignancies20-23. 
Third, pancreatic intraepithelial neoplasia (Pan-IN) is an accepted precursor lesion of 
pancreatic cancer in which the accumulation of genetic abnormalities is accompanied 
by the progression of dysplastic features of the ductal epithelium24.
We aimed to investigate the diagnostic yield of a first time EUS screening investiga-
tion in all individuals with an increased risk for the development of pancreatic cancer, 
including individuals from families with FPC, known inherited genetic syndromes with a 
high risk of developing pancreatic cancer, and hereditary pancreatitis.
mETHODS
Inclusion
After extensive evaluation by a clinical geneticist those individuals estimated to have a 
lifetime risk for the development of pancreatic cancer of 10% or more based on available 
evidence from the literature were eligible for pancreatic screening. Diagnoses in these 
individuals and their families are depicted in Table 2.
Families with Hereditary Breast and Ovarian Cancer (HBOC) syndrome, Lynch 
syndrome and Li-Fraumeni syndrome were only eligible when familial clustering of 
pancreatic cancer occurred with at least 2 affected family members. Further inclusion 
criteria were: mutation carriers of known pathogenic mutations. Individuals had to be 
Table 1: Genetic syndromes with a known elevated lifetime risk for pancreatic cancer
Syndrome Gene lifetime risk RR
Fammm CDKN2a 10-15% 20-34
HbOC bRCa2 5% 10
HbOC bRCa1 ?? 2
Hereditary pancreatitis PRSS1/TRY1 30-50% 50
lynch syndrome mlH1/mSH2 ?? ??
Peutz-Jeghers syndrome STK11/lKb1 36% 136
FaP aPC ?? 4
li-Fraumeni syndrome p53 ?? ??
FPC ?? Up to 50% 18-57
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asymptomatic for signs or symptoms that could be attributed to PC and age 40 or older 
(or at least 5 years before the youngest affected case in the family). Enrolment for the 
study started in March 2005 and is ongoing. All individuals signed informed consent 
before participating in this study. Individuals were not included if they underwent 
abdominal imaging by either CT, MRI or EUS in three years previously.
Endoscopic ultrasonography
All EUS procedures were performed by 3 experienced endosonographers (J.W.P., P.F., 
and M.J.B; each with an experience of > 2500 EUS procedures). Both electronic radial 
(Olympus UC-160 AE, Olympus Europe, Hamburg, Germany with Aloka α5 ultrasound-
processor, Zug, Switzerland) and curvilinear (Olympus UCT / UCP 160, Olympus Europe, 
Hamburg Germany with Philips HDI 5000 ultrasoundprocessor, Philips Healthcare 
Medical Systems, Best, Netherlands) instruments were used according to the personal 
preference of the endosonographer. Procedures were performed under conscious seda-
tion with midazolam and/or fentanyl intravenously. Imaging of the pancreas was done 
from the duodenum and stomach in a standardized fashion. Video and still images were 
obtained from the uncinate process, pancreatic head and periampullary region, neck, 
body and tail of the pancreas. Abnormalities specifically looked for were mass lesions, 
cystic lesions, duct aberrations, and signs of chronic pancreatitis. The diagnostic criteria 
used for chronic pancreatitis have been published previously25. Fine needle aspiration 
(FNA) was not performed during the initial procedure. In case of abnormal findings at 
EUS, EUS was followed by CT scan and/or MRI and multidisciplinary discussion of all 
findings.
RESUlTS
Between April 2005 and October 2007 46 individuals were prospectively included in the 
protocol for a first time EUS screening investigation. Characteristics are given in Table 2. 
Table 2. Characteristics of asymptomatic high-risk individuals who underwent screening EUS.
age (mean/range) Sex
male/female
Familial pancreatic cancer (≥ 2 FDR) 21 53 (32-68) 11 / 10
FAMMM syndrome (CDKN2A) 13 52 (41-75) 3 / 10
HBOC (BRCA1) 3 43 (41-44) 1 / 2
HBOC (BRCA2) 2 42(42) 1 / 1
Peutz-Jeghers syndrome 2 40 (34-45) 2 / 0
Hereditary pancreatitis 2 40 (37-43) 0 / 2
Li-Fraumeni syndrome (p53) 1 40 0 / 1
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All individuals were Caucasian. No complications related to the EUS investigations oc-
curred. Twenty-one individuals s in this cohort stemmed from families with FPC. Of note, 
the majority of individuals screened, twenty-three in total, were therefore from families 
with a well-defined genetic syndrome associated with an increased risk of pancreatic 
cancer. Thirteen were from families with FAMMM, five from families with HBOC and clus-
tering (at least 2 cases) of pancreatic cancer and carrying a BRCA1(n=3) or BRCA2 (n=2) 
mutation. Two individuals were known to have Peutz-Jeghers syndrome, two patients 
hereditary pancreatitis with both clinical and EUS signs of chronic pancreatitis, one had 
a proven PRSS1 mutation, and finally one patient with Li-Fraumeni syndrome and a 
proven p53 mutation.
mass lesions
In three individuals out of 44 (6.8%) asymptomatic mass lesions in body or tail of the 
pancreas were found (table 3). The first patient was a 69 year old male with a proven 
pathogenic BRCA2 mutation and familial clustering of pancreatic cancer (2 affected 
family members). He underwent EUS screening during which an approximately 29 
mm mass lesions in the pancreatic tail was identified (figure 1). The rest of the pancre-
atic parenchyma showed some signs of chronic pancreatitis with hyperechoic strands, 
hyperechoic foci and lobularity of the parenchyma. The lesion was closely related to 
splenic artery and vein but without vascular involvement. CT scan did not reveal distant 
metastases and surgical resection was performed. During surgery pancreatic tail and 
Figure 1: hypoechoic mass in tail of pancreas, adjacent to splenic artery and vein
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spleen resection were performed. Histopathological examination revealed an approxi-
mately 30 mm moderately differentiated adenocarcinoma in the pancreatic tail with 
perineural and vascular invasion. Nine lymph nodes were identified in the resection 
specimen of which one contained metastasis (T3N1M0, stage IIb). No adjuvant therapy 
was administered. After an uneventful recovery from surgery 10 months later a local 
recurrence of the tumor was demonstrated and he died 16 months after surgery.
The second patient was a 76-year old female from a genetically proven FAMMM fam-
ily. EUS showed atrophy of the pancreatic tail with a dilated main pancreatic duct that 
tapered into an ill-defined mass at the level of the pancreatic body. CT scan showed this 
mass without signs of vascular involvement or metastases. The patient underwent surgi-
Table 3: Patients with pathological findings at EUS
ID Sex age Genetic 
background
EUS mRI CT nr. EUS 
features 
of chronic 
pancreatitis
5 F 52 Suspicious 
for FAMMM 
with UV 
CDKNA2
Multifocal branch 
type IPMN 8 – 15 
mm
Multifocal branch 
type IPMN
Two areas with 
less enhancement 
corresponding 
to cystic lesions 
observed with EUS 
and MRI
0
9 F 48 FPC Branch type IPMN 
5 mm in pancreatic 
head; hepatic 
adenoma
Hepatic adenoma; 
small abnormal 
area in pancreatic 
head; too small for 
characterization
Not performed 0
18 M 69 HBOC 
(BRCA2)
Mass 27 mm 
pancreatic tail
Not performed Suspicious mass 
pancreatic tail
1
21 M 57 FPC Branch type IPMN 
4 mm in pancreatic 
head
Not performed Not performed 1
31 M 54 FPC 2 branch type IPMN 
5 mm in pancreatic 
body
0
33 F 42 HBOC 
(BRCA1)
Branch type IPMN 5 
mm pancreatic body
0
34 F 75 FAMMM Mass 50 mm 
pancreatic tail
Suspicious mass Not performed 1
35 F 51 FAMMM Mass 10 mm 
pancreatic tail
No abnormalities 0
36 M 57 FAMMM Branch type IPMN 7 
mm pancreatic body
0
37 M 59 FAMMM Branch type IPMN 
6.5 mm pancreatic 
tail
0
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cal resection of pancreatic body and tail with en bloc resection of the spleen. Histology 
revealed a poorly differentiated ductal adenocarcinoma with a diameter of 5 cm with 
perineural invasion and 4 out of 8 regional lymph nodes were tumour positive (T3N1M0, 
stage IIb). After adjuvant chemotherapy the patient is doing reasonably well, now 18 
months after surgery.
The third case involved the daughter of patient 2, 51 years old, also a proven CD-
KN2A carrier. EUS showed a small (10 mm) hypoechoic mass lesion in the pancreatic 
body. MRI and CT did not show any abnormalities. En bloc resection of pancreatic body, 
tail and spleen was performed. The resection specimen contained a 12 mm moderately 
differentiated ductal adenocarcinoma without nodal involvement (T1N0M0, stage Ia). 
Sixteen months after surgery local recurrence and liver metastases were demonstrated 
and the patient is currently receiving chemotherapy and doing quite well.
Cystic lesions
In seven patients (15.9%) small cystic lesions were identified. Details of these patients 
can be found in Table 3. The size of the lesions was between 4 and 15 mm. All cystic 
lesions were unilocular without intramural nodules or solid components and with EUS 
communication with the main pancreatic duct was at least very likely. In one patient, a 
52-year-old female from a family with familial pancreatic cancer, multifocal (three) cystic 
lesions were found in the head, body and tail of the pancreas (Figures 2 and 3).
Both EUS findings and MRI were highly suggestive of branch type IPMN since these 
cysts clearly communicated with the main pancreatic duct. On CT scan no further 
abnormalities were found. During 2 years of follow-up with both EUS and MRI/MRCP 
no apparent changes in these lesions have been observed. For the cystic lesions in the 
remaining individuals, due to their small size and the absence of signs suggestive of 
malignancy, a policy of intensive follow-up with bi-annual EUS and MRI was chosen as 
well. These individuals, as are all other participants, were included in a prospective study 
in which the yield of EUS and MRI are compared.
Extra-pancreatic findings
In a 40-year-old female with Li-Fraumeni syndrome and a proven p53 mutation a 25 mm 
mass lesion of the left adrenal was identified during EUS. Endosonographic examination 
of the pancreas was normal. The left adrenal was laparoscopically resected and contained 
a non-malignant, non-functioning adenoma. Recovery from surgery was uneventful.
In a 48 year old woman from a family with FPC a 16 mm hypoechoic lesion without 
an obvious central scar was seen in the left liver lobe. EUS-FNA demonstrated this lesion 
to be a hepatic adenoma and no change has occurred during 18 months follow-up.
Screening high-risk individuals 25
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Figure 2: EUS image of unilocular cyst in tail of pancreas in patient with FPC
Figure 3: MRI image of multifocal branch type intraductal mucinous neoplasia in a patient with familial 
pancreatic cancer highlighted by the white arrows
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Complications
During a total of 46 EUS investigations no complications have occurred. All individuals 
left the hospital maximally 2 hours after the procedures.
DISCUSSION
In this study we have shown that EUS-based screening of individuals at a high risk of 
developing pancreatic cancer is feasible and safe. Although the number and length 
of follow-up of individuals included in this study is too small to answer the question 
whether this improves outcome in individuals with a family history of PC it is clear that 
first time EUS yields a considerable number of both malignant and potentially premalig-
nant lesions which is in line with previous studies from the US in cohorts which mainly 
consisted of families with familial pancreatic cancer. These studies also demonstrated 
the ability of EUS to identify both mass and potentially premalignant lesions in up to 10% 
of asymptomatic persons22,23. In symptomatic individuals from FPC kindreds however 
multifocal dysplasia was detected in 7 out 14 patients that underwent pancreatectomy 
after abnormal ERCP and EUS26.
Modalities that have been used to screen high-risk individuals are CT-scan, endo-
scopic retrograde cholangio-pancreaticography (ERCP), magnetic retrograde cholan-
giopancreaticography (MRCP/MRI) and endoscopic ultrasound (EUS). Although there is 
no scientific evidence to support the use of CT scan for this purpose, it is used by several 
institutions27,28. The sensitivity of CT-scan in detecting small pancreatic lesions is lower 
compared to EUS, thereby limiting its potential usefulness for screening purposes29. 
Perhaps the most important consideration is the fact that the cumulative radiation dose 
of repeated CT scans should not be neglected, especially in individuals already at an 
increased risk of developing cancer.
Although MRI does not involve radiation exposure and therefore is perhaps more 
suitable for use in a surveillance setting, it has not been formally investigated in indi-
viduals at risk for pancreatic cancer. From comparative studies it is known that the sen-
sitivity of MRI in detecting small (<3 cm) lesions is comparable to helical CT-scanning. 
An additional value of MR is the visualization of the pancreatic duct and cystic lesions 
through the use of MRCP sequences. The use of secretine improves visualization of 
the pancreatic duct and cystic lesions30. Furthermore, another benefit of MRI images 
compared with EUS is that they are relatively easy to compare over time. The inherent 
complication risks do not make ERCP a suitable test for screening purposes.
EUS seems to be an almost ideal test for imaging of pancreas and detecting early le-
sions. Indeed, several studies have shown in still relatively small cohorts, mainly consist-
ing of individuals with familial pancreatic cancer, its ability to identify early neoplastic 
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lesions22,23,26. Although EUS is an invasive procedure that usually requires conscious 
sedation, the complication risk of diagnostic EUS is very low31. EUS is however an op-
erator dependent technique that requires considerable skills and experience to reliably 
examine the pancreas32.
Our study is the first study on this subject in Europe and differs in one important 
aspect from previously published studies in that the proportion of individuals with a 
clearly defined genetic syndrome was much higher. Whether this explains solely the 
higher incidence of both solid lesions and cystic precursor lesions remains to be inves-
tigated although all mass lesions in our series were found in mutation carriers. The aim 
of the present study was not to establish differences between these groups and lacks 
statistical power to reliably ascertain whether this is explained by genetic background. 
Furthermore, other risk factor, e.g. smoking, needs to be taken into account. The inci-
dence of cystic lesions in FPC individuals in our series is 15% (3 out of 20), which is still 
higher than in the US series mentioned above.
Several important questions still need answering. Obviously, it is not the goal of an 
oncological screening program to find advanced cancers. This applies in particular to pan-
creatic cancer with its dismal prognosis. The detection of asymptomatic (advanced) malig-
nancies will only introduce a lead time bias since individuals will become patients earlier 
without improving the actual prognosis. This is illustrated by the patient with a BRCA2 
mutation who survived only 16 months after the detection of an asymptomatic carcinoma 
followed by a radical surgical resection and the patient who underwent resection of a very 
small cancer and still developed local recurrence and liver metastases despite a radical 
resection with negative lymph nodes. One could argue however, that screening started 
too late in the three patients with advanced lesions and that having commenced screen-
ing at an earlier stage in their lives might have detected these lesions at a curable stage. 
This however should be demonstrated in larger prospective series, preferably multicenter, 
before embarking on any formal screening and surveillance program in these families.
One argument for this is the ability of EUS to identify these precursor lesions in 
the form of cystic lesions as shown by our study and others22,23,26. Although in 2 out 
of 3 resection specimens at the edges some formations of pancreatic intraepithelial 
neoplasia (PanIN) grade I-II were found, at present there is no reliable way to identify 
these Pan-IN’s with EUS. It might be that Pan-IN’s are represented by the occasionally 
observed extensive changes in the pancreatic parenchyma in these individuals that are 
reminiscent of chronic pancreatitis (Table 3). It is possible to acquire pancreatic tissue 
for histopathological evaluation either through surgery or EUS guided with a thrucut 
needle. At present the potential complications of these procedures combined with the 
possible patchy distribution of Pan-INs withhold us from this strategy. We also do not 
know at the current time whether the finding of Pan-INs justify a total pancreatectomy 
given its inherent morbidity and mortality.
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Another important and still unanswered question is how to manage the IPMN-like 
cystic lesions that we and others found to be present at an relatively high frequency in 
individuals at high risk of developing pancreatic, especially in light of the assumption 
that these may represent precursor lesions of pancreatic cancer. It is known know from 
several retrospective cohort studies that the likelyhood of malignancy in branch type 
IPMN’s without involvement of the main pancreatic duct, intramural nodules or solid 
components is quite small. In sporadic cases a follow-up policy with regular interval 
screening for these lesions is safe and acceptable33-36. However, the biological behavior 
of such lesions in patients with a hereditary increased risk for the development of cancer 
is not known. Whether these high-risk patients should be offered surgery at an earlier 
stage than what is considered acceptable in sporadic cases or if the same wait-and-see 
policy can be adopted is unknown. It is also unclear whether the possible development 
of these precursor lesions into more advanced neoplastic or even malignant lesions is 
gradual over time with ample opportunity for early detection during surveillance, or 
sudden and abrupt. These very important questions need to be addressed in further 
follow-up studies.
When the principles formulated by the World Health Organization in 1968 with re-
gard to screening for disease are applied to EUS based screening of high-risk individuals 
for the development of pancreatic cancer, most of these criteria are fulfilled.37 Despite 
the fact that we have not yet identified the best management of patients with precursor 
lesions nor have evaluated the cost-effectiveness of EUS-based screening of individuals 
at risk, this strategy at present seems to be the most appropriate and sensible. However, 
because of the many unanswered questions that still remain we strongly believe this 
should only be done in research programs with well-established protocols and regis-
tries. We have therefore started in the Netherlands a prospective study in which the 
yield of annual EUS and secretin-administered MRI will be compared in mutation carriers 
of PC-prone syndromes, other syndromes with PC clustering and FPC.
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abSTRaCT
background
Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is considered a valuable 
and safe technique for further investigation of pancreatic cystic lesions. In the framework 
of a prospective study on the accuracy of EUS-FNA we report our initial technical results 
regarding puncture access, sample adequacy, and complications
methods
Consecutive patients with indeterminate pancreatic cystic lesions underwent EUS and 
EUS-FNA. Pancreatic cyst fluid was collected for cytopathological analysis and measure-
ment of amylase, carcinoembryonic antigen (CEA), and carbohydrate antigen 19.9 (CA 
19.9) levels. Main outcome parameter for this analysis was the percentage of samples 
adequate for cytologic and laboratory analysis.
Results
Of 143 patients (median age 63 years; median cyst size 2.8 cm) who underwent EUS, 
FNA was performed in 128 (90%). The various reasons for not doing FNA included large 
distance between transducer and cystic lesion (n = 9), cyst not seen or too small (n = 2), 
and evident diagnosis not requiring FNA (n = 3). FNA was not possible in four patients 
(technical failures). Cyst fluid sent for cytology provided adequate cellular material in 
44 cases only, accounting for an intention-to-diagnose yield of 31% (44/143). Sufficient 
fluid for biochemical analysis was obtained in 68 cases (49%). Complications occurred in 
three patients (2.4%).
Conclusions
Although EUS-guided FNA was technically feasible in the majority of patients with 
pancreatic cystic lesions (87%), it was possible to obtain a classifying cytopathologic 
diagnosis and a chemical analysis in only a third and a half of cases, respectively.
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INTRODUCTION
An increasing number of individuals are diagnosed with cystic lesions of the pancreas 
because of more frequent use of cross-sectional abdominal imaging techniques such 
as computed tomography (CT) and magnetic resonance imaging (MRI). In two recent 
studies the prevalence of cystic pancreatic lesions was 2.6% and 2.4%, respectively [1, 
2]. Although little is known about the natural history of small asymptomatic cysts, it is 
well known that a subset of pancreatic cysts have malignant potential [3 – 5]. Whereas 
simple cysts seem to be harmless, mucinous subtypes including mucinous cystic 
neoplasms (MCNs) and intraductal papillary mucinous neoplasms (IPMNs) have an un-
disputed malignant potential [4, 6 – 8]. For this reason, the majority of pancreatic cysts 
are extensively analysed in order to decide whether surgery or follow-up is indicated. 
In the diagnostic work-up, imaging tests such as dedicated CT and MRI are excellent 
diagnostic modalities to describe morphologic features of pancreatic cysts [9, 10]. In 
addition, endoscopic ultrasound (EUS) has emerged as valuable in the evaluation of 
pancreatic cystic lesions, providing fine detail of the morphological characteristics of 
the cyst[11 –13]. Nevertheless even after high resolution imaging using either technique 
it is still difficult to distinguish between the different types of pancreatic cysts based 
on morphologic criteria only [14, 15]. EUS-guided fine needle aspiration (FNA) may be 
helpful in achieving a diagnosis by providing pancreatic cyst fluid and is considered by 
many to be a safe and valuable technique[16 – 18]. However, cytopathological examina-
tion is often nondiagnostic due to the low cellularity of the cyst fluid obtained [14, 19]. 
The value of cyst fluid tumor markers is also controversial [14, 16, 20, 21]. Despite the 
large number of reports on the value of cytology and tumor markers, there is to our 
knowledge no prospective study reporting the actual percentage of consecutive cases 
where EUS- guided FNA is technically successful in obtaining a sufficient amount of cyst 
fluid for performance of cytological and laboratory investigations of the fluid.
We initiated a prospective cohort study involving patients with cystic lesions of the 
pancreas, with a standardized protocol which includes, among other techniques, EUS-
FNA. In this study we investigated the technical success and safety of FNA in a prospec-
tive cohort of consecutive patients with cystic pancreatic lesions of unknown origin.
PaTIENTS aND mETHODS
Study design
This was a prospective, observational cohort study of consecutive patients referred to 
the Departments of Gastroenterology and Hepatology or Surgery at our institutions for 
the evaluation of cystic pancreatic lesions. The study was performed in The Netherlands, 
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at the Departments of Gastroenterology and Hepatology of the Academic Medical 
Center at the University of Amsterdam and of the Erasmus MC University Medical Center 
in Rotterdam. Approval for the study was given by the local ethics committees of both 
centers. Written informed consent was obtained from all patients before they entered 
the study. Enrolment started in December 2006 and is ongoing.
Patients
Consecutive patients above 18 years of age with a cystic pancreatic lesion of unknown 
aetiology seen on cross-sectional imaging (transabdominal ultrasound, CT, MRI) were in-
cluded in our study after written informed consent had been obtained. Exclusion criteria 
included the following: known coagulation disorders (prothrombin time-international 
normalized ratio [Pt-INR] > 1.5, partial thromboplastin time (PTT) > 50 s, platelets < 50 
000/nL), acute pancreatitis in the previous 6 months, and a synchronous malignancy 
elsewhere in the body.
EUS procedures
All patients received one dose of intravenous prophylactic quinolone prior to the proce-
dure followed by oral quinolone for 3 days after the procedure in order to minimize the 
risk of infectious complications.
For the EUS procedure, patients were placed in the left lateral position. Procedures 
were performed with patients under conscious sedation with intravenous midazolam 
and/or fentanyl. Four experienced endosonographers (J. W. P., J. E. H., M. J. B., P. F.), who 
had each carried out more than 500 EUS examinations of the pancreas, performed all 
the procedures, using linear-array echo endoscopes (GF-UC(T)140(P); Olympus Medical 
Systems, Hamburg, Germany).
All procedures were done according to a standardized protocol. When the lesion 
was identified, the following morphologic characteristics were recorded at the time of 
examination: location of the cyst, cyst diameter, multiplicity of cysts, microcystic ver-
sus macrocystic character, maximal wall thickness, presence of septations, nodules or 
calcifications, communication with pancreatic duct, dilatation of pancreatic duct, and 
presence or absence of vascular involvement.
For EUS-guided FNA, lesions in the pancreatic head were approached via the duode-
num, while lesions in the body and tail were targeted transgastrically. Color Doppler was 
used to identify intervening blood vessels and to diminish the risk of bleeding. Reasons 
for nonperformance of FNA could be: intervening normal pancreatic tissue over a dis-
tance of more than 1 centimeter, unavoidable intervening vessels, strong suspicion of a 
large complex (debris) pseudocyst in the presence of parenchymal features of chronic 
pancreatitis with a presumed increased risk of infection, or clear suspicion of malignancy 
with straightforward indication for surgery.
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EUS-guided FNA was done using a 19- or 22-gauge needle (Wilson-Cook, Limerick, 
Ireland) at the discretion of the endosonographer. All lesions were preferably punctured 
with a single pass to minimize the risk of infection through repeated punctures. Once 
the needle was inside the lesion, a vacuum was applied and the contents of the cystic 
lesion were aspirated, with the needle being moved slowly back and forth through the 
lesion until no more fluid could be obtained. If solid components were visualized they 
were specifically targeted with the needle. At both centers, patients were observed in 
the recovery area for a minimum of 2 hours after the procedure.
Cyst fluid analysis
After aspiration, the cyst fluid was divided to provide material for cytopathologic exami-
nation, biochemical analysis, and research purposes. The cytopathologic examination 
was considered the most important and thus cyst fluid was primarily used for this. All 
cytological specimens were processed as direct smears of aspirated material (on eight 
glass slides).
Secondly, aspirate was sent for biochemical analysis of amylase levels and tumor 
markers (carcinoembryonic antigen [CEA], carbohydrate antigen 19.9 [CA 19.9]). The 
aspirates were delivered immediately after the procedure and a minimum of 500 μl was 
needed for determination. Tumor markers and amylase were measured with commer-
cially available immunoassays.
When sufficient fluid (2ml) was available, spin cytology was also carried out. Depend-
ing on the amount of fluid, additional fluid was stored for research purposes in a freezer 
at −80°C.
Complications
Complications were defined as any unexpected event occurring during or after the pro-
cedure that caused morbidity or mortality [22]. Complications that might occur during 
or within 2 hours of the procedure were defined as immediate; complications occurring 
within 30 days after the procedure were defined as early; and complications occurring 
more than 30 days after the procedure were regarded as late [23]. Definition of severity 
of complications was based on the length of hospitalization: mild < 3 days, moderate 
4 – 10 days, and severe > 10 days or admission to the intensive care unit or department 
of surgery [23].
Patients were asked to contact the hospital in case of abdominal discomfort, pain, 
or fever. In addition, patients were seen at the outpatient clinic between 1 and 2 weeks 
after the procedure for discussion of the results, enquiry about complications, and deci-
sions about further management.
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Data collection and statistical analysis
Data were collected and recorded in a prospective database. Statistical analysis was per-
formed using SPSS 16.0 (Statistical Pack- age for the Social Sciences, Chicago, Illinois). 
Quantitative data are presented using median values with the range or mean values 
with standard deviations, wherever appropriate. For the comparison of continuous 
variables, appropriate t tests or nonparametric tests were used. P values (two-sided) of 
less than 0.05 were considered statistically significant.
RESUlTS
Patient characteristics
Between December 2006 and September 2009, 143 consecutive patients (median age 
62.8 years, range 19 – 80; women 54%) were included in the protocol and underwent 
EUS. A total of 65 patients (45%) had abdominal complaints at the time of presentation. 
In the other 78 patients the cyst was considered to be an incidental finding on either 
ultrasound, CT or MRI.
Median cyst size was 28 mm (range 7 – 220): 14 cysts (10%) had a size of 1 – 10 mm, 
38 (27%) were 11 – 20 mm, 33 (23%) were 21 –30 mm, 19 (13%) were 31 – 40 mm, and 
39 cysts (27%) were > 40 mm in size. Anatomically, 71 of the lesions (50%) were in the 
pancreatic head, 37 (26%) in the body and 35 (24%) were in the tail. Table 1 shows the 
characteristics of the patients and the cyst features.
Table 1: Evaluation of pancreatic cysts by endoscopic ultrasound-guided fine needle aspiration (EUS – 
FNA): characteristics of patients (n=143) and cysts
Gender, female, n (%) 78 (54)
Age, median (range), years 63 (19-80)
Patients with abdominal complaints*, n (%) 64 (45)
Cyst size, median (range), mm 29 (7 – 220)
Pancreatic location, n (%)
Head 71 (50)
Corpus 37 (26)
Tail 35 (24)
FNA performed, n (%) 124 (87)
Fluid volume obtained, median (range), ml 3.0 (0.5 – 600)
* In the remaining patients, the cyst was an incidental finding
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Technical success
EUS-guided FNA was done in 128 out of 143 (90%) patients. It was not done in 15 
patients for the following reasons: risk of post-procedural pancreatitis because the dis-
tance between the transducer and cystic lesion was considered to be too great (n = 8) ( 
figure 1); unavoidable intervening blood vessel (n = 1) (figure 2); presumed pseudocyst 
with the EUS image compatible with chronic pancreatitis (n = 2); image compatible with 
cyst- adenocarcinoma with a clear indication for surgical resection, to avoid the risk of 
seeding (n = 1); cyst not identified at EUS examination (n = 1); cyst size considered too 
small for successful puncture (n = 1); and the lesion was hyperechogenic (n = 1). In this 
Figure 1: Pancreatic cyst: endoscopic ultrasound-guided fine needle aspiration (EUS – FNA) was not done 
because of the distance between the point of entry to the pancreas and the cyst was too great.
Figure 2: Pancreatic cyst: endoscopic ultrasound-guided fine needle aspiration (EUS – FNA) was not done 
because of intervening blood vessels.
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last patient EUS showed a benign-appearing, poorly demarcated, hyperechoic area in 
the pancreatic head. Review of the MRI images and report suggested that this was not a 
cyst but a lesion compatible with fatty tissue.
Fluid could not be obtained in four of the 128 patients in whom FNA was done 
because of technical failure of the puncture.
The median size of the cysts in which FNA was performed was 29 mm (range 7 – 220) 
versus 15 mm (range 9 – 65) for the cysts in which FNA was not performed (P = 0.025). 
Median amount of cyst fluid obtained at EUS-FNA was 3 ml (range 0.5 – 600). Material 
was sent for cytology from 124 patients (87% of all patients). A classifying diagnosis 
was obtained in 44 (31% of all patients). The median size of the cysts with a classifying 
diagnosis was 29 mm (9 – 220) compared with 28 mm (7 – 140) for the cysts without a 
classifying diagnosis (P = 0.396).
Sufficient fluid was available for biochemical analysis in 80/143 cases (56%) and 
analysis succeeded in 70/143 (49%). Median size of cysts for which biochemical analysis 
was performed was 33 mm (7 – 220) versus 22 mm (7 – 145) for the cysts without bio-
chemical analysis (P = 0.072). Findings are summarized in figure 3.
Figure 3 Evaluation of pancreatic cysts: technical success of endoscopic ultrasound-guided fine needle 
aspiration (EUS – FNA)
EUS – FNA of pancreatic cysts 39
3
Safety
Three patients (2.4%) developed complications: two had symptoms consistent with an 
infection of the pancreatic cyst and one developed mild pancreatitis.
In one of the patients with infectious complications, a 140-mm cystic lesion in the 
tail of the pancreas had been punctured. The patient presented with abdominal pain, 
fever and elevated white blood cell count. Abdominal CT did not show signs of perfora-
tion or leakage and infected pancreatic cyst was considered to be the most likely cause 
of the fever and abdominal pain. The patient was admitted and received intravenous 
antibiotics, upon which the symptoms resolved and the patient was discharged after 
7 days. At 2 months later she underwent surgery with complete resection of the lesion. 
During surgery no signs of the earlier infection were seen. Histopathology showed a 
mucinous cystadenoma without signs of malignancy.
The second patient had a 33-mm cyst in the corpus and presented a week after the 
procedure with fever, abdominal pain and nausea. Laboratory tests showed that the 
C-reactive protein (CRP) level was raised and the amylase level was normal. Transab-
dominal ultrasound was performed and showed no signs of perforation, leakage, or 
pancreatitis. The patient was treated as an outpatient with oral antibiotics for 5 days, 
after which the symptoms resolved.
The third complication occurred in a patient with a 28 mm cystic lesion in the cor-
pus. The patient presented with abdominal pain within 24 hours after EUS-guided FNA. 
Laboratory tests showed an increased amylase level of 435 U/L and raised CRP of 64.2 
mg/L. This patient was also observed as an outpatient with a diagnosis of EUS-associated 
pancreatitis and symptoms spontaneously resolved within a week, without medication.
DISCUSSION
Cystic lesions of the pancreas can be subclassified into mucinous and nonmucinous cysts. 
Whereas nonmucinous cysts are usually harmless and do not require follow-up, muci-
nous cysts may have a malignant potential and require surgical resection or surveillance 
depending on size and other characteristics. Even with currently available diagnostic 
modalities, accurate diagnosis is still challenging. The dilemma for clinicians is that on 
the one hand patients should not be exposed to unwarranted surgery or surveillance 
with associated morbidity or even mortality, but on the other hand a correctly indicated 
resection or surveillance of a malignant or premalignant cyst should not be withheld. 
In recent years EUS has evolved into a technique that is widely used to obtain detailed 
images of the pancreas including of pancreatic cysts [15]. Despite the high resolution 
of the EUS images, there is controversy about the accuracy of EUS in discrimination 
between mucinous and nonmucinous cysts [15, 24, 25]. FNA is considered to be an 
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important technique in the diagnostic work-up of pancreatic cysts. Many studies have 
been published reporting on the performance and yield of FNA for the evaluation of 
pancreatic cysts but little is known on the technical success and safety of this procedure. 
Therefore, the aim of this prospective two-center study was to investigate the technical 
success and safety of EUS-FNA in our prospective cohort of patients in all of whom EUS-
FNA was planned.
In our study a total of 143 persons underwent EUS, and FNA could be performed in 
128 (90%) of them. In some cases no puncture was done, for various reasons including 
unfavorable location: more than 1 cm of pancreatic tissue would have to be passed to 
puncture the cyst and the risk of causing pancreatitis was considered too high. Another 
reason for not carrying out the puncture was the presence of an unavoidable interven-
ing blood vessel.
Cytological examination was performed in all cases in which fluid was obtained but 
a classifying diagnosis was only obtained in approximately one third of cases (31%). 
Other studies performed so far have focused on the sensitivity of cytology to predict a 
mucinous cyst. Two studies have reported similar results with sensitivities of 13% and 
35%, respectively [26, 27]. These numbers are lower than those reported in another pro-
spective study by Frossard et al. [28]; in that study cytological analysis was performed 
in 127 patients with pancreatic cysts and a classifying diagnosis was provided in 98 
cases (77%). However, in that study an additional minibiopsy was obtained and a cell 
preparation processor was used which provided a monolayered cell population. Suc-
cessful cytopathologic analysis is largely dependent on acquiring a sufficient number of 
cells in the specimen. We conclude that the interpretation of these cytologic specimens 
remains challenging, even in the hands of experienced pathologists.
Our second goal for analysis after cytopathology was biochemical analysis of CEA, 
CA 19.9 and amylase. This was possible in only approximately half of the patients (49%), 
mainly because we primarily chose to send material for cytological evaluation and in 
many cases no fluid was left for biochemical analysis. In an additional 10 cases, material 
was sent to the laboratory but analysis could not be done because of high viscosity 
or an insufficient amount of fluid. Cyst fluid biochemical analysis (amylase) and tumor 
markers have been evaluated for several years on the basis that markers secreted into 
the cyst fluid might identify the epithelial lining. Markers commonly used are CEA, CA 
19.9, CA 15.3 and CA 72.4 [18, 29 – 31], amongst which CEA is considered one of the best 
discriminatory markers for the diagnosis of mucinous cystic neoplasms [20], providing 
the highest sensitivity and specificity in most studies.
We also looked at the correlation between the size of the cysts and the success of 
FNA. Cysts in which FNA was performed were significantly larger than cysts in which no 
FNA was performed. Since the latter cysts were smaller it is more likely that the distance 
between the transducer and the cystic lesion was larger in the cases in which no FNA 
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was performed. However, cysts for which a classifying diagnosis was obtained were 
not significantly larger than cysts without a classifying diagnosis. The cysts for which 
biochemical analysis was performed were not statistically significantly larger than the 
cysts for which it was not done, although a trend (P= 0.07) was found.
The overall complication rate was 2.4% (3 of 124 patients) with one patient being ad-
mitted to hospital and two treated as outpatients. There were no deaths and no patients 
required surgery. In two patients the cyst was infected after FNA and one patient suffered 
from a mild pancreatitis attack. This complication rate is comparable to that reported in 
the study by Lee et al. [32], where a retrospective analysis of 603 EUS-FNA procedures 
of pancreatic cysts showed 13 complications (2.2%). Two earlier studies showed higher 
complication rates of 3.5% and 14% after FNA for pancreatic cysts [33, 34]. In the study 
with a complication rate of 3.5% prophylactic antibiotics were also administered [33], 
whereas no antibiotics were given in the one with the 14% complication rate [34]. The 
majority of complications after FNA are mild, and the most common complication is 
pancreatitis though the latter was not the case in our study. Infection of cysts after FNA 
is rare, and data are lacking that support the use of prophylactic antibiotics although it is 
common practice in most centers. Furthermore, to minimize the risks of subsequent in-
fection one should keep the number of punctures to a minimum and attempt to aspirate 
the cyst completely whenever possible. Intracystic hemorrhage is a rare complication 
that occurred in 6% of all cases reported by Varadarajulu et al. [35]. We did not identify 
any intracystic hemorrhage, but we may have missed instances since this often occurs 
without clinical symptoms.
To interpret the results of this study, the following strengths and limitations have to 
be considered. The study is strengthened by its collection of a large prospective cohort 
of consecutive patients, in contrast to the retrospective studies published earlier [32, 
34]. In addition, all EUS procedures were carried out by four endosonographers with 
extensive experience in pancreatic EUS. Finally, standard follow-up was done 7–14 days 
after the procedure.
A limitation of the study is the potential selection bias since both the hospitals are 
tertiary referral centers. Additionally, in some patients FNA was not done, because of 
clinical considerations, although the protocol did specify performance of FNA in all pa-
tients. Another limitation could be that we may have missed some mild early complica-
tions since patients were only seen in the outpatient clinic 7–14 days after the procedure. 
In some studies patients were seen 1 or 2 days after the procedure [33, 34]. Finally, we 
do not yet have long-term follow-up of our patient cohort. Long-term surveillance of all 
patients will show the true value of EUS-FNA in cystic lesions of the pancreas, but the 
present study was only investigating the technical success and safety of EUS-guided FNA.
New methods to improve the yield of FNA are urgently required. The current yield 
is often small; this may be caused by the microcystic aspect of some cysts, the high 
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viscosity of the fluid, or by the minimum amount of fluid required for certain analyses. 
The standard use of a 19-G needle could be helpful to aspirate both larger cysts and 
cysts which contain fluid with a high viscosity. Also the development of new techniques 
to minimize the fluid needed for analysis may well be valuable. In addition, the develop-
ment of new techniques to increase the cellularity of the fluid obtained could be help-
ful. Two recent reports study a new type of brush (EchoBrush, Cook Medical, Limerick, 
Ireland) aimed at improving the yield of cytologic examination [36, 37]. The EchoBrush is 
limited in that it can only brush cysts that are at least 2 cm in size. Another limitation of 
the EchoBrush has been the relatively high rate of complications. Since the procedures 
were performed by highly experienced endosonographers, it might be difficult to intro-
duce this technique in a community setting. These studies suggest that this relatively 
new technique improves the yield, but larger randomized trials are necessary to confirm 
these results and to define the safety profile of this more aggressive approach. Existing 
tumor markers have only limited value and identification of more sensitive biomarkers 
is needed. New techniques including proteomics and molecular analysis may be helpful 
for the differential diagnosis of pancreatic cysts.
This study shows that EUS-FNA of cystic pancreatic lesions is safe but that the overall 
diagnostic value is limited. A definite cytopathological diagnosis was obtained in only 
31% and a biochemical analysis in only 49%, even though EUS-FNA was technically pos-
sible in the majority of patients.
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abSTRaCT
background
In some patients suspected of pancreatic cancer no mass can be detected by MDCT-scan 
as the cause of biliary obstruction.
methods
All patients suspected of pancreatic cancer between January 2007 and 2009 with a 
negative MDCT were identified from a database.
Results
MDCT was performed for suspected pancreatic cancer in 290 patients, in 258 a pan-
creatic mass was found. MDCT failed to establish a diagnosis in 32 (11%). In 23 (74%) 
with a complete EUS the cause of the obstruction was correctly diagnosed. A mass 
in the pancreatic head was found in 15 patients; 13 patients had a malignant tumour 
and 2 patients a benign cause of obstruction. Further, EUS diagnosed 3 patients with a 
superficial adenoma of the papilla and 8 patients with a benign cause of the obstruc-
tion. In 5 patients EUS couldn’t detect the cause of obstruction but finally a pancreatic 
malignancy was diagnosed. The PPV of EUS was 86% and NPV 63%. Accuracy of MDCT 
and EUS decreased in the presence of pancreatitis or a biliary endoprosthesis.
Conclusion
In patients suspected of pancreatic cancer where MDCT fails to demonstrate the cause 
of obstructive jaundice, EUS identifies 74% of the underlying diseases correctly.
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baCKGROUND
Pancreatic adenocarcinoma has a mortality rate almost equal to its incidence rate.[1] 
The only curative treatment is surgical resection, however most patients present at an 
advanced stage and only approximately 15% of patients are eligible for resection at time 
of diagnosis.[2, 3] It is important to detect pancreatic tumours at an early, locoregional 
stage because these patients are most likely to benefit from resection. Helical multi-
detector computed tomography (MDCT) is the preferred initial imaging modality for 
patients suspected of pancreatic cancer in most centers because of a high sensitivity 
for detecting and determining resectability of pancreatic or peri-ampullary masses and 
the ability to demonstrate distant metastases.[4-7] If MDCT doesn’t show the cause of 
obstruction either MRI or endoscopic ultraonography (EUS) is the propagated next step. 
EUS has a high sensitivity for detecting pancreatic and peri-ampullary masses,[4, 6, 8] 
differentiating these from other causes of cholestasis like choledocholithiasis.[9] Fur-
thermore EUS has the possibility to obtain tissue for diagnosis by fine needle aspiration 
(FNA). However, this technique is invasive, operator-dependent and might be influenced 
by the presence of biliary endoprosthesis.[6] We retrospectively studied the value of EUS 
in patients suspected of pancreatic cancer with a negative MDCT.
mETHODS
All patients referred to an academic tertiary referral centre (Erasmus MC, University 
Medical Center; Rotterdam, the Netherlands) or a large teaching hospital (Maasstadziek-
enhuis; Rotterdam, the Netherlands) for suspected pancreatic head malignancy 
between January 2007 and January 2009 were retrospective included in a database. 
Inclusion criteria were painless jaundice or a combination of cholestasis, weight loss 
and abdominal discomfort or back pain. These patients were analysed using a Siemens 
helical multidetector CT-scanner with a non-contrast enhanced scan and a contrast 
enhanced scan in the pancreatic phase after 40 seconds (2,5-3mm slices) and portal 
phase after 80 seconds (5mm slices), according to local pancreatic cancer protocol. 
The MDCT was reported by one of two experienced gastro-intestinal radiologist. We 
consciously choose not to review the original MDCT for this study or videos of the EUS 
but used the original reports to reflect everyday clinical practice. We identified patients 
with a negative MDCT and at least 6 months follow-up from this database. EUS was 
performed under conscious sedation by one of three experienced endosonographers, 
who performed over 500 procedures each. FNA was performed when doubt about the 
diagnosis existed or in case of an unresectable mass to get cytological diagnosis. FNA 
was not performed when morphological appearance suggested a resectable pancreatic 
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cancer on EUS. The EUS was performed with an electronic Olympus curved linear array 
echo-endoscope (Olympus GmbH, Hamburg, Germany) with a Philips ultrasoundpro-
cessor (Philips Medical, Amsterdam, the Netherlands) or with an electronic Pentax 
linear echo-endoscope with an Hitachi ultrasoundprocessor (Hitachi Medical Systems, 
Zug, Switzerland). Patients were discussed in a multi-disciplinary meeting after MDCT 
and EUS. Surgical outcome was reported, as were histopathological examinations of 
resected tumours and intraoperative findings.
RESUlTS
Between January 2007 and January 2009 a total of 290 patients were referred and 
analysed for suspected pancreatic cancer. Reasons for suspicion of pancreatic cancer 
were painless jaundice (60%) or weight loss with cholestasis and/or upper abdominal 
discomfort (40%). These patients included 149 women and 141 men, with a median age 
of 66 years (range 26-87 years). MDCT detected pancreatic masses in 258 patients, with 
a size varying between 6 and 110mm, with a median of 30mm. In 25% of these patients 
an endoprosthesis was present during analysis with MDCT. The MDCT was followed by 
EUS in 242 (94%) of the patients with a pancreatic lesion. In 92 (38%) of the 242 patients 
during EUS an endoprosthesis was present. EUS detected tumours varying between 8 
and 95mm, with a median of 30mm. FNA was performed in 143 patients (59% of EUS); 
in 47% malignant cells were found, in 31% no malignant cells were found, in 15% there 
were not enough cells for cytological examination and in 7% neuro-endocrine cells were 
found. Of the 66 patients with not enough cells for cytological examination or no malig-
nant cells, 47 (71%) were found to have a pancreatic malignancy after all by histological 
examination of the resected specimen, perioperative biopsy in case of unresectability or 
follow-up. In patients with a pancreatic lesion on MDCT, the overall positive predictive 
value (PPV) of FNA for malignancy was 100% and the negative predictive value (NPV) 
29%.
We identified 32 patients (11%) where MDCT failed to determine the cause of bile 
obstruction. In 10 of these patients (30%) a biliary endoprosthesis was present during 
MDCT. All patients with negative MDCT underwent EUS. In one patient EUS was incom-
plete due to extrinsic compression of the descending part of the duodenum.
In figure 1 a flowchart of the patients with a negative MDCT can be found, showing 
the results of EUS and the definite diagnosis.
In 15 patients (48%) with a negative MDCT-scan, EUS detected a mass in the pan-
creatic head with morphological malignant appearance. The tumours varied between 
13-45 mm with a median of 20 mm. In 3 of these patients FNA was obtained which 
showed malignant cells. In figure 2 EUS with FNA of one of these patients is shown.
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Twelve patients underwent additional imaging with ERCP (with biopsy) and/or MRI 
to confirm the suspicion of malignancy. In addition 10 patients were found to have a 
pancreatic malignancy and 2 patients were diagnosed with benign disease (a chole-
dochal cyst and focal pancreatitis). Ten of the 13 patients diagnosed with pancreatic 
cancer, underwent exploratory surgery: 7 pylorus-preserving pancreaticoduodenecto-
mies (PPPD) were performed, 2 palliative surgery (due to vascular invasion) and in one 
Figure 1 flowchart of patients with a negative MDCT with results of EUS and definite diagnosis
Figure 2: Endoscopic ultrasonography with fine-needle aspiration of a suspected lesion in the pancreatic 
head of a patient with a negative helical multidetector CT scan
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patient no resection was performed. Histological examination showed adenocarcinoma 
in all patients, resected tumours varied in size between 15mm and 40mm. Three patients 
were considered to be unfit for surgery due to co-morbidity and underwent endoscopic 
palliative treatment.
EUS: superficial adenoma of the papilla
In 3 patients a papillary tumour without infiltrative growth was found during EUS. FNA 
was obtained of 2 patients and showed no malignant cells. One patient underwent a 
PPPD- procedure due to the size of the tumour and one an endoscopic resection. In 
both patients histological examination showed adenoma. The third patient with a papil-
lary tumour had an endoprosthesis in situ during MDCT and EUS and FNA could not 
be obtained. The patient underwent ERCP with biopsy that showed malignant cells. A 
PPPD-procedure was performed and histological examination showed adenoarcinoma 
(10mm).
EUS: benign cause of the obstruction
EUS found a benign cause of obstruction in 8 patients. In one patient main duct intra-
ductal papillary mucinous tumour (IPMT), based on a dilated pancreatic duct with filling 
defects and a gaping papilla, was diagnosed. In 2 patients a post-infectious stenosis 
of the distal common bile duct was found and treated endoscopically. In 3 patients 
EUS revealed cholelithiasis as the cause of obstruction and with ERCP the stones were 
extracted. In one patient a pseudocyst was found, for which an expectant policy was 
followed and in one patient primary biliary cirrhosis (PBC) was diagnosed which was 
treated with medication. All patients had follow-up of at least six months. The patient 
with IPMT was not operated due to her age and clinical condition and had follow-up for 
over 2 years with EUS and MDCT and no signs of malignant behaviour were found.
EUS: no detectable cause of the obstruction
In 5 patients analyzed for painless jaundice with negative MDCT and subsequent nega-
tive EUS, clinical follow-up and/or additional imaging revealed a malignant lesion of the 
pancreatic head. In 3 of those patients an endoprosthesis was present during EUS. In the 
first patient analysis with EUS showed severe chronic pancreatitis and FNA couldn’t be 
performed due to vascular structures. The patient was treated with an endoprosthesis. 
Due to significant co-morbidity that precluded surgery no further attempts to establish 
a definite diagnosis were made. After 3 months abdominal ultrasound showed a pan-
creatic mass and liver metastasis. Primary analysis of the second patient with MDCT, 
EUS and MRCP didn’t show the cause of obstruction, but signs of pancreatitis were 
present. Because of the elevated bilirubin an endoprosthesis was placed by ERCP and 
after 3 weeks the EUS was repeated. During this repeated EUS examination a suspected 
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malignant lesion of 18 mm in the pancreatic head was seen and FNA was obtained, 
which showed malignant cells. A PPPD was performed and the pathologic examination 
showed a T3N1 adenocarcinoma of the pancreatic head of 23mm. The third patient was 
analyzed for painless jaundice and ERCP was suspicious of a pancreatic mass. Subse-
quent analysis with MDCT-scan and EUS (both with the biliary endoprosthesis in situ) re-
vealed initially no cause of the stenosis and no mass could be visualized. However, after 
6 weeks the MDCT-scan was repeated and an 18 mm suspected malignant, unresectable 
tumour of the pancreatic head was diagnosed due to encasement of the mesenteric 
artery. The fourth patient presented with an episode of acute pancreatitis. MDCT-scan 
after recovery showed a dilated common bile duct and pancreatic duct without a mass. 
EUS failed to show a mass either, but additional MRI/MRCP after 2 weeks showed a 
mass peri-ampullary. Subsequent ERCP with biopsy showed neuro-endocrine cells. A 
PPPD was performed and a 15 mm neuro-endocrine carcinoma with one lymphnode 
metastasis was found. The fifth patient had obstructive jaundice and was treated with 
an endoprosthesis. Subsequent MDCT and EUS didn’t show a mass or cause of obstruc-
tion. ERCP after 1 and 3 weeks for endoprosthesis replacement showed a stenosis of the 
choledochal duct, but brush cytology and biopsy didn’t show malignant cells. A PPPD 
was performed and the pathologic examination showed a T2N0 adenocarcinoma of the 
pancreatic head of 19mm.
Overall in our study the accuracy of EUS in determining the cause of obstruction in 
patients with a negative MDCT was 74%, with a positive predictive value (PPV) of 86% 
and a negative predictive value (NPV) of 63%.
DISCUSSION
MDCT and EUS are useful and nowadays most often used imaging techniques for di-
agnosing and staging pancreatic cancer.[4, 10] In the work-up of patients suspected of 
pancreatic cancer the first step in most centers is MDCT, because of the high sensitivity in 
detecting pancreatic or peri-ampullary masses and the ability to demonstrated distant 
metastasis ( lung and liver). In our study MDCT failed to clarify the cause of cholestasis in 
32 patients (11%) and in 31 patients a complete EUS examination could be performed. 
After additional imaging, histology and follow-up 19 (61%) of these patients were found 
to have a pancreatic or peri-ampullary malignancy, thus 12 negative MDCT’s were con-
sidered to be true negative. In our analysis of the database MDCT has a sensitivity of 
93% for detecting the cause of biliary obstruction. This is comparable with other studies 
that showed a sensitivity of 83-93% for detecting pancreatic masses with MDCT.[4, 6, 
8] Of the 19 carcinomas that weren’t found with MDCT- scan, 13 (68%) were discovered 
on initial EUS, which resulted in 8 potentially curative PPPD-procedures. The survival 
54 Section 1
rate of patients after PPPD for pancreatic malignancies after 3 and 5 year is respectively 
10% and 5% for tumours larger than 4 cm and 56% and 40% for tumours smaller than 
2 cm.[11] Patients with a histopathological stage I tumour (T1-2N0M0) have a 3 years 
and 5 years survival rate of respectively 45% and 15-26%,[2, 11] compared to stage II 
tumours (T3 or N1M0) with a 3 years survival rate of 8% en no survivors after 5 years.
[11] Some authors propose that EUS is particularly useful for the detection of smaller 
tumours (<2cm), but insufficient data are present to support this.[4, 6] In our patients 
the size of the detected tumours between EUS and MDCT-scan didn’t differ. There is also 
the benefit of EUS to obtain cytology when in doubt about the diagnosis and a mass is 
visualized. In 3 patients with negative MDCT and a mass on EUS, FNA showed malignant 
cells. In almost half of all patients with a suspected malignant mass on MDCT and EUS, 
no malignant cells or not enough cells for cytological examination were obtained. 71% 
of these patients were found to have a pancreatic malignancy after all by histological ex-
aminations and/or follow-up. This emphasizes that a FNA can be a useful in diagnosing 
malignancy, but that cytology without malignant cells doesn’t exclude a malignancy.
In our 31 patients suspected of pancreatic cancer where MDCT fails to demonstrate 
the cause of obstructive jaundice, EUS identifies 74% of the underlying diseases cor-
rectly. EUS has a PPV of 86%, comparable with literature.[4, 6, 8, 10, 12] In 6 patients 
the malignant tumour was only diagnosed after additional examinations and follow-up, 
which makes the NPV of EUS in our study 63%, low compared to literature.[6, 8, 13] The 
low NPV we found is possibly due to factors known to influence the outcome of EUS. In 
3 out of 5 patients with a false negative EUS, during EUS a biliary endoprosthesis was in 
situ. Endoprosthesis are known to influence the outcome of EUS.[7, 14, 15] In one study 
the NPV of EUS in detecting pancreatic masses decreased from 70% to 21% (P<0,001) 
when an endoprosthesis was in situ.[6] Other factors known to influence the outcome 
of EUS are signs of chronic pancreatitis or a recent episode of acute pancreatitis, which 
were present in 4 of our 5 patients with a false negative EUS.[14, 15] Using EUS as imag-
ing method, chronic pancreatitis makes the detection of pancreatic cancer more difficult 
and additional analysis with PET-CT might be perfomed.[16] Also a prominent ventral/
dorsal split may increase the likelihood of a false negative EUS.[14] Endoprosthesis are 
also found to lower the sensitivity and NPV of MDCT by alleviating biliary dilatation and 
producing artifacts that obscure anatomic detail and the assessment of vascular inva-
sion.[16, 17, 18] In our population during analysis with MDCT 26% and during EUS 36% 
had an endoprosthesis in situ.
So in conclusion, in case of an equivocal MDCT in patients with an obstructive 
jaunidice the next step should be EUS, because of the high accuracy in detecting 
pancreatic or peri- ampullary masses and choledocholithiasis. When EUS shows an 
unresectable tumour or doubt about the diagnosis exists, FNA should be performed. We 
strongly advise to perform MDCT and EUS before drainage of the biliary tree with an en-
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doprosthesis. The presence of a biliary endoprosthesis decreases the value of MDCT and 
EUS in the detection of pancreatic or peri- ampullary masses. In addition, preoperative 
biliary drainage in patients undergoing surgery for cancer of the pancreatic head should 
only be done after good consideration, because it increases the rate of complications.
[19] In case of an uncertain diagnosis after (repeated) MDCT-scan or EUS, additional 
imaging with ERCP with biopsy and brush should be performed to identify patients with 
pancreatic or peri-ampullary malignancies. The value of an additional MRI (or MRCP) 
in patients with an obstructive jaundice without a suspected mass or other cause of 
obstruction requires further investigation, since the overall detection rate for pancreatic 
carcinoma is comparable to MDCT.[20-22] MDCT is superior to MRI in assessment of 
locoregional extension of pancreatic carcinomas, since 3D reformations are excellent 
to delineate arterial or venous encasement. [23, 24] The superior tissue contrast of MR 
imaging makes it favourable for the definition of cysts and septations, but suspected be-
nign causes of obstruction preferably need confirmation with cytology of histology. On 
the basis of detection rate, assessment of loco-regional extension and cost-effectiveness 
considerations the diagnostic approach to the characterization of solid pancreatic le-
sions should be performed with MDCT and we suggest the use of MRI when pancreatic 
findings are equivocal or inconclusive and in case of cystic lesions.
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INTRODUCTION
EUS is a sensitive method for detecting intra-intestinal and extra-intestinal mass lesions 
and peri-intestinal lymphadenopathy (1-4). EUS-guided fine needle aspiration (EUS-
FNA) has a diagnostic accuracy of 60% to 90% (5-7). Cytological study of the material 
obtained by FNA allows evaluating cellular findings suggestive of malignancy (aniso-
nucleosis, nuclear membrane irregularity and nuclear enlargement). Unfortunately, 
inflammation causes a reactive and regenerative process leading to cellular changes, 
undistinguishable from well-differentiated neoplasia solely based on cytological evalu-
ation. Moreover, certain neoplasm’s such as lymphoma and stromal tumors are difficult 
to diagnose without histological samples, because in these cases tissue architecture and 
cell morphology are essential for accurate pathological assessment including immuno-
histochemical analysis (5, 8-10).
Whereas FNA only provides cells, largely disrupted from their original arrangement, 
larger-caliber cutting needles allow for true biopsy specimens (11-18). These specimens 
have been obtained by several routes (percutaneous, intraluminal and surgical) (16-22). 
Safety and accuracy of cutting biopsy have been demonstrated (16, 22-24).
Various EUS-guided techniques have been explored to retrieve tissue specimens, in-
cluding FNA and Tru-Cut needles, with variable success and complication rates (25-29). 
Of particular interest is the Quick-Core® needle, designed to operate through an echo-
endoscope. EUS-guided use of Quick-Core® needle has demonstrated that histological 
samples representative of the target organs can be obtained safely (30-31). However, 
there are certain drawbacks with the Quick-Core® needle that restrict its use in clinical 
practice. Most importantly, its diagnostic yield is strongly limited for lesions located in 
pancreatic head due to mechanical friction of the needle firing mechanism ensuing 
from the bended scope position (32-35).
To overcome this limitations a new 19-gauge fine needle biopsy (FNB) device has 
been designed (Cook Endoscopy Inc (Limerick, Ireland). Aim of the present study was to 
evaluate the feasibility, yield and diagnostic accuracy of this newly developed needle. 
Targets included intestinal and extra-intestinal mass lesions and peri-intestinal lymph-
adenopathy.
maTERIal aND mETHODS
Patients, procedure and examination technique
For this multicenter study, the performance data of a newly designed 19-gauge FNB 
from five centers (Marseille, Milan, Rotterdam, Rome, and Santiago de Compostela) were 
pooled. FNB needle was used in consecutive patients referred for EUS-guided tissue ac-
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quisition to evaluate intraintestinal or extraintestinal mass lesions and/or peri-intestinal 
lymph nodes, between March and July 2010.
EUS-FNB was performed using a convex array echoendoscope (Pentax EG-3870UTK® 
or Olypmus UCT-140®). Tissue acquisition was done with the newly designed 19-gauge 
Echotip Ultra FNB needle, featuring ProCore reverse bevel technology (Figure 1). The 
needle is 1.705m long, made of stainless steel with a nitinol stylet. The stylet running 
through the cannula of the needle is matching the tip bevels. The sheat is 5.2Fr and the 
reverse bevel length is 4mm. Handle material is Lexan-121, Polystryene & Dynaflex.
Tissue acquisition was done according to a standard protocol but depending on 
local preference, certain differences were allowed: 1. Puncture with or without stylet, 2. 
Number of to and fro movements within the lesion (1 versus 3-4), 3. Number of passes 
(1 versus 2-3), 4. Use of the stylet versus flushing with water to harvest the core sample 
from the needle. Technical details of the standard tissue acquisition protocol were as fol-
lows. After the target lesion was endosonographically visualized and the region scanned 
for vessels using color and pulsed Doppler, FNB was performed either from duodenum, 
stomach, esophagus or rectum depending on lesion location. The FNB needle was 
advanced into the target tissue under endosonographic guidance. Once the lesion was 
penetrated, the stylet was removed and suction was applied for 10 to 20 seconds using 
a 10mL syringe while moving the needle to and fro within the lesion either 1 time or 3-4 
times. Suction was released before removing the needle. One to three needle passes 
were performed. Tissue samples were recovered in cytolit and/or formalin by pushing 
Figure 1: Detailed image of the tip of the new histology needle showing the notch in which the tissue 
sample is caught during puncture
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the stylet through the needle or by flushing the needle with 5cc of saline. All samples 
were processed at the pathology departments for histological analysis. There was no 
pathologist present in the endoscopy room and FNB samples were recovered and stored 
for further processing by the endoscopist. FNB samples in a particular center were 
evaluated by either one dedicated pathologist with a particular interest and expertise 
in evaluating tissue materials obtained via EUS or by multiple more general oriented 
pathologists. Samples were embedded in paraffin. Tissue sections of 3-4µ were stained 
by the haematoxylin-eosin technique for morphological evaluation and/or different im-
munohistochemical analysis. If pathologists were not able to obtain a core for histologi-
cal evaluation, they processed the same material as cellblock for cytological evaluation.
Gold standard reference diagnosis of malignant versus benign disease
A final diagnosis of malignancy or benignancy was made according to either one of 
the following reference methods: 1) Definite benign or malignant histological diagnosis 
based on surgical resection specimens from operated patients; 2) Cytology or histol-
ogy findings with definite proof of malignancy in patients with unresectable tumors 
according to EUS and CT scan findings and compatible clinical follow-up; 3) Cytology or 
histology findings without proof of malignancy and a minimum clinical follow-up time 
of six months.
Outcome parameters
Primary outcome parameter was the percentage of cases in which pathologist classified 
the quality of the sample as optimal for histological evaluation. Pathologists defined 
optimal histological sample that one suitable for histological evaluation by means of 
being able to obtain a real core sample, including recognizable structures of the tar-
geted lesions. Pathologists grade less than optimal those cases in which the sample 
was suitable for histological evaluation, but without a real core or when the core was 
fragmented and difficult to be evaluated (36-37). Percentage of cases in which a final his-
tological diagnosis was obtained was also evaluated. Visibility of the needle during the 
puncture, ease of FNB needle insertion through the scope, ease of FNB needle removal 
from the scope, ease of removal the stylet after advancement of the FNB needle in the 
target lesion, and optical impression of the tissue sample obtained after puncture by the 
endoscopist were also evaluated.
To assess the optimal tissue acquisition protocol, regression analysis was performed 
including variables such as puncture with or without stylet, number of passes, number 
of to and fro movements, use of stylet versus water flushing to harvest the core sample, 
puncture location (duodenal versus the rest), and whether one dedicated pathologist 
with a particular interest and expertise in evaluating tissue materials obtained via EUS or 
more generally oriented pathologists were involved in the analysis of the sample.
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The study was approved by each local institutional review board and conducted 
in accordance with the Declaration of Helsinki and its amendments, and Good Clinical 
Practice guidelines. All patients provided written informed consent to the study.
Data analysis
Results are shown as percentage and 95% confidence interval (CI). Normally distrib-
uted variables are presented as mean with standard deviation and range. A descriptive 
analysis is performed. Results are compared by chi-square test or Fisher’s exact test as 
appropriate. A multivariate stepwise logistic regression analysis was also performed in 
order to determine variables independently associated to the obtainment of adequate 
histological specimens. Sensitivity, specificity, positive predictive value, negative predic-
tive value, and overall accuracy were also calculated. Because historical information on 
the performance of FNB needle were not available, formal sample size calculation was 
not performed. In order to minimize the impact of a potentially insufficient sample size, 
accuracy data are shown with 95% confidence interval.
RESUlTS
109 patients (mean age 60.3±16.5 years, range 16-88, 57 female and 52 male), with 114 
lesions (mean size 35.1±18.7 mm) were evaluated. Indications are listed in Table 1.
Table 1. Indications for EUS-FNB from all centers, percentage of adequate histology sampling and 
percentage of cases with correcti diagnosis
lesion No. adequate histology
sample, no. (%)
Correct diagnosis,
no. (%)
Pancreatic tumor 47 45/47 (95.7) 42/47 (89.4)
Mediastinal lymph nodes 17 14/17 (82.3) 14/17 (82.3)
Intraabdominal lymph nodes 14 10/14 (71.4) 11/14 (78.6)
Subepithelial tumor 11 10/11 (90.9) 9/11 (81.8)
Intraabdominal masses 5 4/5 (80.0) 4/5 (80.0)
Lung tumor 4 4/4 (100) 4/4 (100)
Perirectal lesion 4 4/4 (100) 4/4 (100)
Diffuse pancreatic enlargement 3 2/3 (66.7) 2/3 (66.7)
Left adrenal gland mass 3 3/3 (100) 3/3 (100)
Masses adjacent to gut 2 2/2 (100) 2/2 (100)
Gut wall thickening 2 2/2 (100) 2/2 (100)
Paravertebral mass 1 1/1 (100) 0/1 (0)
Mediastinal mass 1 1/1 (100) 1/1 (100)
Total 114 102/114 (89.5) 98/114 (85.9)
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When analyzing all 114 cases included in the study, 84 lesions (73.7%) were finally 
considered as malignant and 30 lesions (26.3%) as benign. Final diagnosis was based 
on surgical specimens in 21 cases (15 malignant and 6 benign lesions). In 69 cases final 
diagnosis was based on the cytological or histological findings with definite proof of 
malignancy. Finally, in 24 cases without proof of malignancy final diagnosis was based 
on cytology or histology findings and a median follow-up time of 6.6 months (range 6-8).
EUS-FNB was technically feasible in 112 cases (98.24%). According to lesion location, 
all 79 punctures performed through esophagus, stomach and rectum were successful 
(100%), while two failures (33/35, 94.28%) occurred when puncture was performed 
through duodenum. Two failure cases included an intra-abdominal aorto-cava lymph 
node and a pancreatic head tumor in which removal of the stylet proved impossible.
There were no complications related to the technique.
The FNB device was easy to insert into the scope in all 114 cases (100%). The needle 
emerged from the scope easily in 93 cases (81.6%), with difficulty in 20 cases (17.5%), 
and with great difficulty in one case (0.9%). This appeared to be only a problem when 
punctures were performed through the duodenum with the scope in a bended posi-
tion (57.1% vs 0%, p<0.001). Removing the stylet after puncturing the lesion was easy 
in 75 cases (65.8%), hard in 21 cases (18.4%), and impossible in 2 cases (1.7%). In 16 
cases (14.1%) puncture was performed without stylet. Difficulties in removing the stylet 
was mainly related to punctures performed through the duodenum (79.1% vs 2.6%, 
p<0.001). The visibility of the needle was judged as optimal in 103 cases (90.3%), while 
in the remaining 11 cases suboptimal visibility was mainly related to a reduced visibility 
of the tip of the needle at the site where the notch is located (figure 2).
Figure 2: EUS-guided fine-needle biopsy of an intra-abdominal lymph node, corresponding to a 
lymphoma. The needle and needle tip are well visible.
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Figure 3: Core sample obtained with EUS-guided fine needle biopsy with the new histology needle after 
it has been flushed into a tube containing a liquid-based preparation.
Figure 4: Histological tissue preparation of a pancreatic adenocarcinoma obtained by EUS-guided fine 
needle biopsy (H&E, orig. mag. X 10)
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A sample suitable for pathological evaluation was obtained in 112 lesions (98.24%). 
When evaluating the sample optically after the needle content was flushed into cytolit 
and/or formalin, a tissue core could be observed in 78 cases (68.4%) (Figure 3); a tissue 
core mixed with blood in 15 cases (13.1%), multiple small core fragments in 12 cases 
(10.5%), only blood in 5 cases (4.4%) and scarce sample in 2 cases (1.75%).
Sample quality according to the pathologist was adequate for full histological 
assessment in 102 lesions (89.47%) (Table 1) (Figure 4). In the remaining 10 cases the 
sample was adequate for cytological evaluation (sample was processed as a cellblock).
Regarding the methodology of the procedure, 98 attempts (85.9%) were performed 
with stylet and 16 (14.1%) without stylet. In 96 punctures (84.2%) 3-4 to and fro needle 
movements through a lesion were performed and only 1 movement was done in 16 
punctures (14.1%). In 89 cases (78.1%) only one needle pass was performed, 2 needle 
passes in 20 cases (17.5%) and 3 were done in 5 cases (5.3%). In 47 cases (41.2%) the 
sample was recovered by flushing saline through the needle, in 31 (27.2%) cases by in-
jecting air, and in 34 cases (29.8%) by inserting the stylet through the needle. In 79 cases 
(69.3%) the sample was analyzed by a dedicated pathologist with extensive experience 
in evaluating EUS acquired samples, while in 35 cases (30.7%) this was done by patholo-
gists for whom this was not routine.
At univariate analysis the only variable associated with obtaining an optimal sample 
for histological analysis and making correct final diagnosis was the intervention of an 
experienced pathologist to evaluate the sample (table 2). In the multivariate stepwise 
logistic regression analysis this did not change (odds ratio 6.04 (95%CI 1.43-25.53); 
p=0.014 and odds ratio 3.19 (95%CI 1.01-10.10); p=0.048, respectively).
A final diagnosis was provided in 112 (98.2%) cases, and in 98 (85.96%) this diagnosis 
proved to be correct according to the gold-standard (97 cases with the histological 
Table 2. Univariate analysis of variables associated with obtaining an optimal sample for histological 
evaluation and obtaining a correct final diagnosis
Variables Obtaining an optimal sample for 
histological evaluation OR (95% CI); 
P value
Obtaining a correct final 
diagnosis OR (95% CI); 
P value
Puncture through duodenum vs other 
sites
0.38 (0.11 – 1.30); p = .11 0.50 (0.17 – 1.48); p = .21
Puncture with stylet vs without stylet 0.52 (0.06 – 4.39); p = .54 0.36 (0.04 – 3.00); p = .33
No. of to-and-fro movements (3-4 vs 1) 0.52 (0.06 – 4.39); p = .54 0.36 (0.04 – 3.00); p = .33
No. of needle passes (2-3 vs 1) 0.67 (0.17-2.56); p = .56 0.51 (0.16-1.66); p = .26
Retrieving the sample (air/stylet vs saline 
solution)
0.43 (0.11-1.71); p = .22 0.60 (0.19-1.87); p = .38
Dedicated pathologist vs multiple 
pathologists
5.55 (1.54 – 19.94); p = .004 3.56 (1.20-10.53); p = .02
OR, Odds ratio; CI, confidence interval
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evaluation and one by the cell-block analysis). Table 1 shows the percentage of correct 
diagnosis. When evaluating the performance of the needle for the detection of malig-
nancy, sensitivity, specificity, positive predictive value, negative predictive value, and 
overall accuracy were 90.2% (95%CI: 83.2-97.3), 100% (95%CI: 98.3-100), 100% (95%CI: 
99.3-100), 78.9% (95%CI: 64.7-93.2), and 92.9% (95%CI: 87.6-98.1), respectively.
DISCUSSION
The present study shows that in the majority of cases it is possible to obtain adequate 
tissue samples for histological evaluation with the use of a newly designed EUS histol-
ogy needle. The percentage of correct diagnoses reaches 86%, with an overall diagnostic 
accuracy for the detection of malignancy of 92.9%. The success of this novel technique 
seems to be dependent on the involvement of a pathologist with experience in handling 
and dealing with materials obtained by FNA/FNB. Differences in the technique of tissue 
acquisition did not show statistical significance in the present data set.
In many patients it is essential to obtain a tissue diagnosis to guide treatment. 
EUS-guided tissue sampling has emerged as a valuable technique for many indications 
(4). Conventional EUS-FNA has certain limitations. Its sensitivity drops by 10-15% in 
the absence of an on-site pathologist to evaluate the cellular adequacy of the samples 
(36). Without on-site evaluation, the recommended number of passes is 5-7 for solid 
pancreatic lesions and 2-3 for lymph nodes. In pancreatic cases, this necessitates the 
use of additional needles in 15% of cases, increasing the overall procedural time (9). 
The lack of cellular arrangement and preserved tissue architecture in cytology samples 
limits the possibility of making an adequate diagnosis (34). Furthermore, the yield of 
cytology in certain tumors such as lymphoma, poorly differentiated adenocarcinoma, 
and stromal tumors is limited; as for adequate diagnosis and subtyping in these cases 
immunohistochemistry is of pivotal importance. Sensitivity of EUS-FNA is also uniformly 
poor when used in certain anatomic locations such as thickened gastrointestinal wall or 
focal intramural lesions (5, 38).
In order to circumvent these problems related to cytological evaluation, sev-
eral attempts have been undertaken to obtain EUS-guided core tissue specimens for 
histopathological analysis. Initial efforts were directed towards using large caliber 
(18-21-gauge) needles (25, 26) or even the standard 22-gauge needle (27). For instance, 
Binmoeller et al (25) were able to obtain adequate tissue core specimens in 40 out of 
45 patients with pancreatic masses by using an 18-gauge needle. However, sensitivity 
for detection of malignancy was only 53%. On the other hand, Iglesias-Garcia et al (27) 
were able to obtain an adequate tissue sample for histological diagnosis of pancreatic 
masses in 95% of patients with a high diagnostic accuracy by recovering the pancre-
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atic EUS-FNA specimen into a 10% formol solution by injection of saline through the 
needle. However, no further studies confirmed these data. Nowadays, the most widely 
use needle for obtaining histological samples by EUS is the Quick-Core® needle (29), 
which allows obtaining histological samples safely and being representative of the 
targeted organs (30, 31, 35). Several nonrandomized retrospective studies have com-
pared sensitivity and diagnostic accuracy of EUS-FNA and EUS-guided biopsy with the 
Quick-Core® needle. Although biopsy with Quick-Core® needle has no clear advantage 
over EUS-FNA in terms of overall sensitivity and diagnostic accuracy, it does provide a 
more specific diagnosis in selected cases (34, 39) requiring less needle passes (29). More 
recently, combination of EUS-biopsy with Quick-Core® needle and EUS-FNA has shown 
a higher overall diagnostic yield compare to when each technique is performed alone 
(40-42). The overall accuracy of EUS-biopsy in these latter studies ranges between 61% 
and 84%. In our study, using the EUS-FNB needle a sample adequate for full histological 
evaluation was obtained in about 90% of the evaluated lesions. In the remaining cases, 
moreover, the collected sample allowed for cytological or cell block analysis.
In cases in which only one needle pass was performed, the overall accuracy of EUS-
FNB was 89.6%. It is also noteworthy that such high accuracy rates were obtained from 
all sorts of lesions. In fact, focusing on some specific cases, we were able to correctly 
diagnosis and subclassifing different types of lymphomas, subepithelial tumors (GIST vs. 
leiomyomas), and pancreatic metastasis from different primaries such as colon cancer 
and lung cancer, and autoimmune pancreatitis. This illustrates the potential benefit and 
impact on patient management of this novel EUS-FNB device. An important advantage 
of this device is that overcomes certain shortcomings of Quick-Core® needle. Diagnostic 
yield of Quick-Core® needle biopsy is strongly limited for lesions that need to be punc-
tured from duodenum, caused by the rigidity of the needle, limiting the degree of the 
echoendoscope tip deflection required to bring the target lesion into an adequate posi-
tion for puncture (29, 32, 34, 35). Also, the bended scope position induces considerable 
friction within the needle firing mechanism that may impair its proper function. With the 
novel EUS-FNB histology needle, puncturing from a duodenal position was successful in 
33 out of 35 cases and was not negatively associated with the sample quality. However, 
puncturing from a duodenal position was more difficult and in many cases the EUS-FNB 
needle needed to be pushed out of the scope in stomach before advancing the scope 
into the duodenum. EUS-FNB through the esophagus, stomach and rectum was easy 
and uneventful in the remaining 79 cases.
A critical point in the present study is the use and definition of the gold-standard 
reference method. Ideally, when the pathological results of the EUS-FNB are negative, 
histological confirmation from surgical specimens would be the gold-standard, which 
cannot be obtained for ethical reasons in patients in whom surgery is not indicated. 
In these specific cases, clinical follow-up for at least 6 months with repeated imaging 
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procedures (EUS and CT) use in our study although not ideal is a well-accepted reference 
standard.
Safety of EUS-FNA is well established (43) and complication rates range between 1% 
and 2.5% (44). Small cases series have reported complications rates from EUS-guided 
Quick-Core® biopsy to range from 2% to 4%, with the largest study showing a complica-
tion rate of 2.4% (35). In our present series of 114 cases there were no complications 
associated to the procedure. Therefore, the use of EUS-FNB needle seems as safe as the 
standard FNA or Quick-Core® needle.
In conclusion, performing a EUS-guided biopsy with the new histology needle is 
feasible and safe for histopathology diagnosis of intraintestinal and extraintestinal mass 
lesions in this consecutive series of patients. It offers the possibility to obtain a core 
sample for histological evaluation in the majority of cases, with an overall diagnostic 
accuracy over 85%. From the limited data available, with all the reservations taking 
into account the design of this study, the observation emerges that a dedicated expert 
pathologist is likely to have significant impact on final accuracy.
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abSTRaCT
aim
To evaluate the interobserver agreement among pathologists in grading the quality of 
specimens obtained with a new 19-gauge endoscopic ultrasound histology needle.
methods
This multicentre prospective study involved 50 slides prepared using material obtained 
with the new needle. Five experienced pathologists independently reviewed all of the 
samples, and made assessments of the following features: the presence of a core, the 
adequacy of the specimen, the interpretability of the specimen, and the possibility of 
performing additional analyses using the material. Interobserver agreement, deter-
mined by Fleiss’ kappa statistic and 95% confidence intervals (CIs), was used as the 
primary outcome measure.
Results
Overall, the presence of a core was reported in 88% of cases with good agreement among 
the pathologists (κ= 0.61; 95% CI 0.52–0.70). The specimens were adequate in 91.2% of 
cases, and Fleiss’ κ was 0.73 (95% CI 0.61–0.81). The interpretation of the specimens was 
reported to be ‘easy’ in approximately 87% of cases, with moderate agreement among 
the pathologists (κ = 0.44; 95% CI 0.35–0.53). The possibility of performing additional 
analyses from the same sample was rated as positive in approximately 91%, with good 
agreement (κ = 0.66; 95% CI 0.58–0.75).
Conclusions
There was excellent interobserver agreement among pathologists in the assessment of 
the histological material, especially with regard to sample adequacy.
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INTRODUCTION
Endoscopic ultrasound (EUS) is an established method for detecting intraintestinal and 
extraintestinal mass lesions and peri-intestinal lymphadenopathy.1–4
The diagnostic yield of EUS-guided biopsies depends on the characteristics of target 
tissues and technical factors, such as type of needle used, biopsy technique, and sample 
processing method. Other important factors include expertise and clinical interaction 
among endosonographers and pathologists; this is particularly facilitated by on-site 
interpretation, which significantly increases the diagnostic yield of EUS-guided fine 
needle aspiration (FNA).5,  6 However, depending on logistics and costs, rapid on-site 
cytopathology is not universally available, and, in addition, the yield of cytology in 
certain tumours, such as lymphoma, well-differentiated adenocarcinoma, and stromal 
tumours, is limited, because in these cases the diagnostic workup frequently requires 
immunophenotypic and molecular studies.7–10
Because of these inherent limitations of cytology, there has been increasing in-
terest in histological sampling using needles of a larger calibre. Various EUS- guided 
techniques have been explored for the retrieval of tissue specimens, including FNA and 
Tru-Cut needles, with variable rates of success and complications.11–16
A new 19-gauge fine needle biopsy (FNB) device has recently become available 
(EchoTip ProCore nee- dle; Cook Endoscopy Inc, Limerick, Ireland). We have recently 
published a multicentre study assessing the feasibility and diagnostic accuracy of this 
newly developed EUS 19-gauge histology needle. The study found that this was an easy 
and reliable method for obtaining histological samples of both pancreatic and non-
pancreatic lesions, with an overall accuracy of 86% with only one needle pass.17
One of the key factors in obtaining consistent diagnostic accuracy using this tech-
nique is the involvement of a dedicated gastrointestinal pathologist with experience in 
handling and dealing with materials obtained by FNA.15 However, the reproducibility of 
these results and the interobserver variation among pathologists remain unclear.
The aim of this study was to evaluate the interobserver agreement among gastroin-
testinal pathologists in grading the quality of specimens obtained using the new EUS 
histology needle. Samples from intraintestinal and extraintestinal mass lesions and 
peri-intestinal lymphadenopathy were eligible for this study.
maTERIalS aND mETHODS
For this multicentre study, 50 histological slides obtained with the ProCore needle 
from five centres (Marseille, Milan, Rome, Rotterdam, and Santiago de Compostela) 
were pooled. The study was approved by each local institutional review board. Be-
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cause no direct intervention was made in these patients, informed consent was not 
mandatory.
Between September and December 2010, the ProCore needle was used in con-
secutive patients referred for EUS-guided tissue acquisition to evaluate intraintestinal or 
extraintestinal mass lesions and/or peri-intestinal lymph nodes.
EUS technique and specimen processing
EUS-guided FNB was performed using a convex array echoendoscope (Pentax EG-
3870UTK or Olympus UCT-140/180). All procedures were performed by experienced 
endosonographers, and only one pass was performed.
Tissue acquisition was performed according to a standard protocol, so that each 
centre used the same technique: after the target lesion had been endosonographically 
visualized, and the region had been scanned for vessels by the use of colour and pulsed 
Doppler, FNB with the 19-gauge ProCore needle was performed, from the duodenum, 
stomach, oesophagus, or rectum, depending on lesion location. The FNB needle was 
advanced into the target tissue under endosonographic guidance. Once the lesion 
had been penetrated, the stylet was removed, and suction was applied with a 10-ml 
Figure 1. A tissue core fragment obtained using the ProCore 19-gauge needle, with a dense lymphoid 
infiltrate. This fragment allowed complete immunophenotypic and molecular evaluation, with a final 
diagnosis of T-cell lymphoma.
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syringe. The needle was kept still for approximately 10 s, and was then moved to and fro 
within the lesion three times. Suction was released before removal of the needle. Tissue 
samples were recovered in CytoLyt and/or formalin by flushing the needle with 5 ml 
of saline solution. All samples were processed at the pathology departments for histo-
logical analysis, and in each centre were assessed by one dedicated pathologist with a 
particular interest in evaluating tissue materials obtained via EUS; all of the pathologists 
worked in academic referral centres. Samples were embedded in paraffin following ar-
rival at the pathology laboratory, and tissue sections of 3–4 micrometers were stained 
with haematoxylin and eosin for morphological evaluation.
Study definition
To assess interobserver agreement in analysing specimen quality, the pathologists from 
the five European centres met together (C.D., K.B., G.M., I.A., and G.R.), each of them 
bringing the slides from 10 consecutive cases performed in his or her own centre. Each 
pathologist, independently and blinded to the final diagnosis, made assessments for 
the following features: the presence of a tissue core, the adequacy and interpretability 
of the specimen, and the possibility of performing additional analyses on the acquired 
material, such as immunohistochemistry and fluorescence in-situ hybridization. For 
each specimen, each pathologist received a structured, predefined worksheet to record 
all relevant data.
The adequacy of the specimen for diagnosis was defined as the clear presence of 
target organ cells that allowed the pathologist to obtain an accurate diagnosis. The 
interpretation of the specimen was judged as easy or not easy, taking into account the 
percentage of pathological tissue as compared with the rest of the material on each 
slide. To quantify this, we considered three different classes: < 50% of pathological tissue 
(class 0), between 50% and exactly 70% (class 1), and >70% (class 2).
Each pathologist, in turn, showed his or her own specimens at the microscope (10 
non-selected cases from each centre, numbered from 1 to 10). The microscope room 
was equipped to allow simultaneous visualization of each slide from different observer 
positions by multiple investigators, to allow independent reviewing and scoring. Each 
reviewer was provided with the target organ site, but no other clinical information was 
given. The histological slides were then independently reviewed by five pathologists 
who were blinded to the identity of the patient and the final diagnosis.
After all worksheets had been completed, the data were collected and analysed by 
an endosonographer and a statistician not involved in the evaluation of the slides (M.C.P. 
and M.B.).
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Statistics
Results obtained from different pathologists and different centres were compared by 
use of Pearson’s chi-square test, in order to evaluate possible systematic differences 
(Table 1).
Interobserver agreement was determined by the use of kappa statistics [Fleiss’ 
κ-statistic and 95% confidence intervals (CIs)]. κ -Statistics are widely used and accepted 
coefficients that provide a measure of observer agreement, accounting for agreement 
other than that which occurs by chance alone. κ -Statistics were interpreted according 
to the convention of Landis and Koch18: <0, no agreement; 0–0.20, slight agreement; 
0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agree-
ment; and 0.81–1.0, almost perfect agreement. Statistical significance was established 
as P < 0.05 (two-tailed). All analyses were carried out using STATA version 11.0 (Stata 
Corp., Austin, TX, USA).
Table 1. Rates for tissue cores, sample adequacy and interpretation analysed separately for each of five 
pathologists, with p-values and κ-statistics.
Pathologist
A B C D E p-value Agreement κ (95% CI)
Presence of core (%) 92 88 90 76 92 0.08 0.61 (0.52-0.70)
Slide adequacy (%) 94 92 92 88 90 0.86 0.73 (0.61-0.81)
Interpretation easy (%) 94 86 84 80 90 0.27 0.44 (0.35-0.53)
Further techniques (%) 88 94 86 96 90 0.39 0.66 (0.58-0.75)
CI, confidence interval
RESUlTS
A total of 50 cases were reviewed by five experienced pathologists: 23 samples were 
from the pancreas, 15 from lymph nodes, seven from submucosal lesions, two from 
abdominal masses, one from the adrenal gland, one from a mediastinal mass, and one 
from a peritoneal nodule.
Overall, the presence of a tissue core (Figure 1) was reported in 88% of cases, with 
good agreement among the pathologists (κ = 0.61; 95% CI 0.52– 0.70). We considered 
whether the percentage of slides with a core differed across observers, but we did not 
find a significant difference (P = 0.08).
The specimens were adequate in 91.2% of cases. Specimen adequacy did not sig-
nificantly differ among pathologists (P = 0.86), and Fleiss’ κ was 0.73 (95% CI 0.61–0.81).
For pancreatic specimens, the presence of the core and the sample adequacy were 
significantly better for masses obtained from the stomach and the bulb than for lesions 
obtained from the second part of the duodenum (95.6% versus 71%, P = 0.003, and 
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100% versus 65.5%, P = 0.001, respectively). Agreement among pathologists for pancre-
atic specimens was almost perfect (κ = 0.81; 95% CI 0.68–0.94).
When pancreatic specimens were compared with all other specimens (mostly lymph 
nodes and submucosal lesions), there was no significant difference regarding the pres-
ence of a tissue core (P = 0.09), but the sample adequacy of non-pancreatic lesions was 
significantly better (P = 0.001). The interpretation of the specimens was reported as 
‘easy’ in approximately 87% of cases, with moderate agreement among the pathologists 
(κ = 0.44; 95% CI 0.35–0.53). The interpretation of pancreatic specimens was judged as 
‘easy’ in approximately 84% of cases, and there was no significant difference among the 
observers (P = 0.6).
Rates for tissue cores, sample adequacy and interpretation, analysed separately for 
each of five pathologists, with P-values and κ -statistics, are reported in Table 1.
Overall, the possibility of performing additional analyses from the same sample, such 
as immunohis- tochemistry or fluorescence in-situ hybridization, was rated as positive 
in approximately 91% of samples, with good agreement among pathologists (κ = 0.66; 
95% CI 0.58–0.75).
In analysis of the percentage of pathological tissue reported by the observers, 69% 
of samples were in class 2 (>70% of pathological tissue), 27% were in class 0 (<50%), and 
4% were in class 1 (between 50% and 70%). The relationship between pathological tis-
sue percentage and specimen adequacy is reported in Table 2. We observed a significant 
correlation between the amount of tissue and the percentage of specimens judged as 
adequate for diagnosis (P = 0.001).
Table 2. Relationships between different classes of pathological tissue and specimen adequacy (1, 
adequate; 0, not adequate).
Pathological tissue class Adequacy
0 1 Total
0 (≤ 50%) 19 (90.48) 48 (21.24) 67 (27.13)
1 ( >50% and ≤ 70%) 0 (0.00) 10 (4.42) 10 (4.05)
2 ( >70%) 2 (9.52) 168 (74.34) 170 (68.83)
Total 21 (100) 226 (100) 247 (100)
Data are given as n (%)
DISCUSSION
To our knowledge, this is the first study reporting on interobserver reproducibility 
among pathologists in evaluating the quality of specimens obtained through EUS with 
a needle of large calibre. We found that this new EUS histology needle provides histo-
logical samples that are adequate for diagnosis in the majority of cases (91.2%). The 
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reproducibility among five expert pathologists in the assessment of the adequacy was 
good (κ = 0.73), regardless of the characteristics of the target lesion sampled.
In a recently published multicentre study, we assessed the feasibility and diagnostic 
accuracy of this newly developed EUS 19-gauge histology needle, and reported an 
easy and reliable way of obtaining histological samples of both pancreatic and non-
pancreatic lesions with an overall accuracy of 86% with only one needle pass.17 In a 
multivariate analysis of our data, the only variable associated with obtaining an optimal 
sample for histological analysis and making a correct final diagnosis was the interven-
tion of an experienced dedicated pathologist to evaluate the sample as compared with 
a general pathologist. Since the role of the pathologist appears to be pivotal in the 
interpretation and usability of this tissue acquisition method, the goal of the current 
study was to evaluate the reproducibility of interpretation and perceived adequacy 
of the specimens obtained using the newly designed needle. Only two studies in the 
literature have analysed the reproducibility of cytopathological diagnosis of specimens 
obtained with EUS-guided FNA, and both documented good diagnostic agreement 
between experienced cytopathologists for samples from mediastinal lymph nodes and 
mass lesions.19,20
For this study, each pathologist contributed slides of 10 consecutive patients. 
Consequently, we cannot completely exclude the possibility that pathologists could 
recall their own slides, thereby introducing a potential bias. The effect of this theoretical 
bias on overall agreement should have been towards the null value (decreasing overall 
interobserver agreement: in fact, a pathologist not completely blinded with respect to 
his or her own slides could have a lower level of agreement with all other colleagues). 
A sensitivity analysis repeating the κ calculation, excluding data given by each patholo-
gist when analysing his or her own slides, was performed, and the results did not change 
significantly (data shown in Table 3).
Our study included a large percentage of pancreatic lesions (44%), followed by lymph 
nodes (30%) and submucosal lesions (14%). This is of interest, because the differential 
diagnosis of pancreatic masses is a frequent clinical dilemma, and the cytopathological 
Table 3. Rates for tissue cores, sample adequacy and interpretation analysed separately for each of five 
pathologists, with p-values and κ-statistics, excluding data given by each pathologist when analysing his 
or her own slides (total number in the table = 200).
Pathologist
A B C D E p-value Agreement κ (95% CI)
Presence of core (%) 90 92 90 75 90 0.06 0.59 (0.48-0.70)
Slide adequacy (%) 92 100 90 85 87 0.16 0.67 (0.56-0.79)
Interpretation easy 92 90 82 75 92 0.09 0.40 (0.29-0.51)
Further techniques 85 97 82 95 90 0.12 0.70 (0.59-0.82)
CI, confidence interval
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interpretation of pancreatic lesions is considered by pathologists to be challenging, es-
pecially for well-differentiated carcinoma and those with extensive necrosis. Moreover, 
there are lesions that can show features of both reactive and malignant conditions, and, 
although ductal adenocarcinoma is the most frequent cause of pancreatic masses, other 
neoplasms with different prognoses and treatment options can arise not infrequently 
within the pancreas. For this reason, we separately analysed pancreatic samples, but 
we did not find any significant difference among pathologists in grading adequacy (P 
= 0.92), the presence of a core (P = 0.2), or interpretation (P = 0.6); perhaps even more 
importantly, the evaluation of the adequacy of pancreatic specimens showed the best 
agreement among observers (κ = 0.81), proving that the needle provided reliable tissue 
sampling even in pancreatic masses.
In our study, the adequacy of the specimens significantly improved when the 
percentage of pathological tissue increased, and although this is not synonymous with 
obtaining more material, it seems very likely that, for the evaluation of histological 
material, more is actually better.
The ability to routinely apply additional techniques, such as immunohistochemis-
try or fluorescence in-situ hybridization, on the same material will very likely become 
increasingly important in the near future. Recent advances in molecular diagnostic 
techniques have made it possible to carry out various types of immunostaining and 
gene analysis with a small amount of specimen obtained by EUS-guided FNB.21 It seems 
very likely that medical oncologists will demand a histological specimen of a tumour, es-
pecially in the era of neoadjuvant treatment, to further tailor and individualize therapy 
for a specific patient.
The results of our study are based on the judgement of five highly experienced 
pathologists in the assessment of this type of sample: this is a potential limitation of this 
study, because this does not necessarily represent everyday clinical practice in many 
community hospitals. In the future, it would be of interest to evaluate the interobserver 
agreement among more generally oriented pathologists.
In conclusion, this study shows that the new EchoTip ProCore needle not only 
consistently provides endosonographers and pathologists with adequate histological 
material, but also guarantees excellent interobserver agreement between pathologists 
regarding sample adequacy. These results are particularly encouraging, given that 
samples were largely obtained from lesions in challenging locations, including pancre-
atic head tumours, with only one needle pass.
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INTRODUCTION
Indications to perform endoscopic ultrasonography (EUS) have changed dramatically 
with the introduction of curvilinear-array echoendoscopes. From a solely observational 
diagnostic tool, EUS has turned into an advanced interventional technique offering the 
possibility to not only acquire tissue samples by means of fine needle aspiration (FNA), 
but also to introduce for example drugs by fine needle injection (FNI). In addition, vari-
ous accessories such as radio-opaque fiducials or guidewires can be advanced through 
a needle into a target structure or lesion. Using such guidewires placed under EUS guid-
ance, advanced types of cyst, biliary, and pancreatic drainage procedures can be carried 
out. In this chapter, indications and techniques of advanced interventional therapeutic 
endosonography will be discussed.
EqUIPmENT
Therapeutic endosonography became possible by the introduction of curvilinear-array 
echo endoscopes in which the EUS image is parallel to the working channel, allowing 
instruments to be passed in the same plane under real-time ultrasonographic (US) 
guidance. Table 1 provides an overview of the presently available curvilinear-array 
echoendoscopes along with some of their most important features. To facilitate ma-
nipulation of FNA needles or other devices, curvilinear array echoendoscopes, alike 
side-viewing ERCP endoscopes, have an elevator. The working channels of curvilinear-
array echoendoscopes are as large as 3,8 mm to allow passage of accessories up to 10 
Fr. Image resolution and penetration depth of the US image are inversely related and 
depended on the frequency; the higher the frequency, the higher the image resolution, 
but the lower the penetration depth (approximately 2 cm), the lower the frequency, 
Table 1. Presently commercially available electronic curvilinear array echoendoscopes
Instrument US scan 
angle
Frequency 
(MHz)
Tip 
diameter 
(mm)
Insertion 
tube (mm)
Channel 
(mm)
Video: Field of 
view / direction
Tip deflection: 
up/down
Olympus
GF-UC140(P)-AL5 180° 5, 6, 7.5, 10 14.6 (14.2) 12.8 (11.8) 3.7 (2.8) 100° / 55° 
forward oblique
130° / 90°
GF-UC160(P)-OL5 150° 7.5 14.6 (14.2) 12.6 (11.8) 3.7 (2.8) 100° / 55° 
forward oblique
130° / 90°
Pentax medical
EG-3870UTK 120° 5, 7.5, 10 12.8 12.8 3.8 120° / 50° 
forward oblique
130° / 130°
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the lower the image resolution, but the higher the penetration depth (approximately 
7 cm). With the exception of a prototype forward scanning curvilinear-array echoendo-
scopes (XGiF-UCT160) 1, all devices have endoscopic video imaging oblique to the shaft. 
Curvilinear-array echoendoscopes, alike radial devices, have a separate channel to allow 
for water inflation of a disposable balloon mounted on the tip of the instrument. This 
water-filled balloon improves acoustic coupling for transmission of US waves through 
the gastrointestinal wall. However, because acoustic coupling can also be achieved by 
gently maneuvering the transducer onto the mucosa, many endosonographists do not 
use a balloon when using a curvilinear-array echoendoscopes. There is a variety of EUS 
accessories including FNA needles in three different sizes (25, 22, and 19-gauge). For in-
terventional EUS purposes a 22-gauge needle may suffice in cases in which non-viscous 
fluids are to be injected. In other cases, and more in particular in circumstances in which 
a guidewire or fiducials are to be introduced, a 19-gauge needle is mandatory. For EUS-
guided celiac plexus neurolysis a special 20-gauge needle device has been developed 
(Cook Endoscopy, Winston-Salem, USA).
EUS-GUIDED CElIaC PlExUS NEUROlYSIS
In a recent meta-analysis by Yan and co-workers of five randomized controlled studies 
with a total of 302 patients, a disappointing effect of percutaneous or intraoperative 
celiac plexus neurolysis (CPN) on pain management was shown 2. There was a statisti-
cally significant difference in pain scores in favor of CPN, albeit with minimal clinical 
significance. The weighted mean difference in pain scores between both conventional 
treatment (analgesics) and CPN was only 6%. In light of this disappointing clinical effect, 
it has been suggested that the limited efficacy of percutaneous CPN may be caused 
by inadequate targeting of alcohol injection at the site of the celiac plexus. In 1996, 
Wiersema and co-workers introduced a new and possibly more effective technique to 
carry out a celiac plexus neurolysis (CPN) under EUS-guidance  3. In this technique, a 
puncture needle is inserted through the dorsal stomach wall under real-time EUS guid-
ance, immediately adjacent and anterior to the lateral aspect of the aorta at the level 
of the celiac trunk (figure 1). Once the needle is positioned 3 to 5 ml of bupivacaine 
(0.25%) is injected for local anaesthesia followed by 10 ml pure alcohol (96%). This is 
then repeated at the opposite site. Some prefer not to inject bilaterally, but inject in the 
midline anteriorly to the celiac trunk. There are no data available showing that either 
one of these techniques is superior. The EUS-guided approach is considered safer than 
the traditional percutaneous approach because of its close approximation to the celiac 
trunk avoiding puncturing a needle alongside the spine or through intra-abdominal 
organs.
Therapeutic EUS 93
7
No studies have been published comparing percutaneous CPN with EUS-guided 
CPN, nor any controlled randomized trials comparing EUS-guided CPN with conven-
tional opioid treatment. EUS-guided CPN has been utilized in patients with painful 
chronic pancreatitis and patients with oncologic type pain due to inoperable pancreatic 
carcinoma. For the latter indication, two prospective cohort studies have been pub-
lished. Gunaratnam and co-workers performed a study in 58 patients of whom 78% 
experienced a decline in pain scores after the EUS-guided CPN 4. This effect lasted for 24 
weeks when adjusted for morphine use and adjuvant therapy. Five patients experienced 
procedure-related transient abdominal pain. No major complications were seen. In the 
second prospective study performed by Wiersema and co-workers, 30 patients (pancre-
atic carcinoma n=25, intra-abdominal metastases n=5) underwent EUS-guided CPN  3. 
Pain scores were significantly lower compared with baseline scores at 2, 4, 8, and 12 
weeks after EUS-CPN. At these follow-up intervals, 82% to 91% of patients required the 
same or less pain medication than at baseline and 79% to 88% of patients had persistent 
improvement in their pain score. Complications were minor and consisted of transient 
diarrhea in four patients. Recently, Levy and co-workers showed that celiac ganglia can 
be visualized at EUS 5. Ganglia were typically seen between the celiac trunk and the left 
adrenal being hypoechoic, oblong or common shaped, often with an irregular edge, 
and often containing a hyperechoic focus or strands. There size ranged from 2 by 3 mm 
to 7 by 20 mm. The total number of ganglia in patients ranged between 1 and 4 and 
more than 1 ganglion was seen in 5 out of 9 patients. The authors speculated that direct 
targeting of these ganglia might improve the efficacy of the EUS-guided CPN. Whether 
such an approach would be feasible and leads to an improved outcome with respect 
Figure 1. EUS- guided celiac plexus neurolysis.
1a 1. abdominal aorta, 2: celiac trunk, 3: superior mesenteric artery. The celiac trunk is visualized by 
tracing the aorta as the first vessel that braches of the vessel below the diaphragm. The needle (white 
arrow) is advanced just above the celiac trunk. 1b. Scope is torqued a few degrees laterally and the needle 
(white arrow) is advanced further alongside the celiac trunk. Once alcohol injection starts, the image gets 
blurred. This procedure is repeated at the other side.
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to pain control remains to be proved. Recently, Gleeson and co-workers prospectively 
showed that in a series of 200 patients celiac ganglia were identified in 81% of cases, 
typically located to the left of the celiac artery, anterior to the aorta  6. Future studies 
should address questions such as whether EUS-guided CPN is superior to conventional 
medical treatment and percutaneous CPN and whether direct EUS-guided targeting of 
celiac ganglia has additional treatment benefits.
EUS GUIDED FNI IN TREaTmENT OF PaNCREaTIC CaNCER
Based up on the safety and feasibility profile of FNA and experiences with EUS-guided 
CPN, FNI has gradually matured and expanded the indication for interventional EUS 
even further. At present, EUS FNI for intratumoral pancreatic cancer therapy involves an-
titumoral agents, immunotherapy, and ablative techniques. In the past years a number 
of studies have been published with different agents injected by EUS-FNI in pancreatic 
tumors including lymphocyte cultures (Cytoimplant) 7, viral vectors (TNFerade) 8, 9, and 
oncolytic viruses (ONYX-015) 10.
Chang and co-workers performed a phase 1 trial in which EUS-FNI intratumoral 
injections of activated alogenic mixed lymphocyte culture (Cytoimplant) were given in 
8 patients with unresectable pancreatic cancer 7. Various doses were given by a single 
injection. There were no procedure related complications, but grade 3 and 4 toxicities 
occurred in 7 patients, the most frequent one being fever. All toxicities were reversible. 
On follow-up investigations by computed tomography there was a partial response in 
two, minimal response in 1, stable disease in 3, and progression of disease in 2 patients. 
A randomized trial comparing Cytoimplant with gemcitabine was started, but is cur-
rently not recruiting patients. Apparently, the study was stopped prematurely due to a 
worse outcome in the Cytoimplant group, but results have not been published yet.
TNFerade is a replication deficient adenovirus vector that incorporates the human 
tumor necrosis factor alpha gene which is regulated by a radiation inducible promoter 
(Egr-1). Animal data in mice provide rational for local delivery of human tumor necrosis 
factor alpha in which a host dependant response(s) for TNFerade was found on primary 
lesion as well as lymph node metastasis 11. Farrell and co-workers conducted a phase I/
II multicenter trial in which TNFerade is injected intratumorally by EUS-FNI, computed 
tomography, or percutaneous ultrasound guidance (PUG) in combination with con-
tinuous intravenous infusion of 5-fluorouracil (200 mg/m2/day, 5 days per week) and 
radiotherapy (50 Gy)  8. Preliminary data on 50 patients of which 27 had delivery by 
EUS-FNI and 23 had delivery by PUG did not show significant differences in treatment 
response based on the route of delivery. A partial response was seen in 13% versus 10% 
and stabilization in 73% versus 75% of patients, respectively. Dose limiting toxicity was 
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seen in 3 patients after EUS-FNI, with pancreatitis in two and biliary obstruction in one. 
Meanwhile a multicenter phase II/III trial is carried out in which patients with unresect-
able pancreatic adenocarcinoma are randomized to be treated according Standard Of 
Care (SOC) therapy alone or TNFerade with SOC. Final results are eagerly awaited with 
an interim analysis showing a trend towards an improvement of one-year and overall 
survival with TNFerade 9.
ONYX-015 (Onyx Pharmaceuticals,USA) is an oncolytic attenuated adenovirus 
modified selectively to replicate in and kill cells that harbor p53 mutations. Hecht and 
co-workers undertook a trial of the feasibility, tolerability, and efficacy of EUS injection 
of ONYX-015 into unresectable pancreatic carcinomas 10. Twenty-one patients with lo-
cally advanced adenocarcinoma of the pancreas or with metastatic disease, but minimal 
or absent liver metastases, underwent eight sessions of ONYX-015 delivered by EUS 
injection into the primary pancreatic tumor over 8 weeks. The final four treatments 
were given in combination with gemcitabine. After combination therapy, 2 patients had 
partial regressions of the injected tumor, 2 had minor responses, 6 had stable disease, 
and 11 had progressive disease or had to go off study because of treatment toxicity. No 
clinical pancreatitis occurred despite mild, transient elevations in lipase in a minority of 
patients. Two patients had sepsis before the institution of prophylactic oral antibiotics. 
Two patients had duodenal perforations from the rigid endoscope tip. No perforations 
occurred after the protocol was changed to transgastric injections only.
There are two orphan techniques which are not so much ‘fine needle injection’ 
procedures but comprise of ‘fine needle introduction’ of an accessory device aimed to 
destroy the tumor mass. One of these techniques is EUS guided radiofrequency ablation 
which has been tested some years ago in a pig model 12. Although complications were 
relatively mild and pathology showed a well demarcated acute coagulation zone of 8 to 
10 mm in all specimens, no subsequent (human) trials have been undertaken to further 
explore the use of this technique. The same holds true for yet another experimental 
technique, EUS guided photodynamic therapy, in which tumor damage is induced by 
photochemical tissue necrosis after intravenous administration of a photodynamic 
agent. This was also tested in a pig model 13. Three pigs were pretreated with porfimer 
sodium. Next, a laser fiber with a 1 cm cylindrical light diffuser was passed through a 
19 G needle into the liver, kidney, spleen, and pancreas. Energy was delivered to a total 
of 50 joules of 630 nm over 125 sec. There were no procedure related complications. 
Pathology review showed areas of necrosis of approximately 3.5 mm2 with some hem-
orrhage and granulation tissue.
Despite initial excitement about the technical feasibility of EUS-guided FNI to treat 
pancreatic cancer, this technique has not yet become a mainstream indication for EUS. 
This is primarily due to difficulties in developing effective drugs for intratumoral injec-
tions, but progress in this area is eagerly awaited and expected the coming years.
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EUS-GUIDED ImPlaNTaTION OF RaDIO-OPaqUE maRKERS (FIDUCIalS)
With the ongoing developments of radiotherapy, and more in particular the utility 
of multiple narrow beams stereotactic radiosurgery to deliver very high single radia-
tion doses to treat tumors more effectively, the issue of safety in relation to accurate 
targeting of the radiation beam has become an important issue. For this purpose these 
radiotherapy delivery systems use real time imaging guidance  14. In some instances, 
like for example brain tumors, anatomical landmarks such as bony structures in the 
skull serve as a reference point, but for soft tissue tumors in areas like the chest or 
the abdomen this does not suffice. In these cases the implantation of radiographic 
markers, or so-called fiducials, has shown to be a valuable alternative 15. Traditionally 
these fiducials were implanted surgically or percutaneously under ultrasonographic or 
CT guidance X 16. Since surgery is invasive and some lesions are difficult to access per-
a	   b	  
c	   d	  
Figure 2. EUS-guided placement of fiducials to guide cyberknife radiation in a patient with a small, 
cytologically proven, local recurrence of gastric cancer after surgical resection.
2a. EUS-guided puncture of malignant mass lesion close to splenic artery with 19 G needle (white arrow). 
2b. EUS guided advancement of fiducial through a 19 G needle with pusher rod. De fiducial has just 
disengaged from the needle tip and is visualized as a hyperechoic structure with an acoustic shadow. 2c. 
X-ray image showing a fiducial just being pushed out the 19 G needle. 2d. X-ray image showing the tip of 
the 19 G needle and 2 fiducials that have already been place inside the mass lesion
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cutaneously, EUS has been proposed as an attractive alternative implant modality 17, 18 
(figure 2).
Pishvaian and co-workers performed a prospective study to evaluate the safety and 
feasibility of placing fiducials in mediastinal and intra-abdominal tumors under EUS 
guidance in 13 patients scheduled for high precision CyberKnife frameless image-guided 
stereotactic radiosurgery 18. The fiducials used were cylindrical gold seeds with a length 
of 3 or 5 mm and a diameter of 0.8 mm customized to fit in a 19-gauge needle. Under 
curvilinear array EUS-guidance a 19-gauge fine needle was positioned in the target area 
and fiducials were placed through the needle lumen. The position of the fiducials was 
verified by EUS and by fluoroscopy. For accurate fiducial tracking by the CyberKnife 
system, a minimum of 3 fiducials were inserted around the tumor area or at the edges 
of the tumor itself, there was an angle of at least 15 degrees between any 2 fiducials, 
and the minimum distance between 2 fiducials was aimed to be 2 cm. EUS-guided 
fiducial placement was successful in 11 out of 13 patients (84.6%) with tumors in differ-
ent locations such as the retrocrural area at the dome of the diaphragm, porta hepatis, 
gastro-esophageal junction, mediastinum, thoracic paraspinal area, and pancreas. A 
total of 3 to 6 fiducials were placed in each patient. In the first 8 patients no prophylactic 
antibiotics were given. After one patient developed an infectious complication possibly 
related to the procedure, the following 5 patients received prophylactic antibiotic at the 
time of the procedure (ciprofloxacin 400 mg intravenously) followed by a 3-days course 
of oral ciprofloxacin (500 mg twice a day). Forward-loading the fiducials and pushing 
them through the needle can be problematic. First, in cases when the echo-endoscope 
tip is angulated, as is commonly the case for pancreatic head tumors, it is often difficult 
to advance the fiducials through a standard 19G FNA needle. Second, the use of the 
stylet often introduces air into the tumor, which obscures EUS visualization and may 
hamper proper delivery of fiducials. To overcome these problems Owens and Savides 
introduced a new technique in which the fiducial is back-loaded into the 19G needle 
and held in place with sterile bone wax that allows for easy fiducial delivery and elimina-
tion of air introduction 19.
EUS GUIDED DRaINaGE OF PaNCREaTIC FlUID COllECTIONS, abSCESSES 
aND INFECTED NECROSIS
The first endoscopic cyst-gastrostomy and cyst-duodenostomy were performed by 
Sahel and co-workers and Cremer and co-workers in 1982 20, 21. Endoscopic drainage of 
pseudocysts became an increasingly popular technique because of the relatively low 
complication rate compared to surgical and percutaneous treatment and comparable 
success rates. Soon in the development of the technique it was shown that routine 
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radial EUS undertaken before endoscopic cyst drainage increases the safety of the 
procedure by determining the most optimal site for access and avoiding accidental 
puncture of interposing vessels between the stomach wall and the cyst  22, 23. Of equal 
importance, EUS prior to attempted cyst drainage can be helpful in identifying cystic 
neoplasms in 3 to 5% of cases  22,  24. Nevertheless, despite the use of radial EUS and 
marking the optimal site of puncture, endoscopists were still dependent on the bulge 
of cyst into the lumen of stomach or duodenum. One of the most important steps in 
the development of interventional EUS was taken by Grimm and co-workers in 199225. 
They created a fistula between stomach and cyst with the aid of a linear echoendoscope. 
Due to the small working channel of only 2.0 mm, the endoscope had to be exchanged 
for a regular side-viewing endoscope after puncture and guidewire placement in the 
pseudocyst under EUS guidance. This procedure was further developed by Giovannini, 
Wiersema and Chak26-28. With the introduction of therapeutic linear echoendoscopes 
with working channels of 3.7 mm (Olympus, Japan) or 3.8 mm (Pentax, Japan) it is now 
possible to achieve adequate drainage with placement of multiple large-bore stents and 
a nasocystic catheter without changing the endoscope. Because of these developments 
the endoscopist is no longer dependent on a visible bulge to puncture the cyst and is 
able to choose the safest and shortest puncture route avoiding blood vessels and other 
organs under real-time EUS vision.
Several non-randomized case series suggest that EUS guided pseudocyst drainage 
is more safe than traditional “blind” techniques 29, 30. To date, only one randomized trial 
has been published comparing the two methods24. In a series of 30 patients with both 
bulging and non-bulging cysts, patients randomized to EUS guided drainage could all 
be treated successfully (100%), whereas this was the possible in only 5 of 15 patients 
(33%) assigned to conventional drainage. All remaining 10 patients subsequently 
underwent successful EUS guided drainage. There were no differences in the occur-
rence of complications. Given the study design, potential bias favoring EUS guided 
drainage cannot be excluded, but it does show a 100% success rate, including failed 
“blind” cases. To date, in most centers with an interventional endoscopy unit, EUS 
guided drainage is the preferred treatment for most pseudocysts. Only cases that are 
not amenable for endoscopic treatment because of a location too distant from the 
stomach or duodenum wall or failures of endoscopic treatment are referred for surgi-
cal or percutaneous intervention. In our institution, as in other centers, the attention 
has shifted to endoscopic treatment of patients with more complicated diseases, e.g. 
infected pseudocysts, pancreatic abscesses and walled-off pancreatic necrosis 31, 32. De-
spite the fact that no randomized trials exist comparing either surgical, percutaneous 
or endoscopic treatment, some recent retrospective series have shown that endoscopic 
treatment of infected necrosis in acute pancreatitis patients might be a viable alterna-
tive to surgery 33-35.
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Definitions and indications for intervention
Considerable controversies exist about the nomenclature of peri-pancreatic fluid col-
lection despite the attempt to unify terms with the Atlanta classification system 36. Most 
authors agree to divide peri-pancreatic fluid collections in three categories: 1 acute fluid 
collections, 2 pseudocysts, and 3 walled off pancreatic necrosis (WOPN) 33. Acute fluid 
collections occur early in the course of acute pancreatitis, have no defined wall and usu-
ally disappear after several weeks although they can become very large. Endoscopic in-
terventions are hardly ever necessary. Acute pseudocysts, defined as well-circumscribed 
homogenous with a well-defined wall require intervention only when symptomatic, i.e. 
pain, infection or obstruction of the gastrointestinal tract or bile duct. Size in itself is not 
an indication for drainage since spontaneous regression or disappearance is frequently 
observed. Pseudocysts can also occur in the setting of chronic pancreatitis and have the 
same radiological appearance as acute pseudocysts. Indications for drainage are driven 
by either symptoms (pain, infection and obstruction) or size. Most experts advise drain-
age if the size of the pseudocyst is larger than 6 cm since this might increase the risk of 
complications, mainly bleeding and infection 37. Walled-off pancreatic necrosis (WOPN) 
is also described as organized pancreatic necrosis. As long as no infection occurs treat-
ment is usually conservative. If infection occurs drainage is mandatory.
Procedure and Technique
Antibiotic prophylaxis is generally applied to decrease the risks of infectious compli-
cations after failed drainage or incomplete drainage of septated or communicating 
cysts. It is mandatory to have adequate surgical backup. Drainage can be performed 
under conscious sedation although it can be helpful to do the procedure under general 
anesthesia, especially if multiple cysts need to be drained or the drainage procedure 
needs to be combined with ERCP. Usually the procedure is started in the left-lateral posi-
tion. Depending on local anatomy it can sometimes be helpful to turn the patient to 
the prone position. Fluoroscopy is mandatory even though it is technically feasible to 
drain a pseudocyst with a single stent using only EUS guidance. While the transgastric 
or transduodenal drainage of fluid collections has become an established technique, 
the procedure is quite demanding and usually requires more ERCP than EUS skills. In 
fact, EUS is required only for the first part of the procedure to get safe access into the 
fluid collection. There are several different techniques to perform EUS-guided drainage 
of a pancreatic fluid collection. Application is largely based on personal preference and 
experience. Nevertheless, some general considerations can be made with respect to the 
technical procedure.
The procedure is started with a therapeutic linear echoendoscope. The optimal site 
for puncture is chosen based on distance from the gastric wall and interposing blood 
vessels. Generally a distance of 1 cm (or less) is considered safe although even when the 
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distance between gastric wall and pseudocyst is much larger, up to 2,5 cm, it is often 
possible to create an endoscopic cyst-gastrostomy. Access can be gained with either a 
specially designed cystotome or with a regular 19G needle. A potential disadvantage of 
the cystotome is that the EUS visibility of the inner part, which is basically a needle-knife 
sphincterotome, is sometimes not so clear and that the inner catheter is rather floppy 
(figure 3).
These characteristics make it sometimes more difficult to use. To avoid such prob-
lems, a regular 19G needle can be used to gain access (figure 4). Once the needle is 
inside the fluid collection, 10 cc’s of the cyst fluid are aspirated for culture, cytology 
and biochemical markers (amylase, CEA) and subsequently 10 to 20 cc’s of contrast are 
Figure 3. EUS guided puncture and drainage of large pseudocyst using the cystotome.
3a. The inner 5 Fr catheter (white arrow) with a metal tip of the cystotome is advanced through the 
stomach wall into the pseudocyst using electrocautery under EUS guidance. Some electrocautery artifacts 
are visible (broken white arrows). There is also some blood (dotted white arrow) twirling to the bottom of 
the pseudocyst. 3b. Using electrocautery on the metal tip (white arrow), the 10 Fr outer catheter of the 
cystotome is advanced over the inner catheter into the pseudocyst. 3c. The fistelous tract through the 
stomach and cyst wall created by the 10 Fr electrocautery tip of the outer cystotome catheter is nicely 
visible. Two pigtail stents have already been positioned. The guidewire is advanced into the cyst to place 
a nasocystic catheter for irrigation. 3d. 48 hours after the initial EUS-guided pseudocyst drainage, the 
fistula was dilated up to 18 mm and endoscopic debridement was commenced removing large chunks of 
necrotic tissue.
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injected. This sometimes delineates communication with the pancreatic duct, but more 
importantly it shows the size and shape of the cyst making it easier to interpret the 
position of guidewires later in the procedure. After puncture a stiff long ERCP guidewire 
is left in place and dilation of the cyst-gastrostomy fistula is mandatory. If however a 
dilation balloon cannot be passed successfully into the cyst, the outer part of the cysto-
tome can be advanced over the guidewire into the cyst using electrocautery. The use of 
a regular sphincterotome is associated with an increased risk of bleeding.
It is generally accepted that placement of multiple stents reduces the chance of clog-
ging and improves eventual outcome. Through the outer part of a cystotome or via an 
8.5 Fr stent introduction system (OASIS; Cook Endoscopy, Winston-Salem, USA) a second 
Figure 4. EUS-guided puncture and drainage of large infected pseudocyst using a 19 G needle.
4a. A 19 G needle (white arrow) is positioned using EUS guidance for transgastric puncture (stomach wall: 
broken arrow) of a large pseudocyst. 4b. The 19 G needle is advanced into the pseudocyst under EUS 
guidance. The acoustic shadow of the needle is well visible. 4c. A guidewire has been advanced into the 
pseudocyst through the 19 G needle. The needle has been removed and a 8 mm dilation balloon has been 
introduced over the guidewire into the cyst. Using endoscopy and fluoroscopy the balloon is adequately 
positioned to dilate the fistulous tract. 4d. The guidewire is still safely positioned within the pseudocyst 
after the balloon has been removed. Some blood can be seen twirling within the cyst cavity after balloon 
dilation. 4e. Immediately after the balloon is deflated, pus is gushing from the pseudocyst into the 
stomach. 4f. Two 7 fr pigtail stents have already been positioned and a third stent is being pushed into 
the pseudocyst.
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wire can be placed inside the cyst and 2 stents can be placed easily 38. It is advisable to 
use double pigtail stents (7 Fr) for drainage because compared to straight stents, they 
are less traumatic to the cyst wall, thereby reducing the chance of bleeding 39. If there is 
a clinical suspicion of infection it is advisable to place a 6 Fr nasocystic catheter and start 
cyst irrigation with 1 liter of water or saline per 24 hr with manual boluses of 100 – 200 
ml every 4 to 6 hours depending on cyst size and aspect. If the cyst contains debris 
and solid or necrotic material an endoscopic re-intervention should be considered 
after 1 to 2 days with further dilation of the fistulous tract up to 18 mm and endoscopic 
debridement using a regular forward viewing endoscope. Necrosectomy is usually best 
done with a dormia basket or a Roth net. Occasionally a grasping forceps can be useful. 
Usually several repeat procedures are necessary until viable tissue of the wall of the 
cyst is clearly visible. In between these procedures cyst irrigation is maintained using a 
nasocystic catheter.
Complications
The main complications of endoscopic drainage of pancreatic fluid collections are infec-
tion, bleeding, perforation, stent migration, and stent dysfunction. Reported frequen-
cies in the literature vary markedly, between 11 and 37%, at least partly due to different 
patient populations investigated  29, 31, 39, 40. In general, complication risk increases with 
increased complexity of the procedure, especially when underlying pancreatic necrosis 
is present. Infection is probably the most frequent complication after endoscopic drain-
age. The use of prophylactic antibiotics might decrease this risk. The most important 
risk factor is incomplete drainage. This can be due to stent clogging or migration, non-
communicating cyst compartments, and, most importantly, the presence of pancreatic 
necrosis. Most cases with infectious complications can be managed endoscopically by 
transmural necrosectomy 34, 41. Bleeding is less frequently encountered when using EUS 
guided drainage. If bleeding occurs from the site of the cyst-gastrostomy, it can usually 
be managed endoscopically. Presence of a pseudoaneurysm must be excluded. Overt 
perforation is rather uncommon with most series reporting perforation rates below 5%, 
although in earlier series this percentage was somewhat higher 32, 39, 40, 42, 43. Experience is 
therefore likely to be of influence. Most cases of perforation involve leakage of pancre-
atic juice in the peritoneum. When the drainage procedure was technically successful 
and adequate positioning of stents in the cysts cavity is confirmed on CT scan, this can 
usually be managed conservatively. The fistula will mature in 1 to 3 days and leakage 
will stop.
Outcome and results
Results in general are best for uncomplicated cysts in chronic pancreatitis. The efficacy 
of transmural endoscopic drainage in these patients is more than 90% and has therefore 
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become treatment of choice in centers where this expertise is available, although no 
prospective controlled series are available in which percutaneous, surgical and endo-
scopic treatment are compared. A small retrospective case-controlled study in which 
surgical cyst-gastrostomy was compared with EUS-guided endoscopic drainage showed 
comparable success, re-intervention and complication rates 44. However, due to a shorter 
mean hospital stay the endoscopic treatment was more cost-effective. Success rates in 
infected WOPN are considerably lower at around 70%, even in centers with considerable 
experience 31, 34.
Drainage of pelvic abscesses
In three published case series of 12, 4 and 4 patients it was shown that it is possible to 
drain pelvic abscesses with the aid of a linear therapeutic echoendoscope  45-47. In the 
first study stent placement was successful in 75% of patients whereas a 100% technical 
success rate was achieved in the latter two. With the aid of basically the same techniques 
as described above an overall success rate was achieved of approximately 75% when 
combined with short-term irrigation of the abscesses. This approach is a promising tech-
nique in patients that are sometimes very difficult to manage surgically or radiologically.
Future developments
Some of the difficulties of EUS guided drainage procedures, especially those related to 
the sometimes awkward maneuverability and to the oblique direction in which force is 
exerted, might be overcome by the use of a prototype forward viewing linear echoendo-
scope. Initial clinical experience in a small case series did suggest that endoscope control 
compares favorably to traditional linear echoendoscopes  1. More trials are awaited to 
demonstrate this and perhaps it will be possible to drain previously inaccessible fluid 
collections with the aid of this endoscope. With the increasing use of transmural endo-
scopic necrosectomy more effective instruments and accessories to evacuate necrotic 
tissue from the drained cavities are eagerly awaited.
EUS GUIDED DRaINaGE OF THE bIlIaRY SYSTEm
The majority of the biliary system can be visualized with EUS. Only visualization of the 
right hepatic lobe is limited but common bile duct, gall bladder and left hepatic duct can 
easily be identified with a linear echoendoscope. This opened up the way for EUS guided 
biliary drainage and rendezvous type procedures. Although endoscopic treatment of 
biliary obstruction through ERCP is successful in approximately 90% of patients, can-
nulation of the major papilla fails in selected cases because of local tumor infiltration or 
(surgically) altered anatomy. Nowadays almost every patient in whom ERCP fails can be 
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managed by percutaneous transhepatic drainage. However, percutaneous biliary drain-
age is associated with considerable morbidity due to bleeding, cholangitis and bile leak-
age in 10–30% of patients 48. The search for an endoscopic alternative for percutaneous 
interventions therefore seems logical and with the ability of linear EUS to gain access to 
transmural structures development of transgastric and transduodenal EUS-guided bili-
ary drainage was inevitable. Most papers on this subject have focused on the transmural 
placement of plastic or self-expandable stents, but rendezvous type procedures have 
also been described. In the next part of this chapter we will describe indications, pro-
cedural technique, complications and outcomes of EUS-guided hepaticogastrostomy, 
EUS-guided choledochoduodenostomy and EUS-guided cholecystostomy.
EUS guided hepaticogastrostomy
Given the excellent visualization of the left liver lobe from the stomach it is not difficult 
to identify dilated bile ducts. Since the right liver lobe is much more difficult to exam-
ine, patients with unilateral dilation of the right biliary system are no candidates for 
this procedure. In theory, all patients with malignant obstruction after failed ERCP are 
potential candidates to undergo EUS-guided hepaticogastrostomy. Several case series 
have shown that the procedure of transgastric stenting is technically feasible and prom-
ising. However, due to the lack of comparative studies with for example percutaneous 
approaches and the small number of patients included, this technique should still be 
regarded an experimental procedure only to be performed in a clinical research set-
ting 49-55.
Procedure
All patients in published series received pre-procedural antibiotic prophylaxis. The bili-
ary system is identified from the stomach at the lesser curvature and a dilated bile duct is 
punctured with a 19G or 22G needle. A 22G needle is more flexible and easier to handle, 
but will only pass a soft and floppy 0.018” guidewire making subsequent interventions 
more difficult. After the stylet is removed from the needle, contrast is injected and a 
cholangiogram is obtained. The next step is passing a long (480 cm) guidewire through 
the needle deep into the biliary system or preferably through the stenosis in the duode-
num. In case of the latter, a rendezvous procedure could be considered provided that the 
papilla can be reached. One of the main concerns in these kind of procedures is shearing 
of the guidewire on the sharp tip of the needle. Modern guidewires are nearly always 
hybrid type wires with a coating and a core. Stripping of the coating can occur with the 
risk of loss of part of the guidewire and subsequent failure to exchange accessories over 
the damaged guidewire. The risk of shearing increases with stiffness of the wire and 
increased angulation of the needle. In both circumstances more force is exerted at the 
tip of the needle. Obviously, repeated in and out movements of the wire when multiple 
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attempts at reaching the desired position also increases the chance of shearing. Some 
form of dilation is necessary to deploy either a plastic stent or a self-expanding metal 
stent (SEMS) through the fistula. For this, a sharp tip ERCP cannula (4.0 Fr) followed by 
biliary dilation catheters up to 8.5 Fr can be used and avoid the use of electrocautery. 
However, in the previously mentioned studies, also small caliber cystotomes ( 6 or 8.5 Fr) 
and needle-knifes have been used with success. After dilation deployment of a stent is 
the final step. Both straight and double pigtail plastic stents have been used and covered 
and uncovered SEMS. At present it is not known which type (or combination of stents) 
is the optimal choice with regard to outcome and occurrence of complications, mainly 
obstruction with subsequent cholangitis, bile leakage and migration. Once the fistula 
has been created and a stent has been in place for several days it is generally easy to 
perform a subsequent procedure and exchange or de-obstruct previously placed stents.
Complications
Overall complication risk in the 20 patients published was 25% without mortality. 
Complications ranged from cholangitis due to stent migration or obstruction, ileus due 
to migrated stents and biloma. Contrary to expectations bile leakage and subsequent 
localized peritonitis was not a major clinical problem, although some post-procedural 
pain was not uncommon.
Outcome
Outcome and results have been generally good in the published patients although one 
should acknowledge that publication bias may be considerable. Re-intervention rates 
were approximately 20%. Before any definite recommendations and conclusions can be 
drawn about this procedure more data are needed.
EUS guided choledochoduodenostomy
In general, indications for EUS-guided choledochoduodenostomy are the same as for 
the hepaticogastrostomy. For this procedure however, the duodenal bulb must be pre-
served and accessible as it is the point of access thereby limiting the patients in whom 
this procedure can be performed. Results of a total of 25 patients have been published 
in several small case series.
Procedure
As with hepaticogastrostomy it is common practice to give pre-procedural antibiotic 
prophylaxis. For transduodenal rendezvous procedures the therapeutic echoendoscope 
should be introduced into the duodenum and after obtaining a straight position as 
in ERCP the echoendoscope should be slowly withdrawn until the usually dilated bile 
duct comes into view from the duodenal bulb. The directional view is then towards the 
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ampulla of Vater, enabling passing of the guidewire after puncture of the common bile 
duct (figure 5). For EUS-guided choledochoduodenostomy it is mandatory to introduce 
the echoendoscope into the duodenal bulb in a long position. From this position the 
ultrasound view is directed towards the liver hilum, enabling stent placement transduo-
denally. In this position either a needle-knife or a 19G needle is introduced into the bile 
duct after which a cholangiogram is obtained. Although hepatic artery and portal vein 
are close by, avoiding them should not be difficult with the aid of Doppler sonography. A 
long guidewire is then left in situ after which, like in performing a hepaticogastrostomy, 
dilation of the fistula is performed with a biliary dilation catheter. Next a plastic stent, 
most authors have used straight stents, or a SEMS can be placed. Subsequent procedures 
can be performed with a regular duodenoscope.
Figure 5. EUS-guided rendez-vous procedure to enable endoscopic retrograde cholangiography after 
failed attempt to cannulate the papilla of Vater.
5a. Linear EUS image showing the common bile duct from the duodenal bulb with a bile stone causing 
an acoustic shadow (white arrow) 5b. EUS-guided needle puncture (white arrow) of the common bile 
duct. 5c. Cholangiogram with contrast injection through the EUS puncture needle. 5d. Advancement of 
guidewire through EUS puncture needle into the common bile duct across the papilla of Vater into the 
duodenum. 5e. Guidewire position after removal of EUS scoop. 5f. Advancement of side-viewing ERCP 
scope into the duodenum in front of the papilla. The guidewire has been retrieved through the working 
channel using a snare. Over the guidewire a cannula is advanced into the common bile duct.
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Complications
In the 25 patients published thus far the complication rate was 19% (5 patients). Two 
cases of biliary leakage led to a localized bile peritonitis and 3 patients had a pneumo-
peritoneum after the procedure. Although all cases could be managed conservatively 
and no procedure-related mortality was observed this complication rate is rather high, 
especially when considering that these procedures were performed at tertiary referral 
institutes by expert endoscopists.
Outcome
Procedural success was achieved in 92% of cases (23 out of 25). All patients had relieve of 
jaundice and cholestasis. Only one study describes long-term follow-up 56. In this paper 
average stent patency of plastic 8.5 Fr stents was an impressive 211 days. Although this 
procedure, as the EUS-guided hepaticogastrostomy, seems a promising and exciting 
alternative to percutaneous drainage in patients that fail ERCP, it is at present too early 
to make any definitive conclusions. Further research is awaited, especially comparative 
randomized trials between EUS-guided choledochoduodenostomy and percutaneous 
approaches.
EUS-guided cholecystostomy
The cornerstone in the management of patients with acute cholecystitis is surgical 
intervention. In patients deemed unfit for surgery the most commonly used alternative 
treatment is percutaneous drainage. Since it is usually easy to identify the gallbladder 
from the gastric antrum and/or the duodenal bulb and it is in close proximity to the 
enteral wall, the concept of transmural drainage of the gallbladder is a logical exten-
sion from other biliary and pancreatic drainage procedures. Internal drainage has 
potential advantages as indwelling percutaneous catheters cause considerable patient 
discomfort. The procedure of EUS-guided cholecystostomy has been described in two 
case series57, 58, including 12 patients in total. All patients were deemed unfit for surgery, 
usually because of severe co-morbidities. The shortest distance to the distended gall-
bladder was chosen from either gastric antrum or duodenal bulb and the gallbladder 
was then punctured with a 19G needle. After contrast injection a 0.035” guidewire was 
placed in the gallbladder. In the Korean series (9 patients) drainage was performed with 
a 5 Fr nasocholecystic catheter after dilation of the tract to 6 Fr. This catheter was left 
in situ until elective cholecystectomy in most cases. Surgery was not hampered by the 
indwelling catheter. In the Belgian series the dilation of the tract was performed with 
either a 6 or 10 Fr cystotome with subsequent placement of a nasocholecystic catheter 
and in one case combined with placement of a double pigtail stent. In the other 2 pa-
tients the nasocholecystic catheter was replaced endoscopically with a double pigtail 
stents several days after initial drainage. All patients did well and had clinical resolu-
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tion of their cholecystitis within 72 hours after the EUS-guided cholecystostomy. There 
was one case of small bile leakage and one pneumoperitoneum, both complications 
could be managed conservatively and were without clinical consequences. Although 
these results are quite promising, obviously prospective randomized trials comparing 
EUS-guided cholecystostomy and percutaneous drainage must be performed before 
any recommendations can be made with regard to the clinical utility of EUS-guided 
cholecystostomy.
EUS-GUIDED PaNCREaTIC DUCT DRaINaGE aND RENDEzVOUS
The main principle of endoscopic treatment in chronic pancreatitis is decompression of 
the duct. It is thought that ductal hypertension, due to stones or strictures, is one of the 
key causes of pain in chronic pancreatitis. Endoscopic treatment, if necessary combined 
with extracorporeal shock wave lithotripsy (ESWL), through ERCP is quite successful in 
experienced hands. It can lead to a major relief of pain in up to 60% - 80% of patients if 
decompression is achieved 59-62. Although a recent prospectively conducted randomized 
trial clearly favored surgery over endoscopic treatment 63 in many institutions endoscopy 
is still first-line treatment and surgery only considered when endoscopic treatment fails. 
Although in expert hands successful cannulation of the pancreatic duct is achieved in 
over 90% of cases selective cannulation sometimes fails 64. Either due to altered surgical 
anatomy, very tight strictures, severe inflammation or pancreas divisum with orificial 
stenosis access can sometimes be impossible. After surgical treatment for chronic pan-
creatitis recurrent disease and complaints are not infrequent. In some series drainage is 
inadequate in up to 20% of patients 65. Depending on the type of surgical intervention 
it can be impossible to continue with endoscopic treatment. Especially after duodenum 
preserving pancreatic head resection according to Beger or a Whipple procedure it can 
be impossible to gain access to the pancreatic duct via ERCP. Recurrence after surgery 
can be caused by recurrent disease or stenosis of the pancreaticojejunostomy. In both 
cases this can lead to dilation of the pancreatic duct. Since, even after surgery, the 
body and tail of the pancreas can be easily identified from the stomach and duodenal 
bulb this enables puncture and subsequent drainage, or a rendezvous procedure if the 
papilla can be reached, of the pancreatic duct via linear EUS. Four papers (cases series, 
retrospective data and 1 prospective study) have been published that evaluated EUS-
guided drainage or rendezvous of the pancreatic duct 66-69. Transluminal drainage was 
attempted in the two papers by Kahaleh and co-workers and Tessier and co-workers 
, whereas Mallery and co-workers describe attempted rendezvous procedures. Both 
techniques were evaluated by Will and co-workers. A total of 65 patients were described 
in these papers.
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Procedure
All patients described did receive pre-procedure prophylactic antibiotics. With the 
therapeutic linear echoendoscope the pancreas is examined from stomach and duo-
denal bulb (figure 6). The site for puncture must be chosen taking different parameters 
into account. Distance to the gastric or duodenal wall is important, but it is also very 
important to obtain a view of the pancreatic duct in a longitudinal way. This enables the 
endoscopist to look “into” the pancreatic duct and makes subsequent interventions over 
a guidewire much easier. Especially in severe calcifying chronic pancreatitis the duct 
may be hard to visualize due to the many acoustic shadows. This is another consider-
ation when determining the puncture site. Finally, every effort should be taken to guide 
the wire towards the pancreatic head and, if at all possible, pass into the duodenum or 
jejunum. This gives the endoscopist more wire “to work with” and reduces the chance 
Figure 6. EUS-guided pancreatic duct – gastrostomy in a patient with pain due to a stricture and duct 
obstruction after surgical pancreaticojejunostomy.
6a. EUS-guided puncture of the dilated pancreatic duct (white arrow) with a 19 G needle (broken arrow). 
6b. Contrast injection through the puncture needle with filling of the dilated pancreatic duct and the 
jejunal loop. The anastomotic stricture is nicely visible (white arrow). A 6 fr. cystotome is advanced over a 
guidewire through the stricture into the jejunal loop. 6c. Puncture hole in the stomach with a guidewire 
in position. 6d. Final situation with distal 7 Fr stent tip positioned in the stomach. The stent has been 
advanced through the stomach wall, pancreatic duct, and stricture and its proximal tip is located in the 
jejunal loop.
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of losing access when exchanging accessories. After successful puncture of the duct a 
pancreatogram is obtained after removal of the stylet. As in biliary drainage procedures 
it is preferable to use a 19G needle since an 0.035” guidewire due to its inherent stiffness 
will facilitate the further procedure. Especially with repeated maneuvers when trying to 
pass a stenosis the risk of shearing of the guidewire increases as described in the section 
on biliary drainage procedures. The EUS part of the procedure ends when the endos-
copist succeeds in passing the guidewire into the duodenum via the major or minor 
papilla. It is advisable to put plenty of guidewire in the duodenum to increase the stabil-
ity of the position when advancing the duodenoscope into position. When attempting 
a transmural drainage the next step is dilating the fistula trajectory. Several methods 
have been described using either a small tip ERCP cannula followed by a biliary dilation 
catheter and/or a biliary balloon dilation catheter or electrocautery with a cystotome. It 
is our personal preference to use the small caliber (6 Fr) cystotome since it is sometimes 
very hard, especially when the position of the echoendoscope is not ideal, to advance 
any accessory into the pancreatic duct due to severe fibrosis and scarring that occurs 
with chronic pancreatitis. When a combined cutting/coagulation current is applied to 
the cystotome passage into the duct is usually successful. If necessary intraductal or 
anastomotic strictures can be dilated with either a biliary balloon dilation catheter or 
the cystotome. The procedure ends with placement of a 7 Fr straight endoprosthesis. 
Several weeks later this can be exchanged for 2 stents, usually without problems with 
the aid of a regular duodenoscope.
Complications
Complication risk of EUS-guided pancreatic duct drainage appears to be quite high and 
can be procedure-related or occur later in time. In two series stent migration and occlu-
sions occurred in 20 to 55% of cases 67, 69 whereas also stent induced strictures were ob-
served on follow-up in one series 69. Procedure-related complications varied between 5% 
and 44%. Most common was post-procedure pain but severe pancreatitis, perforations, 
bleeding and hematoma have been described. The numbers of patients are too small to 
judge whether the type of procedure, especially the dilation modality, is of influence on 
the occurrence of complications. No procedure related mortality has been described.
Outcome
Long-term outcome data are not available. As was to be expected just like after success-
ful ERCP in obstructive chronic pancreatitis approximately 65% of patients experienced 
pain relief immediately after the procedure. The numbers are too small to judge whether 
a drainage procedure or a rendezvous procedure is more effective in pain relief. EUS 
guided drainage of the pancreatic duct at present is a technically challenging proce-
dure with a relatively high complication rate, both procedure related and stent related. 
Therapeutic EUS 111
7
Although there is a subset of patients that can definitely benefit from these techniques 
at present there is insufficient evidence to recommend this procedure on a routine basis. 
It should be further explored as part of a research program.
FUTURE INDICaTIONS FOR THERaPEUTIC EUS
As we have shown in the previous paragraphs the indications to perform EUS have 
shifted and continue to evolve, as many other endoscopic interventions, from being 
a purely diagnostic procedure towards an advanced therapeutic technique. In this last 
section we will discuss some developments on possible future applications of interven-
tional EUS focusing on vascular interventions and the possible role of EUS in NOTES.
EUS and vascular interventions
EUS may have a possible role in both detection and treatment of various lesions re-
sulting in gastro-intestinal bleeding. Due to the detailed images EUS provides it can 
potentially be of great value in both determining the source of bleeding as in directing 
treatment specifically through detailed visualization of local vascular anatomy. This 
first shown to be an effective approach in the localization and treatment of Dieulafoy 
lesions 70. Another more recent paper described the use of EUS in the management of 
5 patients with refractory bleeds of different sources despite intensive endoscopic and 
radiological treatment attempts 71. Real-time EUS visualization was used to inject 99% 
alcohol into small (1–2 mm) feeding vessels of pseudo-aneurysms and Dieulafoy lesions 
in three patients. In the 2 other patients cyanoacrylate was injected into bleeding vessels 
in patients with a duodenal ulcer and a bleeding GIST. Interestingly, it was possible to 
monitor the efficacy of treatment directly by use of Doppler ultrasound. During severe 
gastrointestinal bleeding it can occasionally be very difficult to adequate visualize the 
exact source of bleeding. Since imaging with EUS is not hindered by blood EUS guided 
therapy might be a useful adjunct to the endoscopic armentarium. The development 
of the forward-viewing linear echoendoscope might overcome problems related to the 
sometimes awkward handling of the oblique-viewing linear echoendoscope.
EUS has also been used in transmural endovascular interventions. One case report 
describes the successful insertion of endovascular microcoils through a regular 22G 
needle in a patient with ectopic varices refractory to conventional therapy  72. Several 
animal porcine studies have been performed in which angiography of the major ab-
dominal vessels  73, portal vein angiography and pressure monitoring  74-77 and even 
cardiac catheterization were performed 78. Although apparently safe in a porcine model 
obvious issues of sterility and bleeding risk need to be assessed before any of these 
techniques can be used in humans.
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EUS and NOTES
Apart from safe and effective closure, obtaining a reliable and safe access to the (retro)
peritoneal cavity is also very important for the further development of NOTES. EUS 
might be useful for this since it adequately visualizes surrounding structures, organs and 
major blood vessels. In a porcine model it was shown that through the use of EUS NOTES 
incisions, especially in locations other than the anterior gastric wall, are potentially 
more safe and therefore more versatile 79. Through the use of t-tags that can be applied 
through a regular 19G needle porcine studies have shown that it is possible to effectively 
perform transmural lymphadenectomy 80, gastropexy 81 and tissue approximation 82. To 
date, the most important addition of EUS to NOTES procedures is the identification of 
the best access point for specific procedures 83.
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abSTRaCT
In chronic pancreatitis, therapeutic endoscopy can be considered in three settings; 
drainage of the pancreatic duct, pseudocyst drainage, and treatment of biliary obstruc-
tion. In this chapter these techniques are extensively discussed with a focus on patient 
selection, the drainage techniques and the optimal duration of drainage. The available 
evidence regarding morbidity and mortality and long-term outcomes are summarized. 
Subsequently, an effort is made to establish the future role of endoscopic treatment in 
chronic pancreatitis.
In chronic pancreatitis, therapeutic endoscopy can be considered in different settings: 
drainage of the pancreatic duct to alleviate pain, pseudocyst drainage, and treatment of 
biliary obstruction. These techniques have become increasingly popular over the past 
decades, even though high-quality studies were lacking and the evidence for their ef-
ficacy was mainly based on retrospective studies. Just recently, more information from 
prospective studies has become available.
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PaNCREaTIC DUCT DRaINaGE
Introduction
Chronic pancreatitis is a disease characterized by an ongoing inflammatory process with 
severe pain as the predominant symptom. Although the origin of pain is likely to be 
multifactorial, pancreatic duct obstruction is considered an important etiologic factor. 
Therefore, ductal decompression became standard treatment for patients with painful 
obstructive pancreatitis [1, 2]. Obstruction of the pancreatic duct can be caused by stric-
tures, intraductal stones or, in the majority of cases, by a combination of both. Nowadays, 
improved imaging modalities (high-resolution abdominal computed tomography and a 
3-Tesla magnetic resonance cholangiopancreatography (MRCP)) provide accurate infor-
mation regarding the pancreatic ductal system to allow patient selection for endoscopic 
treatment without performing a retrograde pancreatogram. The aim of endoscopic drain-
age is to decompress the pancreatic duct and restore the outflow of pancreatic juice to 
the duodenum. It involves sphincterotomy, extracorporeal shock-wave lithotripsy (ESWL), 
removal of stones, and dilatation of strictures by means of temporary stent insertion.
Procedural aspects
Pancreatic Duct Stones
Since the introduction in 1987, ESWL has become a cornerstone of endoscopic drain-
age in chronic pancreatitis. ESWL not only improved the results but also expanded 
the indications of endoscopic treatment; floating stones <5–6 mm in diameter can be 
extracted transpapillary with a balloon or small-caliber Dormia basket, but the majority 
of pancreatic stones are impacted and too large to be removed without fragmentation 
[3]. It is important to emphasize that ESWL of pancreatic stones is not a simple technique 
because it requires considerable experience and specialized equipment consisting of 
a forceful electromagnetic lithotripter with a fluoroscopic two-directional targeting 
system (the most commonly used being the Dornier Compact Delta lithotripter, Dornier 
Med-Tech, Wessling, Germany), it is generally executed in expert centers. As treatment 
is painful and time-consuming (a single session takes about 1–2 h), it is best carried out 
with the patient under general anesthesia. Most ESWL sessions are immediately followed 
by an endoscopic procedure to clear the pancreatic duct from stones and evaluate the 
presence of strictures [4–7]. In the largest retrospective study, a mean of 5 sessions was 
necessary to achieve complete fragmentation [8]. Consecutive treatment sessions are 
usually carried out within a few days, during which time the patient remains admitted 
to the hospital. In between sessions an endoprosthesis or nasopancreatic drain can 
be used to prohibit pancreatic duct obstruction by stone fragments and to facilitate 
complete duct clearance.
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ESWL is considered a low-risk procedure with a 5–10% morbidity, acute pancreatitis 
being the most frequent complication [8, 9]. In the past, no mortality was observed, but 
in a recently published prospective study, 1 patient died of a perforated duodenal ulcer 
in which ESWL might have played a causative role [10]. ESWL is effective in experienced 
hands; stone fragmentation is achieved in more than 90% of cases and complete duct 
clearance in 44–74% of patients [3, 5, 6, 8–18]. The best results are reported for solitary 
distal stones in absence of a stricture but multiple, large, and impacted stones are no 
contraindication because the newer lithotripters are able to pulverize these stones 
completely [4, 19].
Pancreatic Duct Strictures
In chronic pancreatitis, fibrotic pancreatic duct strictures require dilatation and temporary 
insertion of an endoprosthesis. Many questions remain regarding the technical aspects 
of this technique. At present, prospective studies comparing different endoscopic treat-
Figure 1: treatment of pancreatic stones
1a: Initial cannulation of severely dilated pancreatic duct with distal stricture via minor papilla with 
tapered tip cannula and hydrophilic wire.
1b: Minor sphincterotomy and filling defects compatible with pancreaticolithiasis
1c: Balloon dilation of distal stricture
1d: Removal of stones with dormia basket
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ment protocols are lacking. Moreover, in retrospective reports, technical details are rarely 
discussed. As a consequence, evidence-based guidelines regarding the need for sphinc-
terotomy and dilation, the choice of stents, or the duration of treatment do not exist.
Despite this lack of evidence, a selective pancreatic sphincterotomy is advocated 
to provide optimal access to the pancreatic duct and facilitate stone extraction. The 
sphincterotomy is performed towards the 1-o’clock position and can be extended safely 
until the first duodenal fold. It should be large enough to allow easy access of instru-
ments and prevent post-papillotomy stenosis. Either the needle-knife technique over a 
stent, or a pull-sphincterotomy can be performed, with similar complication rates of 4% 
in retrospective studies [20, 21]. A recent prospective study reported that the needle-
knife technique was safer resulting in less post-ERCP pancreatitis [22]. In case a distal 
stricture is present, a short-nosed small-bore sphincterotome can also be useful.
Balloon dilatation of the pancreatic sphincter, as applied by Sasahira et al. [12], seems 
an interesting alternative technique but needs further evaluation. One study evaluated 
the benefits of sphincterotomy alone in obstructive pancreatitis (pain improvement 
in 60% of patients), but the size, retrospective nature, and patient population prohibit 
drawing any definite conclusions [23]. There is no evidence to support routine biliary 
sphincterotomy in these patients, unless signs of biliary obstruction are present [24].
Cannulation of the pancreatic duct is usually straight forward although in patients 
with active inflammation identification and cannulation of the papilla can be difficult 
due to edema. Furthermore, in 5–10% of patients access can only be obtained via the 
minor papilla either due to a devised pancreas or because of an impassable stenosis of 
the Wirsung’s duct.
Most strictures can be passed by a regular or hydrophilic 0.035-inch guidewire 
although sometimes the use of a thin 0.018- or 0.021-guidewire is necessary. Tight stric-
tures, which cannot be passed by a 5- or 6-Fr guiding catheter, require dilatation, either 
with a 4- to 6-mm balloon or a graduated dilating catheter. Extremely tight strictures can 
also be dilated with a Soehendra stent retriever which is passed through the stricture 
over a non-metallic wire as a corkscrew.
Subsequently, stent placement can generally be performed with relative ease. For 
pancreatic drainage, a range of stents are available. At first, polyethylene biliary endo-
prostheses were used. Later, stents with multiple side holes were specifically developed 
for pancreatic use, to allow optimal drainage from the side branches. However, the 
benefit of these pancreatic stents was never studied and therefore both stent types 
are used in this setting. Recently, two new model stents have been introduced: these 
so-called S-shaped and wing-shaped stents are presumed to have a longer patency and 
less chance of migration, but this needs to be proven prospectively [25–27]. Stents have 
a wide variety in diameters from 3 to 12 Fr. Laugier and Renou [28] were the first to 
suggest that a larger stent circumference results in a better outcome. The current trend 
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is to use a stent with the largest possible diameter, and to insert an increasing number 
of stents with each consecutive procedure to further dilate the stricture in analogy with 
the treatment of benign biliary strictures [29–31].
Perhaps the most interesting question regarding endoscopic dilatation of the pan-
creatic duct is how long a stent should be left in place. So far, the effect of stent duration 
on treatment outcome was never properly investigated and the two possible stent 
exchange protocols (either to change the stent at prescheduled intervals or to exchange 
‘on demand’ meaning when symptoms of obstruction recur) have not been compared.
Exchanging the stent on a regular basis has the advantage of preventing recurrent 
symptoms due to stent obstruction [32, 33]. Furthermore, this will limit treatment 
duration because stricture resolution is frequently evaluated and treatment may be 
terminated as soon as the obstruction has resolved. Shorter treatment duration might 
be important in the light of two findings. First, some studies suggest that the presence 
of a stent leads to progression of duct damage in patients with chronic pancreatitis, 
but most of these changes seem reversible [34–37]. A more important reason to limit 
the treatment duration is the prospective observation that many patients experienced 
considerable pain during stent therapy, a finding that might even be aggravated if 
multiple stents are used [10]. The single argument in favor of a long stenting period is 
the belief that this will improve the efficacy of stricture dilation and reduce the chance 
of recurrence, although evidence to support this assumption is lacking. In published 
series the stent duration ranged from 5.5 to 28 months, but the reported efficacy and 
recurrence rate did not vary accordingly [10, 19, 28, 29, 38–45]. Only three studies have 
evaluated prognostic factors of outcome in pancreatic stenting, but none found a 
significant benefit of a longer treatment duration [10, 28, 38]. Furthermore, even when 
assuming that clinical success is achieved only after years of treatment, it is impossible 
to know whether pain relief was accomplished by the endoscopic intervention or if it 
was a consequence of the natural course of the disease [16, 46].
Outcome
There is sufficient data to conclude that endoscopic pancreatic drainage in chronic pan-
creatitis is technically feasible and safe. Morbidity is observed in 6–58%, but most com-
plications are stent-related and easy to treat [10, 19, 28, 38, 39, 41–44]. However, since 
the introduction of endoscopic treatment, surgical techniques have evolved too, and 
the high complication rates of a decade ago are no longer applicable [47–49]. Therefore, 
the central argument in comparing endoscopic and surgical drainage has shifted from 
safety to efficacy. This comparison is complicated by the lack of high-quality reports 
on endoscopic drainage; most studies were retrospective, had a heterogeneous patient 
population, did not use well-defined treatment protocols and most importantly, they 
failed to use uniform and validated outcome measures [19, 28, 38, 39, 42, 43].
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Despite the above-mentioned limitations, some conclusions regarding the role of 
endoscopic drainage of the pancreatic duct in chronic pancreatitis can be drawn. Surgi-
cal drainage (by a pancreaticojejunostomy according to Partington-Rochele [50], or in 
the presence of an inflammatory mass, by a Beger or Frey procedure, achieves long-term 
pain relief in 65–85% of patients [51–58]. After endoscopic drainage, retrospective stud-
ies report a highly variable complete pain relief of 15–84% [19, 28, 29, 38, 39, 42–44]. 
Only two randomized trials have been published that compare endoscopic and surgical 
drainage in a prospective manner and both report a clear-cut benefit of surgery [10, 
41]. A possible pathophysiological explanation for this finding is offered by Reber et 
al. [59] who showed in an animal study that surgery is more effective in alleviating the 
parenchymal pressure due to the opening of the pancreatic capsule. Moreover, in both 
randomized trials the outcome of endoscopic treatment was disappointing and much 
worse than would have been expected based on the available retrospective data.
In the first study, Dite et al. [41] observed complete pain relief in 14% of patients 
only. However, the general opinion regarding this study is that it cannot be considered 
a fair comparison between the two treatment options because surgery on the one 
hand encompassed more than just a drainage procedure, and endoscopic drainage 
techniques did not meet the current standards. In the second randomized trial, which 
was published last year by our group in the New England Journal of Medicine, complete 
or partial pain relief was observed in 32% of patients assigned to endoscopic drainage 
as compared with 75% of patients who underwent surgical drainage [10]. Moreover, 
surgery resulted in a more rapid (within 6 weeks) and sustained pain relief during the 
2 years of follow-up. For patients in the surgical group treatment consisted of a single 
intervention (the surgical procedure), while patients assigned to endoscopic treatment 
underwent a median of 5 therapeutic interventions and suffered considerable pain dur-
ing this treatment period, even with a patent stent in situ. A possible limitation of this 
study is that the patients suffered from extensive disease and therefore, results might be 
different for a population with less complex pathology.
Recently a renowned center for ESWL treatment performed a third prospective ran-
domized trial in which they compared conventional endoscopic treatment consisting 
of ESWL combined with endotherapy (stone clearance and stent placement in case of 
a pancreatic duct stricture) with ESWL alone. After 2 years, pain relief was observed in 
25 of the 48 patients that were analyzed (52%) with an advantage of the ESWL alone 
treatment (58 vs. 46%) [14].
As prospective data suggest that the long-term success rate of endoscopic treatment 
is limited, the question remains if there is a role for endoscopic treatment of pancreatic 
duct obstructions in chronic pancreatitis. First, further development of endoscopic tech-
niques might improve results. To date, studies that focus on the technical aspects of 
endoscopic treatment are rare and conflicting. On the one hand, some authors advocate 
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a more aggressive approach: Costamagna et al. [29] have reported promising results of 
cumulative stenting with a success rate of 84%. Others are investigating less elaborate 
techniques. For instance, as mentioned above, Dumonceau et al. [14] achieved better 
results after ESWL treatment alone than in combination with endoscopic treatment. 
Future prospective studies are needed to solve these issues. Second, a better patient 
selection might improve the outcome. Now that in patients with complex pathology 
(with multiple strictures and stones) endoscopic drainage seems to be inferior to sur-
gery, the interest shifts to patients with less extensive disease. There is evidence that in 
symptomatic patients with a single obstruction or stone, the course of the disease may 
be favorably altered by an early intervention.
Farnbacher et al. [9] found that the only parameter predictive of long-term pain 
relief after endoscopic pancreatic duct drainage was a short duration of disease [10, 
41]. Also, animal studies have shown that pancreatic insufficiency develops early in the 
course of obstructive pancreatitis and becomes permanent within several weeks [60]. 
Therefore, the best way to prevent irreversible damage and pancreatic function loss 
may be to decompress the duct at a very early stage. Moreover, even patients without 
symptoms may benefit from endoscopic drainage. At present, in this third category of 
patients, duct decompression is postponed until symptoms of pain or recurrent flareups 
of pancreatitis develop. Future studies should evaluate if early duct decompression may 
prevent a course of intractable pain in such patients.
Summary
In conclusion, recent evidence suggests that surgery offers a better chance of success 
in patients with extensive obstructive pancreatitis and a combination of strictures and 
multiple stones. However, this does not write off endoscopic pancreatic duct drainage 
in chronic pancreatitis. It may well be that patients with less complex pathology will 
benefit from endoscopic treatment at an early stage of the disease, but this needs to be 
proven. Moreover, endoscopic therapy may still be justifiable in selected patients with 
extensive disease who show a favorable pain response within the first 8 weeks of stent 
treatment. If not, or when stricture resolution is not accomplished after a treatment 
period of 1–2 months, patients should be referred for surgery.
PSEUDOCYST DRaINaGE
Introduction
Pseudocyst formation is a frequent complication of chronic pancreatitis with a reported 
incidence of 20–40% [61–63] and in contrast to acute pancreatitis, spontaneous reso-
lution is rare [64–68]. Two mechanisms of cyst formation have been postulated. First, 
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cysts may follow an acute exacerbation of the disease (‘acute on chronic pancreatitis’) 
when peripancreatic fluid becomes organized in a walled-off collection. The second 
mechanism suggests an obstruction of a side branch of the pancreatic duct that results 
in a saccular dilatation. Pancreatic duct disruption and obstruction often accompany 
pseudocysts in chronic pancreatitis and if a communication between the duct and the 
pseudocyst is present, cyst drainage requires addressing these duct abnormalities be-
cause otherwise they will maintain filling of the cyst [69–71].
In chronic pancreatitis, indications for pseudocyst drainage are persistent symptoms 
and cyst-related complications. Pancreatic pseudocysts may lead to compression of the 
gastrointestinal tract, the biliary system or major vessels. Furthermore, spontaneous 
rupturing, bleeding and secondary infection of the cyst may occur.
Whether asymptomatic pseudocysts should be treated is debatable. The decision 
to drain is made based on the estimated chance of spontaneous resolution on the one 
hand, and the chance of developing complications on the other. Both figures are not 
exactly known for patients with chronic pancreatitis, but they are likely to be less than 
10% [64–68, 72]. Available data suggests that for cysts <6 cm in diameter, the resolution 
rate is even higher and because complications are rare in these small cysts, a wait-and-
see policy is defendable [65, 73, 74]. Moreover, also for larger asymptomatic cysts, a 
conservative follow-up has become more common, although a rapid increase in size is 
still considered an indication for drainage.
Imaging Studies
Prior to drainage, imaging studies are performed. Computed tomography has long been 
the key investigation in this setting. However, MRCP has evolved and provides excellent 
imaging of the pancreas and pancreatic region, comparable with computed tomogra-
phy [75–77]. Furthermore, MRCP has additional value because it can be used to evaluate 
the pancreatic duct and therefore has become the first choice imaging modality when 
pseudocysts are suspected. Further prospective studies are necessary to assess if a MRCP 
can annul the need of a retrograde pancreatogram. Secretin-stimulated MRCP is able to 
visualize the pancreatic duct in 97% of patients but an endoscopic retrograde cholangio-
pancreatography is superior in depicting subtle pancreatic duct abnormalities [78]. At 
present, it has not been ascertained that MRCP is able to diagnose all clinically relevant 
duct abnormalities, in particular ductal communication with the pseudocyst [79].
alternative drainage modalities
Historically, surgical pseudocyst drainage was associated with significant morbidity 
(7–37%) and mortality (0–6%) [80–82] with a recurrence rate of 10% [81, 83–85] and 
therefore less invasive techniques were welcomed. However, in the future, evolvement 
of laparoscopic techniques might expand the role of surgical drainage again [86–88].
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Percutaneous drainage is generally dismissed because it requires the presence of an 
external drain for an extended period of time and because it frequently leads to fistula 
formation [89–91]. At present, endoscopic pseudocyst drainage is the only feasible alter-
native to surgery and can be performed either through the gastrointestinal wall of the 
stomach or duodenum (transmural approach), or transpapillary if a connection of the 
cyst with the pancreatic duct is present.
Procedural aspects
General Aspects
Prior to the procedure a broad-spectrum antibiotic prophylaxis should be administered 
to decrease the risk of infectious complications [92]. The procedure is generally carried 
out under conscious sedation but it can be helpful to perform the procedure under 
general anesthesia, especially if multiple cysts need to be drained or the procedure is 
combined with an ERCP.
Transpapillary Drainage
Transpapillary drainage is the most straightforward and probably the safest drainage 
route [39, 87, 93, 94]. It requires communication of the cyst with the pancreatic duct 
and is performed by inserting an endoprosthesis in the pancreatic duct over a guide-
wire. Whether the endoprosthesis should be advanced all the way into the cyst cavity 
is unknown. Placement of the stent into the cyst may optimize drainage. A possible 
disadvantage may be that the outflow from the pancreatic duct located upstream from 
the cyst is compromised.
Transpapillary drainage is indicated when duct abnormalities (strictures and/or 
disruptions) are present because they will maintain filling of the cyst. Therefore, imaging 
of the pancreatic duct system (by MRCP or ERCP) is recommended prior to drainage. 
Because duct strictures require prolonged dilation treatment, stent therapy is gener-
ally continued well after cyst resolution has been accomplished. The disadvantage of 
transpapillary drainage is that it will often not suffice if a pseudocyst is large or contains 
debris, because a single small-diameter stent cannot provide sufficient drainage. In that 
case, a combination of transpapillary and a transmural drainage is recommended [93]. 
In our practice we consider cysts >6 cm an indication for drainage by multiple routes.
Transmural Drainage
Transmural pseudocyst drainage is achieved by placing stents through the wall of the 
stomach or duodenum. Traditionally, a side-viewing endoscope was used to puncture 
the gastrointestinal wall at the site of most the prominent bulge. With the introduc-
tion of endosonography (EUS), cyst drainage techniques have greatly evolved. At first, 
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a radial echoendoscope was used in a step-by-step procedure to identify the optimal 
drainage site [86, 95, 96]. Subsequently, a side-viewing duodenoscope was introduced 
to perform the drainage procedure.
Later, the single-step technique was developed using a therapeutic linear echoen-
doscope, with a number of potential advantages; it is likely to shorten the procedure 
time and does not carry the risk that the identified drainage site will be lost when the 
endoscopes are switched. Furthermore, real-time vision of the puncture allows better 
identification of the safest and shortest drainage route [97]. In addition, EUS guided 
drainage expanded the indications of pseudocyst drainage because it allows drainage 
of non-bulging cysts. Finally, it allows a better definition of the amount of debris and 
necrosis within the cyst.
Retrospective studies reported conflicting results of this technique and the single 
prospective cohort study did not find a clear difference in safety or efficacy compared to 
the conventional two-step approach. Only one prospective randomized trial compared 
the two drainage procedures and reports a 100% success rate of EUS guided drainage as 
compared to a 33% success rate of the conventional drainage technique, with a similar 
complication rate. At present, the ‘EUS-guided’ technique has been adopted as the 
preferred drainage method by most expert centers [98].
There are several techniques to perform EUS-guided drainage utilizing a range of dif-
ferent accessories. Application is largely based on personal preference and experience. 
Nevertheless, some general remarks can be made with respect to their implementation.
The procedure is started by determining the optimal puncture site, either in the 
stomach or in the duodenum. The site is selected based on the presence of interposing 
blood vessels and the distance between the cyst and the gastrointestinal wall. Generally, 
a distance up to 1 cm is considered safe; however, drainage is possible up to a distance 
of 2.5 cm.
To enter the cyst, a regular sphincterotome is not recommended as it is associated 
with an increased risk of bleeding. Access can be gained with a regular 19-gauge needle, 
or electrocoagulation may be used to burn a hole with a specially designed cystotome. 
An advantage of the latter is that it is relatively easy to introduce a catheter once the 
inner part of the cystotome is inside the cyst. A disadvantage is that the inner part of 
the cystotome is floppy and that its EUS visibility is poor. Furthermore, Monkemuller ob-
served less bleeding when puncturing was performed without electrocoagulation [99, 
100]. Therefore, we prefer to use a regular 19-gauge needle. It is important to puncture 
the cyst as tangentially as possible to decrease the distance that needs to be traversed. 
Once the needle is inside, cyst fluid is aspirated for culture, cytology and analysis of bio-
chemical markers and 10–20 cc of contrast is injected to delineate the cyst. A stiff, long 
(480-cm) ERCP guidewire is then advanced into the cyst to secure access and the most 
difficult part of the procedure, dilation of the cyst-gastrostomy tract, begins. It is almost 
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always possible to follow the wire with an 8-mm biliary dilation balloon. If the dilation 
balloon cannot be passed into the cyst, the outer part of the cystotome can be advanced 
over the guidewire into the cyst using electrocoagulation. Other options include the 
use of a narrow tip ERCP cannula, a biliary dilation catheter, or a 6-Fr cystotome. At this 
stage it is important to use the ultrasound image to keep the optimal position and only 
convert to the endoscopic image after the dilation balloon has entered the cyst cavity.
Insertion of multiple (mostly three) endoprosthesis is recommended to prevent 
clogging and secondary infection of the cyst [101]. After placement of the first stent, 
one needs to regain access into the cyst for subsequent stent placement. This can be dif-
ficult due to a change in the position of the endoscope once the cyst is decompressed. 
Therefore, it is best to introduce a second guidewire before placing the first stent. If a 
cystotome was used to gain access, it is easy to introduce 2 guidewires through the 
outer catheter. Another option is to use an 8.5-Fr stent introduction system (Oasis®; 
Cook Endoscopy, Inc.) which makes it quite easy to place a second wire inside the cyst 
[19]. Generally, 7-Fr stents with a length of 4–6 cm suffice. Stents with a double pigtail 
configuration are advocated because they are safer, with less chance of migration, per-
foration, and bleeding due to erosion of the stent though the cyst wall [87, 96] (fig. 2).
If there is a clinical suspicion of infection it is advisable to place a 6-Fr nasocystic 
catheter and start cyst irrigation with 1 liters of water or saline per 24 h with manual 
boluses of 100–200 ml every 4–6 h depending on cyst size and aspect. When the cyst 
contains debris and solid or necrotic material, an endoscopic reintervention should 
be performed after 1 or 2 days with further dilation of the fistulous tract up to 18 mm 
Figure 2: Transgastric pseudocyst drainage.
2a Fluoroscopic image of the dilation of the cystenterostomy opening with balloon.
2b Endoscopic image of the dilation procedure after the first two pig-tail stents have already been inserted.
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to allow endoscopic debridement with a forward viewing endoscope. A therapeutic 
gastroscope has a better suctioning capability, but is less flexible. Necrosectomy is best 
done with a Dormia basket or a Roth net and occasionally a grasping forceps can be 
useful. If stents are removed during the necrosectomy, it is important to leave at least 
one stent in place to reduce the chance of a blow-out of the cyst due to hyperinflation. 
Usually several repeat procedures are necessary until viable tissue of the wall of the 
cyst is clearly visible. In between these procedures cyst irrigation is maintained using a 
nasocystic catheter.
Before stents are endoscopically removed, cyst resolution is affirmed by an abdomi-
nal ultrasound, computed tomography or MRCP. The optimal duration of drainage is 
unknown, but generally the stents are left in place for at least several weeks [87, 102]. 
In our retrospective study, we observed superior outcome after a drainage period of at 
least 6 weeks, and therefore have adapted our drainage protocol accordingly [86].
Under specific circumstances it is probably safe to leave the stents in situ for an 
indefinite period, e.g. in older patients and in patients that are not able to undergo any 
further interventions. An interesting topic for future research is the use of covered metal 
stents or biodegradable stents instead of plastic stents to maintain the fistulous tract 
between the cyst and gastrointestinal lumen [103, 104].
Outcome
A systematic review of 25 published series regarding endoscopic pseudocyst drainage 
in a total of 569 patients reported an overall success rate of 81% (range 50–100%), a 
complication rate of 12%, a mortality rate of less than 1%, and a recurrence rate of 
14% [87]. However, these studies encompassed patients suffering from both acute and 
chronic pancreatitis, which is relevant because the outcome seems to be more favorable 
for patients with chronic pancreatitis.
Beckingham was the first to observe that the success rate varied according to the na-
ture of the underlying disease (75% in chronic pancreatitis as opposed to 25% in acute 
pancreatitis) [105]. Baron et al. confirmed this finding when he differentiated outcome 
according to acute, necrotizing and chronic pancreatitis and reported that pseudocyst 
drainage was the most effective and the safest for patients with chronic pancreatic with 
a success rate of 92% and a complication rate of 17% [95].
Retrospective studies have suggested a more favorable outcome in patients with a 
cyst located in the pancreatic head [106]. Furthermore, although the transgastric route 
is most often performed, some studies report a slight advantage of the transduodenal-
route [69, 87, 93, 107].
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Summary
For patients with chronic pancreatitis, endoscopic pseudocyst drainage is an effective 
and safe therapeutic modality and should be the treatment of first choice when available. 
However, pseudocyst drainage is a challenging procedure and requires an experienced 
interventional endoscopist. Surgery and percutaneous drainage should be reserved for 
patients in whom endoscopic drainage failed.
bIlIaRY DRaINaGE
Introduction
Approximately 10–30% of patients with chronic pancreatitis will develop a common bile 
duct obstruction during the course of their disease [105]. This biliary obstruction may 
arise from two distinct mechanisms; compression of the duct as a result of periductal 
swelling of the pancreas caused by acute inflammation, or fibrotic structuring caused by 
ductal damage due to the chronic inflammatory process. Biliary strictures are associated 
with a broad spectrum of presentations, from mildly elevated liver enzymes to com-
plete biliary obstruction. Cholangitis is a life-threatening complication and an obvious 
indication for drainage, but subclinical cholestasis requires drainage too, as it may lead 
to secondary biliary cirrhosis. Therefore, biliary drainage is indicated regardless of the 
presenting symptoms [108, 109]. Traditionally, a surgical bypass (i.e., choledochojejunos-
tomy or hepatojejunostomy) was the only treatment option. Although surgery provides 
a definite solution, the associated morbidity and mortality lead to the investigation of 
alternative drainage techniques. At present, endoscopic stenting is often chosen as the 
initial therapy, in analogy with postoperative biliary strictures for which endoscopic 
treatment was reported to be successful in 43–83% of patients [108, 110–113].
Procedural aspects
When a biliary obstruction is suspected, imaging studies (computed tomography or 
MRCP) are necessary to affirm the diagnosis, to rule out malignancy, and to evaluate the 
presence of other pancreatitis associated complications. Subsequently, an endoscopic 
retrograde cholangiogram is performed. A common bile duct stricture is identified as 
a distal narrowing of the duct with prestenotic dilatation and/or delayed runoff of the 
contrast agent. At the start of stent treatment a biliary sphincterotomy is performed to 
facilitate repeat access to the biliary tree and enable insertion of multiple stents later in 
the course of treatment. In case of a tight stricture (which cannot be passed by a regular 
5- to 6-Fr ERCP catheter), dilatation is indicated, either with a balloon or graduated dilat-
ing catheter. Finally, a polyethylene Amsterdam-type stent (10-Fr) is inserted over a guid-
ing catheter, long enough to bridge the stricture (usually 7 or 9 cm between the flaps).
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Generally, after 3 months a cholangiogram is repeated. The stricture is considered 
sufficiently dilated when the stricture-waist and the proximal dilatation have disap-
peared. Furthermore, duct patency can be affirmed with a regular ERCP catheter, which 
should pass the stricture without resistance. In addition, observing a rapid runoff of the 
injected contrast agent (within 1–2 min) is proof of sufficient stricture resolution. When 
the stricture is resolved the stent treatment is terminated, but if the stricture persists, 
treatment needs to be continued. The aim of further stenting should be to maximize the 
dilation force. This is accomplished by inserting multiple stents in a cumulative fashion. 
With each procedure the stricture is first further dilated, followed by the insertion of an 
increasing number of endoprostheses. When stricture resolution is not accomplished 
within a 1-year period (after 3 stent exchange procedures), a successful outcome is 
highly unlikely and surgery should be considered [114].
Figure 3: treatment of benign biliary stricture in chronic pancreatitis via progressive plastic stenting
3a. Short distal stricture at level of pancreatic head with upstream dilation.
3b. Initial placement of single plastic stent.
3c. Over 9 months period placement of 5 10 fr stents.
3d. Result after 1 year treatment.
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An interesting development is the use of self-expandable metal stents as an alterna-
tive treatment. A number of small series showed metal stents to be effective in treating 
biliary strictures due to chronic pancreatitis, but their irremovable nature makes them 
unsuitable for use in this benign disease [104, 115–118]. To overcome this problem, 
removable metal stents were developed, equipped with a covering and extraction lasso 
to enable stent extraction. At present, experience with these stents is limited to several 
positive case reports [103, 119]. Future studies should aim at further improving this 
technique, because the larger stent diameter makes them an attractive alternative to 
dilatation with plastic stents; stent occlusion occurs less often and frequent stent ex-
changes are unnecessary [120]. Furthermore, treatment may be more efficient because 
the maximal dilatation force is effective from the very beginning of endoscopic treat-
ment, in contrast to cumulative insertion of plastic stents in which case the dilatation 
force is gradually increased with each procedure.
Outcome
Obviously, biliary stents are able to resolve cholestasis temporarily, but they are less 
likely to achieve long-term dilatation in patients with chronic pancreatitis. Published 
series reported disappointing long-term success rates of 10–38% using single stents 
[114, 121–124]. Despite the overall poor results of endoscopic treatment, a subset of 
patients might benefit from biliary drainage. Kahl et al. [124] evaluated prognostic 
factors of outcome in biliary stenting and showed that the presence of calcifications 
in the pancreatic head was a strong predictor of a more negative outcome. In the 39 
patients with calcifications, long-term success was achieved in 8% only, whereas in the 
22 patients without calcifications a successful long-term outcome was observed in 59%. 
The explanation for this finding may be found in the different mechanisms of biliary 
obstruction in chronic pancreatitis. Because calcifications are a sign of long-standing 
chronic pancreatitis, one might hypothesize that the strictures in these patients are typi-
cally of fibrotic nature and therefore difficult to dilate. The patients without calcifications 
are more likely to have developed an obstruction secondary to edema, which subsides 
over time and only requires temporary bridging of the stricture.
For this purpose, stent placement is most appropriate. Results from our recently 
published series endorse this theory with the presence of concomitant acute pancre-
atitis resulting in a 95% chance of a successful treatment as opposed to a 24% success 
rate in its absence [114]. This phenomenon might also explain the unusually high 80% 
success rate observed by Vitale et al. [125] after balloon dilatation and stenting of biliary 
strictures; calcifications were present in only 4 out of the 20 patients that were studied.
An obvious way to improve outcome is a more vigorous dilatation of strictures by 
placing multiple stents. In the treatment of postoperative biliary strictures, this has been 
proven highly effective, and Draganov et al. [126] was the first to apply this method to 
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patients with chronic pancreatitis. By inserting a cumulative number of stents with each 
procedure, stricture resolution was achieved in 4 of 9 patients (44%). However, in the 
subgroup of patients with calcifications, the results remained disappointing; stricture 
resolution was accomplished in 1 of 6 patients. Pozsár et al. [127] later placed the maxi-
mal number of stents that the stricture would allow (with a median of 2), which resulted 
in a 60% stricture resolution. Catalano et al. [31] even achieved a 100% success rate in 12 
patients by inserting at least 4 stents.
Serious adverse events of biliary stenting are rare. Stent occlusion is the only com-
plication that is frequently encountered (in most studies in approximately 35%), even 
when stents are exchanged on a regular basis [114, 123, 127–130]. Mostly, this complica-
tion is easily treated by stent exchange. However, in patients with pancreatitis caused by 
alcohol abuse, noncompliance is a considerable risk. Not showing for the arranged stent 
exchange can result in severe cholangitis, sepsis and even death[127, 128].
Summary
At present, endoscopy has become the first-line approach for the treatment of postop-
erative biliary strictures, but strictures related to chronic pancreatitis are much more 
difficult to treat, especially fibrotic strictures, and patients should be informed about the 
limited efficacy. If, nevertheless, endoscopic therapy is chosen, an aggressive approach 
is preferred, with the insertion of a cumulative number of stents earlyin the course of 
treatment. In this respect, the use of removable fully covered selfexpandable metal 
stents is promising because they immediately provide a dilation diameter of 30 Fr which 
is equivalent to seven 10-Fr plastic stents. When the stricture has not resolved within a 
1-year period, the patient should be referred for surgery.
GENERal CONClUSIONS
In chronic pancreatitis, the lack of well-defined clinical trials combined with an evolving 
endoscopic technology has created a strong need for prospective studies to further 
clarify the indications, methods and duration of endoscopic interventions.
Overall, the future of endoscopic treatment in chronic pancreatitis seems to lie in a 
pro-active approach; treating pancreatic duct strictures at an early stage of the disease, 
extensive debridement of pseudocysts, and a fierce dilatation of biliary strictures.
Most importantly, surgery and endoscopic treatment should not be regarded as 
competing strategies but as complimentary treatments. Therefore, during the course of 
endoscopic treatment, patients should be carefully monitored and regularly discussed 
by a multidisciplinary team and when relief of symptoms and/or progression is not sat-
isfactory, surgery must not be postponed. Moreover, when more than one complication 
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is simultaneously diagnosed in a patient, (i.e. a pancreatic duct stricture and a common 
bile duct stricture) surgery might be considered at an earlier stage, because the overall 
chance of long-term endoscopic success decreases with each additional complication.
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abSTRaCT
background and study aims
Anastomotic strictures are an important cause of morbidity after orthotopic liver 
transplantation (OLT). Endoscopic treatment is the primary treatment modality for bili-
ary complications after OLT. The outcome and complications of a progressive stenting 
protocol are largely unknown.
Patients and methods
A longitudinal cohort study of OLTs was conducted. Only patients with late strictures 
were included. Treatment success was defined as cholangiographic stricture resolution 
and liver enzymes returning to normal with follow-up of at least 12 months.
Results
Between May 2000 and June 2009, 375 OLTs were performed. A duct-to-duct anasto-
mosis was created in 304 cases (81%). In 63 patients (21%; 95% confidence interval [CI] 
16.5%–25.6%) an anastomotic stricture developed and progressive stenting was started 
in 35. During treatment two patients died of a non-treatment-related cause and two 
patients underwent a second OLT during stent therapy. Therefore 31 patients were 
available for analysis (male:female 21:10; median age 61 years, range 28–75 years). Pro-
gressive stenting required a median number of 5 endoscopic retrograde cholangiopan-
creatography (ERCP) procedures (range 4–11). A median maximum of 4 stents (range 
2–8) were inserted. A total of 21 patients (67.7%; 95%CI 50.1%–81.4%) developed a 
treatment-related complication. In 33 out of a total of 155 ERCPs (21.3%) a complication 
occurred: cholangitis (n = 12), transient cholestasis (n = 11), post-ERCP pancreatitis (n 
= 7), and treatment-related pain (n = 3). The median follow-up time after stent removal 
was 28 months (range 12–92). Treatment was successful in 25 patients (80.6%; 95%CI 
63.7%–90.8%).
Conclusion
Progressive stenting for anastomotic strictures after OLT is demanding and burdensome, 
necessitating a median of 5 ERCP procedures with complications occurring in one out 
of five procedures. Its success rate however is high (81%), avoiding surgery in the large 
majority of patients.
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INTRODUCTION
After orthotopic liver transplantation (OLT) a considerable proportion of patients de-
velop biliary complications. The incidence, including leakage, strictures, and stone and 
cast formation, is approximately 30% and complications are therefore one of the most 
important causes of OLT-related morbidity [1–5]. At present, endoscopic retrograde 
cholangiopancreatography (ERCP) is considered to be the cornerstone of treatment of 
these complications. Alternative options such as percutaneous balloon dilation of the 
stricture or surgical hepaticojejunostomy are considered to be less efficacious or more 
invasive [6,7].
Strictures after OLT can be located at the biliary anastomosis or can be non-anasto-
motic. Non-anastomotic strictures typically involve the hepatic ducts of the donor liver 
and are thought to be caused by ischemia or donation after cardiac death [8,9]. These 
strictures tend to respond less favorably to therapy and often require a re-transplant, al-
though aggressive endoscopic therapy may slightly improve outcome [10,11]. The vast 
majority of biliary strictures after OLT are at the anastomosis and multiple case series 
have shown a favorable response to various methods of endoscopic therapy including 
balloon dilation, stenting (single or multiple stents), or a combination of both, with suc-
cess rates between 65% and 94% [12–16].
The drawback of these series is that they either do not contain original data or report 
on a small number of patients [12–15]. The largest series published to date (n = 69) also 
included a significant number of patients with early anastomotic strictures, usually 
defined as strictures occurring within the first month after OLT. Due to the particular 
nature of these early strictures, likely being caused by postoperative edema rather than 
ischemia and fibrosis, they tend to respond better to therapy. For this reason the results 
of that series regarding the outcome of endoscopic therapy are probably too optimistic 
for true fibrotic anastomotic strictures [17].
Nowadays, in most institutions a “progressive stenting” protocol is followed whereby 
an increasing number of plastic endoprotheses, tailored to the diameter of the duct, are 
inserted at intervals of 3 months over a 1-year period [18]. However, there are several 
drawbacks to this approach, of which multiple procedures for one treatment cycle is 
the most important one. This results in a considerable burden for both patients and 
endoscopy units. Furthermore, the duration of therapy increases the risk of stent dys-
function and ensuing cholangitis necessitating stent exchange, although this risk prob-
ably decreases with the number of stents placed. For these reasons several case series 
have been published describing the use of fully covered self-expandable metal stents 
(fcSEMS) in patients with anastomotic strictures after OLT [19–24]. When evaluating a 
new treatment methodology such as fcSEMS, it is of particular importance to compare 
its merits with the standard treatment of which outcome and complication risks should 
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be well known. However, there is still a paucity of data on efficacy and complications of 
progressive plastic stenting in patients with OLT and existing data are based on either 
small or non-representative series. We therefore aimed to explore the outcome of a 
progressive plastic stenting protocol in patients with an anastomotic stricture after OLT.
PaTIENTS aND mETHODS
A longitudinal cohort study was conducted based on data recorded in a prospectively 
maintained registry of all adult patients who underwent a deceased donor OLT between 
May 2000 and June 2009. Analysis of these data was done with local institutional review 
board approval. T-tubes were not routinely used during this period. During the study a 
progressive stenting protocol was followed for the treatment of anastomotic stricture. 
Before the inclusion period usually one or two stents were placed and after the end of 
the period most patients with anastomotic strictures were treated with fcSEMS as part 
of a study protocol. In the progressive stenting protocol used during the study period, 
a single 10-Fr endoprothesis was initially inserted. After improvement of clinical and 
biochemical parameters, progressively more stents were placed at 3-monthly intervals 
over a period of 1 year. The goal was to insert as many stents as the diameter of the 
donor hepatic duct allowed for.
Inclusion criteria were the presence of a duct-to-duct anastomosis and signs of 
cholestasis, jaundice or cholangitis. Strictures were defined as relevant when significant 
narrowing or tapering was seen at cholangiography and improvement of cholestatic 
liver enzymes occurred after initial stent placement. With this strategy patients with any 
other cause of liver enzyme disturbances (recurrence of the underlying liver disease, 
rejection) could reliably be excluded and did not undergo progressive stenting.
Exclusion criteria were a presumed dominant stricture at a level other than the anas-
tomosis, a hepaticojejunostomy as primary anastomosis, and early strictures, defined 
as occurring within the first month after OLT and disappearance of stricture after initial 
single stent therapy.
ERCPs were performed under conscious sedation by experienced pancreaticobiliary 
endoscopists. Intravenous antibiotic prophylaxis was routinely given shortly before the 
start of the procedure and continued for 24 hours. In all cases a sphincterotomy was 
performed if not done previously. Balloon dilation of the stricture was performed at the 
discretion of the endoscopist to facilitate stent placement and was never used as a sole 
treatment modality, although virtually all patients (29/31; 93.5%) underwent at least 
one balloon dilation during one or more of the ERCPs.
Statistical analysis was performed with SPSS v 15.0 (Chicago, Illinois, USA). Treatment 
success was defined as absence of a stricture during cholangiography at the end of the 
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protocol, as confirmed by easy passage of an inflated balloon through the anastomosis, 
adequate run-off of contrast, and no recurrence of cholestasis, jaundice, or cholangitis 
due to a recurrent stricture during follow-up. Re-admission to the hospital within 1 week 
or prolonged stay after the procedure was considered a serious adverse event.
RESUlTS
During the inclusion period a total of 375 OLTs were performed (Fig. 1). Of the 304 pa-
tients in whom a duct-to-duct anastomosis was created, 63 developed an anastomotic 
stricture (21%; 95% confidence interval [CI] 16.5%–25.6%). The reasons for not entering 
the progressive stenting protocol in 28 patients were diverse: early anastomotic stric-
ture that responded well to short-term stenting in 16 patients, treatment with fcSEMS 
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Figure 1: Flowchart of patients through the study
CVA: Cerebrovascular accident
fcSEMS: fully covered self-expandable metal stent
HCV: Hepatitis C
ITBL: Ischaemic type biliary lesions
OLT: orthotopic liver transplantation
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in 6 patients, and in 6 patients cholestasis was not caused by a dominant anastomotic 
stricture but by recurrence of the underlying liver disease. Four patients did not com-
plete the protocol: two underwent a second OLT (one because of ischemic type biliary 
lesions, the other because of acute liver failure due to re-infection with hepatitis C), and 
two patients died of unrelated causes (one intra-abdominal bleed, one cerebrovascular 
accident). These four patients were excluded from the analysis.
The characteristics of the remaining 31 patients are shown in Table 1. Patients re-
quired a median number of 5 ERCPs (range 4–11). The median maximum number of 10-
Fr stents was 4 (range 2–8). Complications requiring hospital admission or a prolonged 
stay after the procedure occurred in 21 patients (67.7%; 95%CI 50.1%–81.4%). Calculated 
per procedure the complication risk was lower: 22 serious complications were noted in 
a total of 155 procedures (14.2%; 95%CI 9.6%–20.6%). Complications were cholangitis 
(n = 12; three occurring immediately after ERCP and treated with prolonged antibiotics), 
post-ERCP pancreatitis (all mild, n = 7), and treatment-related pain that responded to 
the use of temporary analgesics (n = 3). Although not uncommon, transient cholestasis 
(n = 11) was not classified as a serious complication. No mortality was observed.
Overall treatment success, defined by absence of recurrence of cholestasis, jaundice, 
or cholangitis due to a recurrent stricture, was achieved in 25 out of the 31 patients 
who completed the protocol (80.6%; 95%CI 63.7%–90.8%). Median follow-up after stent 
removal was 28 months (range 12–96 months).
The six patients in whom the progressive stenting protocol failed were treated either 
with hepaticojejunostomy (n = 5) or placement of a fcSEMS (n = 1).
DISCUSSION
The majority of patients who completed the progressive stenting protocol were suc-
cessfully treated endoscopically. As the study was based on a prospectively maintained 
registry of a rigidly performed protocol and all transplant patients are closely followed 
at our hospital for the remainder of their lifetime the quality of the treatment and follow-
up data is ensured.
Table 1: Patient characteristics
Patient characteristics
Patients in progressive stenting protocol 31
Gender (male/female) 21 / 10
median age (years) 61 (28 – 75)
median follow-up (months) 28 (12 – 92)
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Although patients with anastomotic stricture after OLT are increasingly treated with 
fcSEMS, the evidence for this strategy is scarce given the lack of comparative studies 
and the quality of published data with regard to the outcome of treatment with plastic 
stenting. The introduction of any new technique or method should, preferentially, be 
compared with a standard treatment. This is particularly true for the use of fcSEMS in 
benign biliary strictures, including those occurring after OLT, given the non-negligible 
chance of complications including migration, cholangitis, and secondary strictures 
[19–24]. To truly evaluate and subsequently compare techniques, patient populations 
investigated should be as homogeneous as possible. We therefore took care to include 
only patients with true anastomotic stricture after OLT and excluded all patients with 
early and non-anastomotic strictures. This is of great importance because including 
patients with early strictures of edematous nature, overestimates the true virtues of 
any dilation therapy. This is true for both progressive plastic stenting as well as fcSEMS 
treatment. All patients included in this series had true fibrotic anastomotic strictures. 
Therefore, the current results can be regarded as truly representative for the effect of 
treatment with progressive plastic stenting, and the risk of selection bias by including 
patients with early anastomotic strictures and non-anastomotic strictures is reduced.
The quality of the data and interpretability of results of the present series are also 
substantiated by the length of follow-up, as it is likely that any benign biliary stricture will 
show immediate cholangiographic improvement after a period of (aggressive) stenting, 
whether progressive with plastic or with temporary placement of fcSEMS. The true value 
of outcome data can therefore only be interpreted after significant length of clinical 
follow-up and laboratory evaluation. The minimum follow-up period of 12 months and 
median follow-up of 26 months further increases the strength of the current data.
The overall success rate in this series was 81% which is in line with previously 
published studies [12–16]. This should be regarded as the gold standard success rate 
of a progressive plastic stenting protocol in anastomotic stricture and is the benchmark 
for future studies, for example with fcSEMS. However, the efficacy of this, and other, 
progressive stenting protocols comes at a price. The number of procedures required 
to achieve this efficacy was high and the related costs of procedures, equipment, and 
hospital admissions would be considerable. Furthermore, although these procedures 
are technically not very complicated, the burden for patients should not be underesti-
mated. This is illustrated by the considerable complication risk. The risk of complications, 
mainly cholangitis and pancreatitis, as calculated per patient when available in previ-
ously published studies, is usually lower than in the current study but varies between 
1.4% and 24.3% [12,14,16,17,25]. These differences are more likely to be caused by the 
retrospective nature of previously published studies on this subject than by inherent dif-
ferences in patient care, technique, or differences in patient populations. Nevertheless, a 
per procedure risk of 14.2% for serious complications is substantial.
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In summary, although the endoscopic treatment of biliary anastomotic strictures by 
means of a progressive plastic stenting protocol is demanding for patients and labor 
intensive for healthcare providers, it is highly efficacious and saves 80% of patients from 
undergoing complicated surgical repair or even a re-transplantation.
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abSTRaCT
background
Treatment of patients with anastomotic strictures (AS) after orthotopic liver transplanta-
tion (OLT) by progressive plastic stenting (PPS) is effective, but expensive and burden-
some given the necessity for multiple ERCPs. Recently several case series have been 
published describing the use of fully covered self-expandable metal stents (fcSEMS). It 
is not known whether this approach decreases costs besides potentially reducing the 
number of procedures. We therefore modelled the costs of various fcSEMS scenarios in 
relation to the costs of PPS.
methods
PPS costs were obtained from a longitudinal cohort of 31 AS patients who were treated 
in our hospital with a success rate of 80%. For PPS a median of 5 ERCPs were required 
and resulted in a median of 1 complication per patient. We performed a top-down cost-
analysis of PPS and compared this with the cost of six hypothetical models of fcSEMS 
treatment. Treatment costs were calculated using source data from the financial depart-
ment of our hospital. For this analysis we assumed that the efficacy of fcSEMS treatment, 
i.e. stricture resolution, was equal or greater than PPS and complication rates would 
be equal. The most optimistic scenario assumes that only 2 ERCPs and 1 fcSEMS would 
be required in all patients. We calculated the maximal cost reduction with a stent prize 
of € 1000 (fcSEMS A) or € 1500 (fcSEMS B). We also performed a break-even calculation 
by determining the maximum allowed number of ERCPs with fcSEMS placement per 
patient assuming that the total treatment costs are equal to PPS, with a stent prize of 
€ 1000 (fcSEMS C) or € 1500 (fcSEMS D). Finally, a clinical scenario was modeled assuming 
that a second ERCP with fcSEMS placement was needed in 30% of cases and a third ERCP 
with fcSEMS placement in 10% of cases, with a stent prize of € 1000 (fcSEMS E) or € 1500 
(fcSEMS F) and calculated the cost reduction compared to PPS. ERCP costs without stent 
placement were € 750 and costs of plastic stents € 51 a piece.
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RESUlTS
Per patient costs for PPS were calculated at €4196. The use of fcSEMS reduced costs in all 
scenarios. The highest reduction was achieved in scenarios A and B, respectively €1696 
(40%) and €1196 (29%). In scenarios E and F, allowing for 2nd and 3rd fcSEMS placement 
in a subset of patients the cost reduction was less pronounced but still considerable at 
€996 (24%) and €296 (7%). Finally, in scenarios C and D the mean number of fcSEMS that 
were allowed according to a break-even cost analysis was 1.97 and 1.53 respectively.
Conclusions
Treatment of AS after OLT with fcSEMS compared to PPS potentially saves costs in all 
calculated clinical scenarios and is largely dependent on the price of fcSEMS. Even when 
allowing for 2nd fcSEMS placement in 30% of the patients and 10% a 3rd ERCP with fcSEMS 
placement, total treatment costs are lower. Importantly, this scenario would also result 
in a 50% reduction in the number of ERCPs which should be considered a major benefit 
from the patient’s perspective.
INTRODUCTION
The incidence of biliary complications, including leakage, strictures and stone and cast 
formation, is approximately 30% and therefore one of the most important causes of OLT 
related morbidity[1-5]. While the treatment of both stones and leakage is usually straight-
forward, the treatment of biliary strictures after OLT can be challenging and demanding 
for both physicians and patients. Biliary strictures after OLT are in most instances located 
at the site of the anastomosis[6]. The preferred treatment for anastomotic strictures 
(AS) nowadays is endoscopic since it is superior to percutaneous alternatives and less 
invasive than surgical options[7, 8]. Until recently in virtually all institutions a protocol 
consisting of progressive plastic stenting was used to treat AS. During successive ERCP’s 
at three monthly intervals an increasing number of plastic stents is used to dilate the 
stricture over the course of one year[9]. In the series published thusfar the efficacy of this 
treatment is between 65% and 85%[4, 10-15].
Recently several case series have been published describing the use of temporary, 
removable partially and fully covered self expandable metal stents (pcSEMS and fcSEMS) 
in benign biliary strictures (BBS) including AS after OLT[16-23]. Efficacy with regards to 
stent resolution and complication rate are roughly similar or better compared to PPS but 
at the prospect of fewer ERCP procedures and hospital admittances the use of fcSEMS is 
emerging as an attractive treatment option for OLT patients with AS.
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There are however no data available with regards to the cost-effectiveness of this 
approach. Since trials comparing PPS and fcSEMS in BBS have not yet been published 
and efficacy and complication rates in the published case series are equivalent cost-
effectiveness becomes even more important before this new treatment modality can 
be recommended as standard care especially given the rising costs of healthcare. In 
cost-effectiveness analysis it is conventional to distinguish between the direct costs 
and indirect or productivity costs associated with the intervention, as well as what 
are termed intangibles, which, although they may be difficult to quantify, are often 
consequences of the intervention and should be included in the cost profile.
Examples of direct costs are both medical, e.g. drugs; staff time and costs of equip-
ment and patient related such as transport and out-of pocket expenses.
Examples of productivity costs are production losses and other uses of time.
Intangibles are for example pain, suffering and adverse effects.
It is essential to specify which costs are included in a cost-effectiveness analysis and 
which are not, to ensure that the findings are not subject to misinterpretation.
It is unknown whether the use of fcSEMS decreases costs compared to PPS. A po-
tential benefit of fcSEMS is that ideally only 2 ERCP’s are necessary during treatment. 
A potential disadvantage of fcSEMS is their high cost. To answer the question of cost-
effectiveness on the use of fcSEMS we undertook an analysis on our own cohort of 
patients that were treated in our institution with PPS.
mETHODS
We performed a cost-analysis where in which we modeled the costs of various fcSEMS 
scenarios and compared those with the costs of PPS. The data from PPS were obtained 
from a longitudinal cohort of 31 patients with AS after OLT that were treated in our insti-
tution (Endoscopy 2013). The success rate at 12 months of PPS in this cohort was 80%. To 
achieve this a median of 5 ERCP’s were required with a median maximum number of four 
10 fr. stents at the end of treatment. The rate of major complications was considerable, 
per procedure the complication risk (cholangitis, pancreatitis and post procedural pain) 
was 14% and in total 21 of 31 patients (68%) encountered some kind of complication 
during the course of treatment.
In this cost-analysis, costs were calculated top-down meaning that direct costs were 
retrieved from the source data of the financial department of our institution. With this 
method all costs of the procedure, including used accessories and costs of admittance 
are included in the analysis. Thus calculated we compared the costs of PPS with six dif-
ferent hypothetical scenarios of fcSEMS treatment.
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To perform the analysis we made several assumptions. Firstly, we presumed that the 
efficacy of fcSEMS treatment is equal or better than PPS. Secondly, we assumed that 
complication rates of both treatment options are equal.
The cost of an ERCP without stentplacement was calculated at €750. Costs of plastic 
stent placement were €51 a piece. For the analysis two prices of fcSEMS were used, ini-
tially a price of €1500 was chosen but since the price of fcSEMS is decreasing, scenarios 
with a price of €1000 per fcSEMS were also calculated.
Six scenarios were calculated. Scenarios A and B are the most optimistic in assuming 
that only two ERCP’s and one fcSEMS would be necessary at respectively €1000 en €1500 
per fcSEMS. In scenarios E and F it was assumed that a second ERCP with fcSEMS place-
ment would be necessary in 30% of patients and a third ERCP with fcSEMS placement 
in 10% of treated patients. Finally, in scenario C and D a break-even calculation was 
performed to determine the mean number of ERCP’s with fcSEMS per patient at what 
point the costs of fcSEMS and PPS are equal.
RESUlTS
The results of the analysis are depicted in table 1. The total costs of PPS were calculated 
at €4196. The use of fcSEMS contributed to lower costs in all scenarios. Not surprisingly 
the highest reduction was achieved in the most optimistic scenarios A (cost of fcSEMS 
€1000) and B (cost of fcSEMS €1500) when assuming that only 2 ERCP’s were needed 
in the fcSEMS scenario. If this would be the case a cost reduction of €1696 (scenario A) 
or €1196 (scenario B) can be achieved, reducing costs of treatment by 40% and 29% 
respectively.
In scenarios E (cost of fcSEMS €1000) and F (cost of fcSEMS €1500), assuming perhaps 
more realistically that 30% of patients would need placement of a second fcSEMS and 
Table 1: cost analysis of different scenarios.
Scenario Treatment costs mean ERCPs with
fcSEmS placement
Total ERCPs
per patient
Cost reduction
compared to PPS
PPS € 4196 0 5.0
fcSEmS a € 2500 1.0 2.0 € 1696 (40%)
fcSEmS b € 3000 1.0 2.0 € 1196 (29%)
fcSEmS C € 4196 1.97 2.97
fcSEmS D € 4196 1.53 2.53
fcSEmS E € 3200 1.4 2.4 € 996 (24%)
fcSEmS F € 3900 1.4 2.4 € 296 (7%)
PPS: progressive plastic stenting
fcSEMS: fully covered self expandable metal stent
162 Section 3
10% placement of a third fcSEMS, the use of fcSEMS also would lead to significant cost 
reduction compared to PPS. In scenario E costs would be reduced by €996 (24%) and in 
scenario F still by €296 (7%).
Finally, in scenarios C and D, once again with assumed prices of fcSEMS of €1000 
and €1500 respectively, the break-even point was calculated. This results in the maxi-
mum mean number of ERCP’s with fcSEMS placement allowed to achieve equal costs 
for fcSEMS placement compared with PPS. In scenario C this number is 1.97 meaning 
that if, on average, 1.97 ERCP’s with fcSEMS placement per patient are performed costs 
are equal. If this number is lower, the use of fcSEMS leads to cost reduction. Inversely, 
for higher averages, the use of fcSEMS becomes more expensive. For scenario D this 
number is 1.53.
DISCUSSION
To our knowledge this is the first study investigating the cost-effectiveness of the use 
of fcSEMS in the treatment of patients with AS after OLT. We clearly show that the use 
of fcSEMS not only leads to a decrease in patient burden by reducing the number of 
ERCP’s needed but also leads to a significant cost reduction in all clinical scenarios we 
investigated despite the high prices of fcSEMS in comparison to plastic stents.
For a new technique or method to become accepted efficacy, safety and cost-
effectiveness are equally important. Since no comparative studies have been performed, 
we need to rely on, mainly retrospective, case-series. These have been published on 
both PPS and fcSEMS treatment [4, 10-24]. When both approaches are compared based 
on these data, the treatment of post OLT anastomotic strictures with fcSEMS appears 
to be at least as efficacious as the treatment with PPS. With regards to complications 
per procedure the data are more varying for both methods and difficult to interpret. 
General ERCP risks as post-ERCP pancreatitis and sphincterotomy related complications 
as bleeding and perforation are likely to be similar. Placement of fcSEMS in benign biliary 
strictures, including AS after OLT, however introduces “new” and potentially serious com-
plications such as proximal and distal migration and removal difficulties[16-18, 20, 22].
Nevertheless, this study has several weaknesses. First, the method chosen, a top-
down analysis, potentially misses costs that are not directly handled by the financial 
department. Second, the scenarios chosen were calculated under the assumption that 
both success and complication rates are equal for both scenarios. Given the lack of a 
trial comparing both strategies and the relatively small number of patients in published 
papers this assumption had to be made, especially since the reported complication rates 
for PPS vary between 1.4% and 24%.[11-15, 24] For the case series published describing 
the use of fcSEMS specifically in OLT patients, the complication rate, including migration, 
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varies between 27% and 47%[19, 21, 22, 25]. Since most migrations in these studies 
were without clinical consequences, the premise of an equal complication rate seems 
justified. Efficacy rates in the same series vary between 53% and 94%. It seems likely that 
these differences are at least partially explained by differences in types of fcSEMS and 
the duration of treatment.
Strengths of this study are that the used method of cost calculating is robust, 
especially since data from the financial department were used, and reflect true costs. 
Furthermore, it seems likely that our results, although calculated only for OLT patients 
with AS, can be extrapolated to other patients with BBS. AS after OLT are, in common 
daily practice, rarely encountered and other causes of BBS such as chronic pancreatitis 
and after cholecystectomy are much more common. Since costs of treatment in BBS 
are, as our study shows, largely determined by the number of ERCP’s needed and the 
costs of fcSEMS, the principles and the outcome with regards to costs are likely to be 
interchangeable. However, as in OLT patients, to definitely answer these questions, 
comparative trials are needed.
In summary, our study clearly shows that, when complication and efficacy rates of 
both treatment arms are the same, the use of fcSEMS in the treatment of patients with 
AS after OLT, leads to a substantial cost reduction compared to PPS.
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abSTRaCT
background
Fully-covered self expandable metal stents (fcSEMS) are an alternative to progressive 
plastic stenting for the treatment of benign biliary strictures (BBS) with the prospect of a 
higher treatment efficacy and the need for fewer ERCPs, thereby reducing the burden for 
patients and possibly costs. Key to this novel treatment is safe stent removal.
aim
We investigated the feasibility and safety of stent removal of a fcSEMS (MITech, Korea) 
with a proximal retrieval lasso: a long wire thread integrated in the proximal ends of the 
wire mesh that hangs freely in the stent lumen. Pulling it enables gradual removal of the 
stent inside-out. Secondary aim was success of stricture resolution.
methods
Non-randomized, prospective follow-up study with 3 sequential groups of 8 patients 
with BBS. Patients had strictures either postsurgical (post-cholecystectomy (LCx) or liver 
transplantation (OLT)), due to chronic pancreatitis (CP), or papillary stenosis (PF). Stric-
tures had to be located at least 2 cm below the liver hilum. All patients had one plastic 
stent in situ across the stricture and had not undergone previous treatment with either 
multiple plastic stents or fcSEMS. The first cohort of patients underwent stent place-
ment for 2 months, followed by 3 months if the stricture had not resolved. The second 
and third cohort started with 3 months and 4 months, respectively, both followed by 
another 4 months if indicated. Treatment success was defined by stricture resolution at 
cholangiography, the ability to pass an inflated extraction balloon and clinical follow-up 
(at least 6 months).
Results
23 patients (11 female; 20–67 yrs) were eligible for final analysis. One patient developed 
a malignant neuroendocrine tumor in the setting of CP. Strictures were caused by CP 
(13), OLT (6), LCx (3) and PF(1). In total 39 fcSEMS were placed and removed. Removals 
were easy and without complications. Transient pain after insertion was common (13 of 
23/56%) but was easily managed by analgesics in all patients. Other complications were 
cholecystitis (1), cholangitis due to stent migration (1, stent replaced) or stent clogging 
(2, managed endoscopically) and worsening of CP (2). In these patients, the fcSEMS was 
removed and replaced after pancreatic sphincterotomy and PD stent placement. Median 
follow-up was 15 months (range 11 – 25). Overall treatment success was 61% (14/23); in 
the CP group 46%, in the remaining patients 80% (p=0.11). Patients with stricture resolu-
tion after removal of the first stent (n=7; success 6/7) showed a trent towards a more 
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sustained treatment success than patients who needed a 2nd stent placement (n=16; 
success 8/16); p=0.12).
Conclusions
Removal of a new type of fcSEMS with a proximal retrieval lasso in patients with BBS 
proved easy and uncomplicated. Treatment success for CP strictures was higher com-
pared to what is known from results of progressive plastic stenting protocols. For other 
indications treatment success was comparable to progressive plastic stenting, but with 
the prospect of fewer ERCP procedures.
INTRODUCTION
Benign biliary strictures (BBS) can be caused by a number of conditions, e.g. primary scle-
rosing cholangitis, papillary stenosis, autoimmune pancreatico-cholangitis or bile duct 
stones[1]. The most commonly occurring causes of BBS are however chronic pancreatitis 
and postoperative bile duct injuries, either due to cholecystectomy or anastomotic after 
liver transplantation[2-5]. Adequate and definite treatment is essential since persistence 
of biliary strictures ultimately can lead to secondary biliary cirrhosis apart from jaundice 
and cholangitis[6]. Although surgery is still considered to be the most definitive treat-
ment for BBS, an initial attempt by endoscopic means is usually undertaken given the 
invasive nature of surgical treatment and the relatively low morbidity and mortality of 
endoscopic treatment. The success of endoscopic intervention is highly dependent on 
the underlying cause of the stricture. Whereas in post-surgical strictures success rates of 
endoscopic treatment of up to 80% have been published, strictures due to chronic pan-
creatitis in general respond less favorably to conventional endoscopic treatment with 
success rates of approximately 25%[7-10]. The initial endoscopic treatment protocol 
generally consisted of placement of a single large bore plastic endoprosthesis. This has 
evolved into a more aggressive approach where during a year of endotherapy elective 
stent exchanges every 3 months with placement of an incremental number of stents 
lead to a 89% success rate in a retrospective cohort series of postoperative bile duct 
strictures[11]. Results of this strategy in chronic pancreatic induced biliary strictures, 
especially in calcifying disease, are less impressive although only small case series have 
been published with limited follow-up[12, 13]. However, even under ideal circumstances 
and a favourable outcome, this strategy requires multiple ERCPs with associated risks, 
costs and patient burden. Therefore the use of self expanding metal stents has been 
investigated in BBS. Uncovered SEMS are not usable in BBS since, despite their larger 
diameter, stent clogging occurs almost invariably due to epithelial / mucosal hyperpla-
sia[14-16]. Furthermore removal is extremely hard or impossible. The use of partially 
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covered SEMS has been hampered by increased rates of migration, stent clogging when 
in place indefinitely and removal difficulties [17-20].
For this reason the use of fully covered SEMS (fcSEMS) has been investigated in a 
number of studies, after removal was shown to be possible[21-26]. The main concerns 
of fcSEMS use in BBS are migration and complicated removal due to unraveling of the 
stent.
Several techniques for removal of fully covered stents are available. Firstly the distal 
end can be grasped with a snare and subsequently the entire stent is pulled out. A po-
tential disadvantage of this technique is that the whole surface area of the stent inside 
the common bile duct must detach at the same. A considerable force is sometimes 
needed, especially when deployed across a tight stricture. This increases the chance of 
distortion and disintegration of the stent. Secondly a distal lasso can be used, both for 
stents that have been deployed across the papilla and stents that are placed fully inside 
the common bile duct and use the distal lasso as an anchor[26]. Although the use of a 
distal lasso causes lengthening of the stent thereby facilitating stent removal still the 
entire surface area of the stent must detach from the mucosa of the common bile duct 
at the same time.
For this reason we conducted a prospective, non-randomized sequential group 
study in patients with benign biliary strictures with the aim to investigate feasibility, 
safety and effectiveness of a new type of fully covered SEMS with a proximal lasso. We 
hypothesized that the use of a proximal lasso would enable removal of the stent inside-
out in a more controlled way with less force since the proximal end of the stent would 
be slowly pulled into the lumen. This would enable gradual inversion and detachment 
of the stent. Also the direction of force would be in a straight line with the orientation 
of the stent.
Another possible advantage of a proximal lasso could be that in the case of inward 
migration the long proximal lasso can be maneuvered into the duodenum with the aid 
of a grasping forceps or extraction balloon thereby providing an easy and safe way to 
complete stent retrieval in these cases.
PaTIENTS aND mETHODS
Design
This was a non-randomized prospective follow-up study with a sequential group design. 
Because safety of stent removal was defined as the primary outcome parameter, the 
cohort of 24 patients with BBS was divided into 3 subgroups A, B and C of 8 patients. In 
group A the first stent was removed after 2 months and, depending on the cholangio-
graphic result, a second stent could be deployed and left in situ for 3 months. If in this 
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group stent removal after 2 months proved safe these periods were extended to 3 and 
4 months respectively in group B whereas in group C a maximum of two stents could be 
deployed for two periods of 4 months. Therefore the maximum duration of therapy was 
5 months in group A, 7 months in group B and 8 months in group C.
The primary outcome parameter of the study was successful removal of the stent 
using the proximal lasso. Secondary outcome parameters were stricture resolution, 
complications, ease of stent removal, stent patency, migration rate, integrity of the 
covering membrane and the number of endoscopic procedures.
Stent design, insertion and removal
For this study a novel nitinol prototype fully covered SEMS was used (Hanaro, M.I. Tech, 
Seoul, Korea; figure 1). The stent is double flared as an antimigration feature. The intro-
duction system is 8.5 french and available in 50, 60, 70, 80 and 90 mm total length. The 
diameter once fully deployed is 10 mm. Gold radiopaque markers are on both proximal 
and distal end of the stent to facilitate accurate deployment and positioning. Recaptur-
ing and redeployment of the stent is possible. Both a distal and proximal lasso are at-
tached to the stent. Traction on the proximal lasso causes inversion of the proximal part 
of the stent into the lumen (figure 2a and 2b; video of fluoroscopy at time of removal).
Stents were placed and removed at ERCP by experienced biliary endoscopists (JWP, 
MB) after biliary sphincterotomy. In patients with an intact gallbladder it was attempted 
Figure 1: Prototype Hanaro fully covered stent with proximal and distal lasso
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to position the proximal end of the stent below the level of the cystic duct insertion 
whenever possible.
Removal of the stent firstly was attempted by grasping the proximal lasso with 
grasping forceps or snare. If the lasso could not be identified the stent was swept with 
an extraction balloon in an attempt to pull the lasso into the duodenum. If this failed 
then the distal lasso was used to remove the stent.
All patients with gallbladders and those after livertransplantation received antibiot-
ics periprocedurally during 24 hours.
Patients
Inclusion and exclusion criteria are listed in table 1. The study was approved by our 
institutional review board and all patients gave written informed consent.
In all patients with non-surgical causes of the stricture both cross-sectional imaging 
(CT or MRI) and endoscopic ultrasonography were performed to rule out a malignant 
cause of the stricture. Patients had one plastic stent in situ across the stricture before 
enrollment. Previous treatment with either multiple plastic stents or fcSEMS was not 
allowed.
a b
Figure 2 a and b: Traction on the proximal lasso enables inside-out removal of the stent
Table 1: Inclusion and exclusion criteria.
Inclusion criteria
BBS due to a post surgical injury
BBS due to chronic pancreatitis
BBS due to ampullary stenosis
Age above 18 years
Exclusion criteria
Proximal extend of the stricture less than 2 cm below the liver hilum
Non-anastomotic stricture (post OLT)
Previous treatment with SEMS or more than 1 plastic stent
Refusal to sign informed consent
BBS = benign biliary stricture
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Between September 2008 and December 2009 24 patients were enrolled into the 
study. One patient, included in group B, was removed from the analysis because his 
presumed benign biliary stricture eventually proved to be caused by a malignant pan-
creatic neuro-endocrine tumor (table 2).
Follow up
Patients were followed at the outpatient clinic. Both laboratory parameters and imaging 
methods were used to assess clinical outcome with regards to cholestasis and stricture 
resolution. Treatment success was defined as resolution or improvement of the stricture 
on the cholangiogram, the ability to pass an inflated extraction balloon easily through 
the stricture and the absence of cholestasis during follow up of at least 6 months.
Descriptive statistics were performed and data are presented as numbers with sub-
sequent percentages. All statistical analyses were performed using SPSS version 16.0 
(SPSS Chicago Illinois, USA).
RESUlTS
Outcome
All 23 patients completed the study protocol. All stent placements were technically suc-
cessful (figure 3). Median follow up was 15 months (range 11 - 25). Results with regards 
to overall treatment success are shown in figure 4. Overall success rate was 65% (15 / 23). 
The chance of an overall treatment success was lower in patients with a BBS due to chronic 
pancreatitis (success rate 46%; 6/13) compared to any other cause of BBS (success rate 80%; 
8/10) although this difference did not reach statistical significance (p=0.11). Those patients 
that had resolution of their stricture after removal of the first stent, 6 out of 7 (86%) appar-
ently had a better outcome than those patients that required placement of a second stent, 8 
out of 16 (50%), although this difference also did not reach statistical significance (p=0.12).
The average stent time for treated patients was 5.5 months.
Table 2: patient characteristics
Characteristics No.
Total no. of patients 23
Mean age (y; range) 57 (29 – 74)
Etiology of BBS
 Chronic pancreatitis 13
 Post LTx 6
 Post cholecystectomy 3
 Papillary stenosis 1
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Removals
In total 39 stents were deployed and removed without complications. In one patient 
with chronic pancreatitis and a very tight stricture the wire mesh appeared to broken at 
the time of removal. Despite this the stent could be removed easily and replaced accord-
ing to protocol. Removal was judged to be easy by the endoscopists in all other cases. 
The proximal lasso was hanging in the duodenal lumen in 37 of 39 removals (95%). In 
the other two cases it was possible to retrieve the proximal lasso by sweeping the stent 
with an extraction balloon. Removals were performed with removal of the endoscope.
Complications
Several complications occurred (table 3). We observed one case of cholecystitis 1 week 
after placement of the first fcSEMS that was managed conservatively with antibiotics and 
percutaneous gallbladder drainage. Two patients with chronic pancreatitis developed 
worsening of their chronic pancreatitis within one month after the stent placement. 
Both cases were managed with subsequent pancreatic sphincterotomy and insertion 
a b C
Figure 3. a: Narrow stricture of the common bile duct after laparoscopic cholecystectomy.
b: Deployment of an 8 cm fully covered self-expandable metal stent with a proximal lasso.
C: Cholangiogram after 3 months with a stent in place.
CP	  (n=13)	  
*utc./e	  in	  23	  345ents	  
with	  BBS	  
LTx	  (n=6)	   PS	  (n=1)	  LCx	  (n=3)	  
success	  in	  
6/13	  (46%)	  
success	  in	  
8/10	  (80%)	  
Figure 4: Overall outcome in 23 patients with benign biliary strictures (BBS). CP, chronic pancreatitis; LTx, 
liver transplantation; LCx, laparoscopic cholecystectomy; PS, papillary stenosis.
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of a temporary plastic stent in the pancreatic duct. Despite the antimigratory features 
of the stent used in this study, outward migration three weeks after stent placement 
induced cholangitis in one patient. At repeat ERCP a persistent stricture was observed 
and a second study stent was inserted. Two other cases of cholangitis were caused by 
clogging of the stent and were managed by cleaning the stent with an extraction bal-
loon at 5 and 8 weeks following stent placement.
The most frequently encountered complication was pain immediately after deploy-
ment of the stent. In all cases the pain subsided within 1 week and could be managed 
by temporary analgesics.
DISCUSSION
In this first prospective group sequential study on the use of fcSEMS in patients with BBS 
this novel type of SEMS proved to be effective and both easy and safe to remove. The 
proximal lasso, which is the main new feature of this stent, proved to be advantageous 
and easy to use. In the vast majority of cases the proximal lasso was hanging freely in 
the duodenal lumen and could be easily grasped with either a grasping forceps or a 
snare. When grasped the stent was easily removed inside out without exerting much 
force. This potentially could reduce the chance of complications associated with stent 
removal such as unraveling and bleeding. Furthermore, in a recent paper concerning 
patients with biliary leaks after liver transplantation clinically significant biliary strictures 
developed at the level of the deployed fcSEMS with extensive mucosal ulcerations visu-
alized during choledochoscopy[27]. It is conceivable that this is at least partly due to the 
trauma associated with removal of the fcSEMS.
The outcome with regard to stricture resolution in this study on patients with non 
chronic pancreatitis induced BBS is comparable to the literature[11, 13, 28]. The number 
of procedures needed in a fcSEMS based strategy is expected to be lower than in a 
progressive stenting protocol. However, since no comparative studies exist, care must 
be taken to compare results between studies. Although the difference between chronic 
Table 3: complications
Complications No.
Cholecystitis 1 (4%)
Worsening of chronic pancreatitis 2 (9%)
Cholangitis
 Migration 1 (4%)
 Clogging 2 (9%)
Pain 13 (57%)
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pancreatitis induced BBS and other types of BBS in this study, that was not powered to 
do so, did not reach statistical significance, the results were still less favourable in the 
chronic pancreatitis group. This is in concordance with previously published papers as is 
the final success rate of 46% in our series with a median follow up of 15 months (range 
11 – 25 months) [10, 12, 13, 18, 19, 22, 29]. We also observed a trend towards a higher 
success rate when the stricture had improved significantly after removal of the first stent 
versus those that needed a second stent (success rate 86% vs 50%; p=0.12), but evidently 
the study was not designed and powered to investigate these effects. Furthermore it is 
important to emphasize that duration of stent therapy in our series was relatively short 
since the primary endpoint of the study was a safe stent removal. Given the fact that the 
majority of patients needed a second stent period and that the average time of stenting 
was 5.5 months, outcome might even improve further when patients would get treated 
with a longer indwelling stent time.
A major concern with the use of fcSEMS is the relatively high complication rate. The 
most frequently observed complication in our series was transient pain after deploy-
ment of the stent. This is probably explained by the relatively rapid dilation of the stent 
in the first 24 to 48 hours when it reaches its final diameter and in this sense compa-
rable to balloon dilation of the biliary tract. Although easily managed by temporary 
acetaminophen and/or NSAIDS and explained to the patients, it causes some, albeit 
transient, discomfort. There was no need for early stent removal in any of these patients. 
Cholecystitis can be a complication of any ERCP but it is well known that the risk is in-
creased when fcSEMS are placed[30]. This might be explained by occlusion of the cystic 
duct. In our series we had one case of cholecystitis despite the use of periprocedural 
antibiotics that could be managed conservatively. Another issue with the use of fcSEMS 
is migration. In our series this occurred with one stent in one patient (3%) leading to 
cholangitis around the time of scheduled stent exchange. The migration percentage of 
fcSEMS reported in the literature varies between 0 and 14%[22, 23, 25, 26, 30, 31]. It is 
conceivable that further improvements in stent design, such as double flares in the stent 
we used, or anchoring flaps or a completely intraductally located stent might further 
reduce this potential risk[26, 32]. Two cases of cholangitis were seen in our series that 
necessitated endoscopic intervention. In both cases clogging of the stent with biliary 
sludge was observed and easily managed with cleaning of the stent with an extraction 
balloon without the need for stent exchange.
Despite the routine sphincterotomy before deployment of the fcSEMS we observed 
worsening of chronic pancreatitis in two patients. Although this has been previously 
described and probably explained by pressure exerted by the stent on the pancreatic 
duct in most series this was not a particular concern[30, 33]. Both cases were managed 
endoscopically by pancreatic sphincterotomy and insertion of a plastic stent in the 
pancreatic duct for the duration of biliary stenting. In previously published data the 
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suggestion was made that the risk for developing pancreatitis was increased in those 
patients without pancreatic duct dilation. Both patients in our series however had an 
already dilated pancreatic duct. Clearly, based on only two cases one should be cautious 
to make any recommendations about the prevention of worsening of CP during the 
treatment of BBS with fcSEMS, but this issue definitely deserves further attention and 
consideration.
In summary this study shows that a new type of fcSEMS with a proximal lasso can 
be removed safely and proved efficacious for the treatment of BBS, especially in those 
patients with strictures not related to chronic pancreatitis, at potentially lower costs and 
patient burden, compared to progressive stenting with multiple plastic stents.
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abSTRaCT
background
Most benign biliary strictures nowadays are managed endoscopically with plastic stents 
or with the insertion of a fully covered self-expandable metal stent (fcSEMS). The para-
digm for the treatment of benign hilar strictures precludes the use of fcSEMS because 
such obstructs intrahepatic bile ducts, in particular the contralateral hepatic duct. It is 
unknown whether use of a plastic stent in the opposite hepatic duct after deployment 
of a fcSEMS across the liver hilum provides an adequate solution for this issue.
Objective
To evaluate the use of fcSEMS in combination with a contralateral plastic stent in the 
treatment of benign hilar strictures.
Design
Case series.
Setting
Tertiary referral hospital.
Patients
Two consecutive patients with benign hilar strictures.
Interventions
Placement of an intrahepatically deployed fcSEMS in conjunction with a contralateral 
10 fr plastic stent during 4 to 5 months followed by stent removal and cholangiogram.
Outcome measurements
Clinical and laboratory follow up of at least 9 months.
Results
In both patients the indwell period of stenting was uneventful as was stent removal. Both 
strictures resolved and there were no clinical or biochemical signs of a recurrent stricture.
limitations
Limited number of patients.
Conclusions
Treatment of benign hilar strictures with a fcSEMS deployed across the liver hilum in 
conjunction with contralateral plastic stent placement is feasible without ensuing chol-
angitis due to bile duct occlusion.
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INTRODUCTION
The aetiology of benign biliary strictures (BBS) is diverse and includes among others 
chronic pancreatitis, primary sclerosing cholangitis, auto-immune cholangitis and trau-
ma. In the Western world important causes are iatrogenic, in particular postsurgical after 
cholecystectomy or liver transplantation. The majority of these strictures are, at least 
initially, managed endoscopically. Both temporary placement of multiple plastic stents 
according to a so-called progressive stenting protocol and deployment of removable 
fully covered self expandable metal stents (fcSEMS) have shown promise in this respect 
with high efficacy rates and an acceptable complication risk, even though prospective 
randomized controlled clinical trials are lacking[1, 2].
Although the majority of iatrogenic BBS are located below the hepatic bifurcation 
in up to 14% of cases the stricture extends into or at the level of the hepatic confluence 
[3, 4]. The prognosis of endoscopic therapy in patients with involvement of the liver 
hilum is poor with success rates of 25% or lower[3, 4]. This is at least partly due to the 
fact that placement of multiple plastic stents through these strictures is often difficult 
while treatment success of BBS in general seems dependent upon the aggressiveness 
of stricture dilation, i.c. the number of simultaneously inserted plastic stents[5-7]. In this 
respect the use of fcSEMS is attractive as it has a dilation diameter of 33 fr which is com-
parable to 7-8 plastic stents of 10 fr positioned side-by-side. However, use of fcSEMS has 
not been described in this setting given the high likelihood of occlusion of intrahepatic 
bile ducts., in particular the contralateral hepatic duct and liver lobe. Therefore in all 
published series describing the use of fcSEMS these strictures had to be located at least 
2 cm below the level of the liver hilum[2, 8, 9].
We speculated that the combination of an intrahepatically deployed fcSEMS in con-
junction with contralateral plastic stent placement would provide adequate stricture 
dilation whilst preventing occlusion of the opposite ducts in patients with benign biliary 
hilar strictures.
mETHODS
A novel type of fcSEMS with both a proximal and distal retrieval lasso, a long wire 
thread integrated in the proximal ends of the wire mesh that hangs freely in the stent 
lumen, was used (M.I.Tech, Seoul, Korea; figure 1a). Pulling the proximal lasso enables 
gradual removal of the fcSEMS inside-out and since detachment of the stent from the 
wall of the common bile duct is gradual this feature should facilitate removal of the 
stent. The diameter is 33 french (10 mm) with both proximal and distal flares as an 
antimigration feature. The length, 12 cm, was longer than usual for biliary metal stents 
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and this batch was manufactured specifically for the purpose of transhilar deployment. 
We have extensive experience with shorter versions of this stent in the treatment of 
non-hilar BBS.
ERCPs were performed under conscious sedation. After obtaining a cholangiogram, 
defining hilar anatomy and assessing the extent of the stricture, two guidewires were 
introduced into both the left and right biliary system. A 10 fr plastic stent (Cook En-
doscopy, Limerick, Ireland) was positioned across the liver hilum into the contralateral 
liver lobe. Finally the fcSEMS was deployed alongside the plastic stent with the proximal 
end of the SEMS extending above the stricture. Both stents were removed after 4 to 5 
months and a repeat cholangiogram was obtained.
Patients gave informed consent before the procedure and were informed about the 
new aspects of this treatment.
Case 1
A 36-year-old woman underwent a laparoscopic cholecystectomy for cholecystolithiasis 
that was converted to an open procedure due to an injury of the common hepatic duct. 
The lesion was closed peroperatively, nevertheless postoperatively bile leakage was 
demonstrated at the level of a stricture in the hepatic hilum (Figure 2).
The patient underwent multiple ERCPs with repeated balloon dilation upto 6 mm of 
both left and right system combined with bilateral 10 french single plastic stent place-
ment during 3 months but the stricture did not resolve and she remained stent depen-
dent.. After the patient was referred to our institution, a MRI/MRCP yielded no additional 
information. The hepatic artery was open. After discussing all options, including surgical 
repair, it was decided to re-treat this stenosis endoscopically with a combination of a 
removable covered metal stent and a contralateral plastic stent. ERCP performed in our 
institution revealed that the most severe stenosis was located towards the left system. 
After guidewire placement to both left and right system and balloon dilation up to 6 mm 
a b
Figure 1a. Proximal retrieval loop inside the lumen at the distal 
end of the fully covered self-expandable metal stent.
Figure 1b. Partial inside-out after pulling of proximal retrieval 
lasso
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a 12 cm 10 french plastic stent was placed in the right system and a 12 cm 10 mm fcSEMS 
was placed in the left system (Figure 3).
The postprocedural course was uneventful and no signs of cholestasis or cholangitis 
developed. Antibiotic prophylaxis was given for 72 hours periprocedural. After 5 months 
Figure 2. Postoperative hilar stricture with leakage.
Figure 3. After insertion of both the plastic and fully covered self-expandable metal stents through the 
hilar stricture.
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elective re-ERCP was performed during which the fcSEMS was extracted easily using the 
proximal lasso. After removal of the fcSEMS the plastic stent was removed as well. Oc-
clusion cholangiography revealed complete resolution of the stricture towards both the 
left and the right system (Figure 4). At 11 months follow up, 16 months after insertion of 
the fcSEMS, there are no signs of a recurrent stricture.
Case 2
A 29 year old woman underwent orthotopic livertransplantion from a post-mortem do-
nor 2 years previously because of acute liver failure. Despite an uneventful postoperative 
course she developed a stricture at the level of the anastomosis that was treated with a 
progressive stenting protocol over the course of 9 months with initially good results. A 
maximum of four 10 french stents were inserted during this period. Three months after 
finishing the protocol she developed recurrent cholestasis and repeat ERCP revealed a 
recurrent stricture that extended partially into the liver hilum, mainly towards the right 
system (figures 5 and 6).
At repeat ERCP both left and right system were selectively cannulated and guide-
wires left in situ. After balloon dilation to 6 mm a 12 cm 10 fr plastic stent was placed 
into the left system and a 12 cm 10 mm fcSEMS into the right system. The procedure 
went uncomplicated and cholestasis disappeared. Antibiotic prophylaxis was given 
periprocedurally (72 hours). At 4 months ERCP was repeated and the fcSEMS was re-
moved uneventfully with the aid of the proximal lasso. Afterwards the plastic stent was 
removed. Cholangiography revealed complete stricture resolution. Unfortunately no 
fluoroscopy images of these procedures are available since both ERCP’s were performed 
Figure 4. Occlusion cholangiogram showing complete resolution of the hilar stricture.
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under general anaesthesia at the OR and at that time, no fluoroscopy images could be 
stored. Until now, at 9 months follow up, 13 months after placement of the fcSEMS, there 
are no signs of recurrent strictures.
DISCUSSION
These two cases demonstrate that the use of fcSEMS in the treatment of benign biliary 
strictures affecting the liver hilum is feasible and potentially effective. Both deployment 
and removal of the fcSEMS were easy and without complications. The use of a contra-
laterally postioned plastic stent precluded the feared complication of cholangitis of the 
contralateral system. This was not encountered during a total of 9 months of treatment 
in our two patients. Theoretically the chance of occlusion of a secondary bile duct might 
be larger with deployment of a fcSEMS to the right side since the most commonly oc-
a b
Figure 5a. Left system with hilar stenosis (case 2). 5b. Hilar anatomy (case 2)
Figure 6. Case 2 with plastic stents in situ.
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curring biliary anatomic variant has a bifurcation between right posterior and anterior 
segments above the liver hilum.
Although our 2 patients had BBS that extended into the liver hilum, the same 
technique can also be used in patients that have strictures located very proximal in 
the common hepatic duct in whom normally there would be insufficient space for the 
deployment of a fcSEMS.
Although both our patients had failed stricture resolution after a conventional plas-
tic stenting and showed a satisfactory outcome after fcSEMS treatment, it remains to be 
proven whether this new treatment is more effective than conventional treatment with 
plastic stents. This should preferably be studied in a randomized prospective trial even 
though the relative rarity of this condition will impair such a study. It is not known for 
how long a fcSEMS should be left in situ in this setting. Based on previous experience 
we choose a 4 to 5 month period in an attempt to balance the dilation effect and the 
difficulty of stent removal, both presumably increasing with prolonged in situ duration 
of fcSEMS.
Apart from cholangitis another potential complication would be secondary strictures 
in the intrahepatic bile ducts due to the relatively large diameter of the present fcSEMS 
design in comparison with the diameter of the ducts. A potentially very serious com-
plication and although we have not observed this and potentially the use of a smaller 
diameter stent might decrease the chance of this complication occurring, caution is 
warranted.
In conclusion, we believe that this new approach combining an intrahepatically 
deployed fcSEMS with a protective intrahepatically placed plastic stent into the contra-
lateral liver lobe shows promise in the treatment of benign biliary hilar strictures with 
regard to efficacy and patient burden, since potentially it can reduce the number of 
ERCPs a patient has to undergo substantially. Nevertheless, more experience needs to 
be gained with this approach since especially the safety of this procedure remains a 
concern and might be dependent on local biliary anatomy.
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SUmmaRY aND CONClUSIONS
In the first section of this thesis, Endoscopic ultrasonography in screening and diagnosis 
of pancreatic disease, the role of EUS with regards to its diagnostic value is investigated. 
In chapter 2 we could demonstrate that in a cohort of patients with an increased risk to 
develop pancreatic cancer (PC) EUS is able to accurately confirm or exclude the pres-
ence of benign, premalignant en malignant lesions. Since the prognosis of PC is almost 
uniformely abysmal when diagnosed after the development of symptoms, one of the 
potential ways to improve outcome of this disease is to detect these lesions at an earlier, 
asymptomatic stage. Since the overall incidence of PC is too low to justify population 
based screening, identifying risk groups and offer them a tailored approach with regards 
to screening is at present the only option available. These risk groups are mainly those 
kindreds in whom a hereditary component is present. Some form of inheritance is 
thought to be present in approximately 10-15% of all PC cases.
To identify this hereditary component both awareness of treating physicians and 
surgeons and extensive genetic analysis of affected individuals and families are im-
portant. In our series we could identify a pathogenic mutation in approximately half 
of the screened individuals (52%). Once a mutation in a family has been identified it is 
relatively easy to identify individuals at risk. Furthermore, efficacy and yield of a screen-
ing program will increase when the proportion of individuals with proven pathogenic 
mutations is higher.
We chose to use EUS for screening since with EUS it is possible to visualize the pan-
creas with unsurpassed detail and resolution. A potential drawback is the fact that it 
is a relatively invasive procedure that requires conscious sedation and the results are 
strongly operator dependent.
In our study, describing the results of baseline screening, 44 individuals were 
screened. Twenty-one of them were from families without a known mutation, known 
as familial pancreatic cancer (FPC) whereas the remainder of screened individuals were 
carrier of pathogenic mutations in genes causing Peutz-Jeghers syndrome, hereditary 
breast- and ovarian cancer and familial atypical multiple mole melanoma syndrome. In 
three individuals (out of 44; 6.8%) asymptomatic lesions in body and tail were found 
with diameters of 10, 27 and 50 mm. Despite surgical resection these three patients 
subsequently developed liver metastases and eventually died from there disease. In 
seven individuals (15.9%) cystic lesions with sizes between 4 and 15 mm were found. 
All cystic lesions were unilocular without intramural nodules or solid components. On 
EUS communication with the pancreatic duct was either demonstrated or very likely 
and therefore these lesions were highly likely to be side branch intraductal papillary 
mucinous neoplasias (IPMN). IPMNs are precursor lesions of pancreatic malignancy and 
the much higher incidence than expected in our series but also in some other published 
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cohorts is very likely to be related to the increased risk for the development of pancreatic 
cancer in these families.
Although are study clearly demonstrates that EUS is able to identify asymptomatic 
benign and malignant in a considerable proportion of individuals thought to be at an in-
creased risk to develop pancreatic cancer, this does not necessarily mean that outcome 
for these patients will be better.
Our study is the first study on this subject in Europe and differs in one important 
aspect from previously published studies in that the proportion of individuals with a 
clearly defined genetic syndrome was much higher. Whether this explains solely the 
higher incidence of both solid lesions and cystic precursor lesions remains to be inves-
tigated although all mass lesions in our series were found in mutation carriers. The aim 
of the present study was not to establish differences between these groups and lacks 
statistical power to reliably ascertain whether this is explained by genetic background. 
Furthermore, other risk factor, e.g. smoking, needs to be taken into account. The inci-
dence of cystic lesions in FPC individuals in our series is 15% (3 out of 20) which is still 
higher than in the US series mentioned above.
Clearly a surveillance and screening protocol for pancreatic cancer needs to focus on 
detection and management of premalignant lesions. This is demonstrated by the fate of 
those patients in whom an invasive malignancy was detected. Despite the asymptomatic 
stage and curative surgery these patients underwent, the outcome of their disease was 
not influenced by the early detection. One could argue that screening simply started 
to late in these patients and that earlier screening procedures would have been able to 
detect these lesions at an earlier and potentially curable stage.
Another important and still unanswered question is how to manage the IPMN-like 
cystic lesions that we and others found to be present at an relatively high frequency 
in individuals at high risk of developing pancreatic cancer, especially in light of the as-
sumption that these may represent precursor lesions of pancreatic cancer. It is known 
now from several retrospective cohort studies that the likelyhood of malignancy in 
small branch type IPMN’s without involvement of the main pancreatic duct, intramu-
ral nodules or solid components is quite small. In sporadic cases a follow-up policy 
with regular interval screening for these lesions is safe and acceptable. However, the 
biological behavior of such lesions in patients with a hereditary increased risk for the 
development of cancer is not known. Whether these high-risk patients should be of-
fered surgery at an earlier stage than what is considered acceptable in sporadic cases or 
if the same wait-and-see policy can be adopted is unknown. It is also unclear whether 
the possible development of these precursor lesions into more advanced neoplastic or 
even malignant lesions is gradual over time with ample opportunity for early detection 
during surveillance, or sudden and abrupt. These very important questions need to be 
addressed in further follow-up studies.
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For this reason we have initiated a multicenter prospective study in the Netherlands 
in which the yield of annual MRI and EUS is compared and this study may give us answers 
on the questions raised by our initial study.
An increasing problem in gastroenterology is how to deal with incidentally found pan-
creatic cysts. The prevalence in the overall population is estimated to be approximately 
2.5% and with the increased use of cross-sectional imaging this generally asymptomatic 
lesions are found more often and pose clinicians for diagnostic and therapeutic dilem-
mas. It is well known that a subset of pancreatic cysts have malignant potential, mainly 
mucinous cysts like mucinous cystadenomas (MCA) and intraductal papillary mucinous 
neoplasms (IPMN) whereas simple, congenital or serous cystadenomas generally do not 
require follow-up given the absent or extremely low risk of malignant development. En-
doscopic ultrasound has emerged as a valuable technique for the diagnosis of pancreatic 
cysts given the unrivalled imaging, compared to conventional imaging techniques as CT 
and MRI, and the ability to safely and easily perform EUS guided fine needle aspiration 
(EUS - FNA) of cyst contents and cyst wall. In practice however this procedure is often 
nondiagnostic due to the low cellularity of cyst fluid. The use of biochemical markers in 
the cyst fluid is potentially useful, however no prospective study exists where EUS-FNA 
of cyst fluid is evaluated with regards to being technically possible, safety and diagnostic 
yield. In chapter 3 the results of EUS-FNA in a prospective, observational cohort study of 
consecutive patients with a cystic pancreatic lesion of unknown etiology are described. 
In this study the technical success and safety of EUS-FNA are investigated. Of course 
morphological characteristics such as location, diameter, wall thickness, multilocularity, 
septations, nodules, calcifications and communication with the pancreatic duct were 
also noted, described and registered by experienced endosonographers in two tertiary 
centers. The cyst fluid obtained via EUS-FNA was primarily used for cytopathological 
analysis. Furthermore biochemical markers, mainly carcinoembryonic antigen (CEA), 
carbohydrate antigen 19.9 (Ca 19.9) and amylase levels were determined.
In 128 out of 143 consecutive patients EUS-FNA was performed. Reasons for not 
performing EUS-FNA were diverse but in the majority of cases the endoscopist refrained 
from EUS-FNA due to the necessity to traverse normal pancreatic tissue with the as-
sociated risk of pancreatitis. Overall complications arose in 3 patients (2.4%): 2 had 
symptoms that could be attributed to infection of the cyst and 1 case of pancreatitis 
occurred. Fluid was available for cytological analysis in 124 patients (87%) but a clas-
sifying diagnosis based on cytology was only possible in 44 (31% of all patients). In 80 
out of 143 patients fluid was available for biochemical analysis although analysis was 
successful in only 70 patients (49%).
This study shows that the diagnostic yield even in expert centers of EUS-FNA of 
pancreatic cysts is disappointingly low although technically possible in the vast majority 
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of cases. It was possible to obtain a classifying cytopathological diagnosis in approxi-
mately one-third of cases and sufficient material for biochemical analysis was available 
in only half of the cases. Potentially the diagnostic yield may increase if priority would be 
given to biochemical analysis of the fluid. Furthermore, changing the processing of the 
cytology specimen to a liquid based medium such as ThinPrep or Cytolyte might also 
increase cellularity and diagnostic yield.
Another aspect of the diagnostic value of EUS is discussed in chapter 4. In most cases 
when patients with obstructive jaundice are suspected to have pancreatic cancer, the 
initial imaging modality is a high quality helical multidetector computer tomography 
(MDCT). Sensitivity and accuracy of MDCT with regards to detection of the primary 
tumor and the presence of metastases and determining resectability of pancreatic 
cancer is generally high and improving with further technological developments. 
Despite these characteristics, not infrequently patients suspected to have pancreatic 
cancer do not have a visible tumor on MDCT. We investigated the value of EUS in these 
patients in a multicenter retrospective cohort study. Over a 2 year period all patients 
who with painless jaundice or a combination of cholestasis, weight loss and abdominal 
pain underwent a MDCT according to a local pancreatic protocol and were reported 
by dedicated GI radiologists. EUS was performed by experienced endosonographers. 
During this period 290 patients were analyzed with MDCT for suspected pancreatic 
cancer. A pancreatic mass was found in 258 patients with sizes between 6 and 110 mm 
(median 30 mm). Therefore in 32 patients (11%) MDCT failed to demonstrate the cause 
of obstruction. In 23 of those patients (74%) EUS was able to correctly diagnose the 
cause of obstruction. Fifteen of them were found to have a malignant appearing mass in 
the head of the pancreas (size between 13 and 45 mm), 3 other patients were found to 
have an ampullary adenoma. A benign (or premalignant) cause for the obstruction was 
found in another 8 patients. However, EUS is not perfect: 5 patients with a negative EUS 
and negative MDCT were found to have a malignancy after all. Three of these 5 patients 
had a stent in situ during EUS. This may have had a deleterious effect on the diagnostic 
accuracy in these patients.
To further increase the diagnostic capabilities of EUS - FNA we investigated the feasibil-
ity and yield of a newly developed needle in chapter 5. Since its development more than 
20 years ago, EUS - FNA has proven to be a reliable, safe, sensitive and accurate method 
to provide clinicians with cytological samples of intestinal and extra-intestinal mass 
lesions. However no reliable way to obtain a histological specimen existed. For lesions 
reachable from the esophagus or from the proximal stomach some studies have shown 
promising results with either the use of a large caliber regular 19G needle or with the use 
of a needle with a thrucut mechanism (Quickcore, Cook Endoscopy). In clinical practice 
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however most endosonographers felt that both methods were not reliable especially in 
more difficult circumstances, mainly when used from the duodenum. Since especially 
pancreatic cytology is notoriously difficult to interpret for cytopathologists, the avail-
ability of an EUS needle through which histological specimens could be obtained in 
a reliable and safe way is potentially a breakthrough in EUS. For this reason the later 
named ProCore needle was developed in collaboration with an international group of 
experienced endosonographers and Cook Endoscopy. Our first experiences with this 
needle aimed at acquiring fine needle biopsy (FNB) are described in chapter 4.
This needle is a 19G stainless steel needle with a Nitinol stylet with a reverse cut-
ting bevel of 4 mm located just proximal of the tip of the needle. Tissue acquisition was 
performed in various ways where according to local preference passes were done with 
or without the stylet. Other differences were the number of passes (1 to 3), number of 
to-and-fro passes (1 to 4) and the use of the stylet or flushing with saline to retrieve 
the sample. Further tissue preparation was done as customary with general biopsies 
obtained via endoscopy.
In this multicenter, pooled, cohort study of 109 consecutive patients with 114 intra- 
or extraintestinal mass lesions FNB was attempted. Our main outcome measurement 
was the percentage of cases in which pathologists classified the sample quality as 
optimal for histopathological evaluation combined with the overall diagnostic accuracy.
In all 114 lesions were evaluated (84 malignant, 30 benign). EUS - FNB was technically 
feasible and possible in 112 lesions (98.2%). The sample quality was adequate for full 
histological assessment in 102 lesions (89.5%). This assessment was found to be correct 
in 98 cases (86.0%) based on either definite surgical pathology or clinical follow-up lead-
ing to an overall accuracy of 92.9% with regards to diagnosing malignancy.
The indications for EUS were highly variable although the largest number of patients 
had pancreatic tumors (47). Technically all passes through either esophagus, stomach 
or rectum were successful (n = 79; 100%) whereas two failures (33 / 35; 94.3%) occurred 
when the puncture was performed through the duodenum. In both cases it proved 
impossible to remove the stylet from the needle after targeting the lesion. No complica-
tions related through the EUS procedure were seen.
Despite the slight variations in technique at univariate analysis only the use of a 
dedicated GI pathologist compared to generally oriented pathologists was found to be 
of significance (OR 5.55 (1.54 - 19.94; p = 0.004). We therefore conclude that with this 
new needle it is feasible and safe to obtain a histological biopsy in the vast majority of 
cases even when a transduodenal biopsy has to be performed.
Compared to cytology of the pancreas, pancreatic histology may be easier to interpret for 
pathologists. Furthermore adequate histological specimens enable ample immunohis-
tochemical tests and because the architecture of the specimen is preserved potentially 
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differentiation can be assessed based on the relationship of the tumor with basement 
membrane, blood vessels, nerve tissue en connective tissue. Also a reliable call can be 
made on whether a tumor is invasive or still in the in situ stage. The role of the patholo-
gist is therefore instrumental and in a way endoscopistst and endosonographers are 
mere instruments of the pathologists. However, little is known about the reproducibility 
of the results of the judgments made by the pathology and the interobserver variation. 
We therefore performed a study in chapter 6 to evaluate the interobserver agreement 
between dedicated GI pathologists with regards to grading the quality of specimens 
obtained via the FNB method with a 19G Procore needle on consecutive specimens of 
both lymphadenopathy and mass lesions. The pathologists were blinded to the final 
diagnosis and independently reviewed and scored for the presence of a tissue core, 
adequacy and interpretability of the specimen and the possibility to perform additional 
analyses on the acquired material such as immunohistochemistry and fluorescence in 
situ hybridization. Overall 50 cases were judged, 23 samples were pancreatic of nature, 
15 of lymph nodes, 7 from submucosal lesions, two from abdominal masses and one 
each from the left adrenal gland, a mediastinal mass and a peritoneal nodule.
Specimens were judged to be adequate in 91.2% of cases with a kappa value of 0.73 
(excellent agreement). The presence of a clear tissue core was reported in 88% of cases 
with a kappa value of 0.61 (good agreement). Interpretation of the specimen was judged 
to be easy in approximately 87% of cases with a kappa value of 0.44 (moderate agree-
ment). Additional analyses were possible in in approximately 91% of cases with a kappa 
value of 0.66 (good agreement). We could demonstrate therefore that for dedicated 
and experienced GI pathologists overall there was moderate to excellent interobserver 
agreement on the assessment of material obtained through EUS - FNB.
In recent years EUS is evolving more and more from a purely diagnostic technique, and 
this includes the use of EUS - FNA or FNB, to a therapeutic modality. With this develop-
ment EUS parallels most other endoscopic techniques including gastroscopy, colonos-
copy and ERCP. In chapter 7 an extensive review is given on therapeutic endosonography 
including celiac plexus neurolysis, EUS guided fine needle injection, placement of mark-
ers for radiotherapy, EUS guided drainage of fluid collections and abscesses, drainage 
and access of both biliary and pancreatic ducts and vascular interventions. Although 
various techniques are described in detail along with practical tips and trics we also 
focus on indications, contra-indications, complications and outcome.
The third section of this thesis, novel developments in the endoscopic treatment of 
benign biliary and pancreatic disease deals with various complications of benign biliary 
and pancreatic disease but focuses on the treatment of benign biliary strictures (BBS) 
that can occur as a consequence of both chronic pancreatitis and iatrogenic damage 
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to the bile due to for example a complicated cholecystectomy or after orthotopic liver 
transplantation (OLT) with a duct-to-duct anastomosis.
The first chapter in this section, chapter 8, is an extensive review of the endoscopic 
treatment of chronic pancreatitis and focuses on treating various complications of this 
often debilitating disease. Therapeutic endoscopy can be considered in three settings: 
transpapillary drainage of the pancreatic duct and treatment of ductal strictures and 
stones, pseudocyst drainage and treatment of biliary obstruction. In this review these 
techniques are discussed extensively with a focus on patient selection, techniques and 
duration of drainage and including a summary of the available evidence with regards to 
morbidity, mortality and long term outcome.
Biliary complications after OLT occur frequently. Up to 30% of transplanted patients 
suffer from leakage, strictures and stone or cast formation and biliary complications are 
therefore an important cause of OLT-related morbidity. It is generally accepted that en-
doscopic treatment via ERCP is the cornerstone of management in these patients since 
the alternatives, percutaneous or surgical treatment, are considered to be less efficacious 
or more invasive. The majority of strictures after OLT are located at the anastomosis in 
case of a duct-to-duct biliary reconstruction and are the most amenable for endoscopic 
treatment. Non-anastomotic strictures respond less favorably to endoscopic treatment 
and often require a re-transplant.
The most commonly used approach nowadays for anastomotic strictures is to follow 
a so called progressive stenting protocol whereby an increasing number of plastic endo-
protheses, tailored to the diameter of the duct, are inserted at 3 months intervals over a 1 
year period. Even though this method is nowadays considered to be standard of care the 
quality of data to support this approach is relatively low. Reported success rates are highly 
variable between 65% and 94% and interpretation is also made difficult since it is not 
always well known whether patients with early strictures, caused by edema and usually 
very well responding to therapy, were included as well. Since new therapies are on the 
horizon, mainly temporary treatment with fully covered self-expandable metal stents, it is 
of paramount importance that results, complications and efficacy of previous treatment 
are well known. We therefore aimed to explore the outcome of a progressive plastic stent-
ing protocol in our cohort of patients with an anastomotic stricture after OLT in chapter 9.
Between 2000 and 2009 a total of 375 OLTs were performed. Of the 304 patients in 
whom a duct-to-duct anastomosis was created, 63 developed an anastomotic stricture 
(21%). Twenty eight patients were not treated by progressive stenting for various reasons 
but mainly because of good response to single stenting in patients with early strictures 
(n=16). Four patients did not complete the protocol; two because of a re-transplant and 
two patients died of unrelated causes. In those patients who completed the protocol a 
median of 5 (range 4 - 11) ERCP’s were performed and a median maximum number of 
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10 french stents of 4 (range 2 - 8) were placed. Complications occurred frequently: 21 
patients (67.7%) suffered from them although the complication risk as calculated per 
procedure was lower: 22 serious complications on a total of 155 procedures (14.2%).
Overall treatment success, defined as absence of recurrence of cholestasis, jaundice 
or cholangitis due to a recurrent anastomotic stricture was achieved in 25 out of the 
31 patients who completed the protocol (80.6%) with a median follow-up after stent 
removal of 28 months.
The endoscopic treatment of biliary anastomotic strictures by means of a progressive 
plastic stenting protocol is therefore highly efficacious and saves 80% of those patients 
from undergoing complicated surgery or even a re-transplantation. However this type 
of protocol is demanding for patients, not without complications and labor intensive for 
health care providers.
In chapter 10 we looked at cost effectiveness of progressive plastic stenting versus cov-
ered metal stenting in patients with anastomotic strictures after OLT in a comparative 
analysis. Although, as we have shown in chapter 9, progressive stenting is effective, it 
is also quite burdensome for patients and potentially quite costly given the multiple 
ERCPs that are necessary for completing the protocol. Recently several case series have 
been published describing the use of temporary, removable fcSEMS in benign biliary 
strictures, including anastomotic strictures after OLT. Efficacy and complication rates in 
these series are roughly similar or better compared to progressive plastic stenting. There 
are however no data available with regards to the cost-effectiveness of this approach 
and since no comparative trials have been published we undertook an analysis on our 
own cohort of patients and calculated several clinical scenarios with variable prices of 
fcSEMS and number of treatments needed.
The costs of progressive plastic stenting were calculated based on the cohort of 31 
patients described in chapter 9. A median of 5 ERCPs were necessary and resulted in a 
median of 1 complication. Treatment costs were calculated using source data from the 
financial department of our hospital and for this analysis, based on published series, 
including from our own unit, it seems reasonable to assume that the efficacy of fcSEMS 
treatment is equal or greater than progressive plastic stenting and that complication 
rates would be equal as well. Cost analysis was based on medical direct costs.
Costs of progressive plastic stenting were calculated at €4196. In six scenarios, rang-
ing from very optimistic (patients require only 2 ERCP’s and cost of one fcSEMS is €1000) 
to pessimistic (but probably more realistic) where it was estimated that 30% of patients 
would need placement of a 2nd fcSEMS and 10% even a 3rd. In all scenarios the use of 
fcSEMS lead to a reduction in costs ranging from €296 to €1696. We also calculated the 
mean number of fcSEMS that were allowed per patient to reach a break-even point at 
1.97 (price of fcSEMS €1000) and 1.53 (price of fcSEMS €1500).
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Treatment of anastomotic strictures after OLT with fcSEMS is therefore potentially 
cost-effective in calculated clinical scenarios and largely dependent on the price of fc-
SEMS. Before we can adopt this strategy as routine clinical practice however we need 
true randomized trials since this analysis is based on several assumptions that are based 
on either retrospective studies or case series.
As demonstrated and discussed in chapter 9 and 10 the use of fcSEMS in the treatment of 
anastomotic strictures after OLT but also in other benign biliary strictures is potentially 
very promising. One major concern however is the removability of these SEMS since not 
removing them almost invariably leads to patency problems. It is already known for a 
long time that uncovered SEMS are not removable and therefore not usable for treat-
ment of benign diseases. Although this in general is less of an issue with partially and 
fully covered SEMS, several removal problems have been described including bleeds, 
perforations and surgical repair.
Several techniques for removal of fcSEMS are available. The distal end can be grasped 
with a snare with subsequent removal of the entire stent. Another technique makes use 
of a distal lasso and although traction on this lasso lengthens the stent, with both tech-
niques the whole surface area of the stent must detach from the wall of the bile duct at 
more or less the same time and considerable force is sometimes needed, leading to an 
increased chance of distortion and disintegration of the stent.
We therefore investigated the feasibility and safety of stent removal of a novel type 
of fcSEMS in chapter 11. This stent has a proximal lasso that enables removal of the stent 
inside-out in a more controlled way with less force since this would enable gradual 
inversion and detachment of the stent with the direction of force in a straight line with 
the orientation of the stent. Another potential advantage could be that in the case of 
proximal migration this lasso could be manipulated towards the duodenum with the aid 
of balloon or grasping forceps and thereby providing an easy and safe way to complete 
stent retrieval.
We conducted a non-randomized prospective follow-up study with a sequential 
group design. Twentyfour patients were treated in three groups. Group A underwent 
stent placement for 2 months, if necessary after removal followed by another stent 
placement for 3 months. For group B this was 3 + 4 months and for group C 4 + 4 
months. Unfortunately one patient did not have a benign stricture but a malignant due 
to a neuroendocrine tumor and fell out of the protocol and the analysis. The remain-
ing 23 patients had strictures due to chronic pancreatitis (n=13), OLT (6), laparoscopic 
cholecystectomie (n=3) and papillary fibrosis (n=1). In total 39 fcSEMS were deployed 
and removed without complications. In one patient with chronic pancreatitis and a very 
tight stricture the wire mesh appeared to be broken at the time of removal. Despite 
this, the stent could be removed easily and replaced according to protocol. In all other 
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cases removal was easy. The proximal lasso was seen in the duodenal lumen in 37 of 39 
removals and could be used for removal. In the remainder of cases the proximal lasso 
could be retrieved after sweeping of the stent with an extraction balloon.
Several complications were observed: one case of cholecystitis, two cases of wors-
ening of chronic pancreatitis and three cases of cholangitis; one of them because of 
migration and two because of stent clogging. Frequently patients had transient, but 
sometimes severe, pain subsiding within the first week and manageable by temporary 
analgesics.
The overall success rate after a median follow-up of 15 months (range 11 - 25) was 
65% (15 out of 23). The chance of success was considerably lower in those with a BBS 
due to chronic pancreatitis (46%; 6 / 13) than in those with other causes (80%; 8 / 10) 
although this did not reach statistical significance (p = 0.11). Those patients that had 
stricture resolution after removal of their first stent (86%; 6 / 7) seemed to have a bet-
ter outcome than those patients that required placement of a 2nd stent (50%; 8 / 16) 
although this difference yet again did not reach statistical significance (p=0.12)
Of course our study was not powered to detect differences in outcome with regards 
to stricture resolution, nevertheless our results in both chronic pancreatitis patients and 
those with other causes of BBS are more or less in line with those from previously pub-
lished series. It is conceivable that with longer indwelling stent time results could even 
improve further. The primary endpoint of our study with this newly developed type of 
fcSEMS was safety and feasibility of removal via a proximal lasso. In the vast majority of 
cases the lasso could easily be grasped with a snare or forceps and traction on this snare 
led to easy and controlled removal without excessive force. What is clear from this study 
is that, despite the attractive starting point of potentially reduction of number of ERCPs 
needed for treatment, the risk of complications of fcSEMS treatment is not negligible 
and potentially serious.
At present, based on our study and also other published series, it is still too early to 
recommend treatment of BBS with fcSEMS as standard of care. A randomized controlled 
trial, sufficiently powered to detect difference in treatment outcome, is needed before 
any definite recommendations can be made.
We, in chapter 11, and others have shown that the use of fcSEMS for the treatment of 
benign biliary strictures is effective and reasonably safe. However the only experience 
with fcSEMS was limited to those strictures that were located at least 2 cm below the 
hilum and although this is the case for the majority of BBS up to 14% of these strictures 
extend into or at the level of the hepatic hilum. Traditionally these patients are managed 
endoscopically although this is particularly difficult for these type of strictures since in 
general the outcome is dependent on the aggressiveness of dilation, i.e. the number of 
stents inserted, and this is technically much more difficult to achieve bilaterally through 
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a hilar stricture. The use of fcSEMS in this setting, potentially very attractive since a large 
dilation diameter can be achieved with placement of a single stent, has never been 
described however due to the high likelihood of occlusion of intrahepatic bile ducts 
caused by the covering of these stents. We speculated that the combination of an intra-
hepatically deployed fcSEMS in conjunction with contralateral plastic stent placement 
and published our results of the first two patiented treated this way in chapter 12. For 
these patients we used a specially developed fcSEMS of the same design as described in 
chapter 11, only now with a length of 120 mm.
The first patient was a 36 year old woman with a history of a complicated cholecys-
tectomy who developed a hilar stricture at the site of previously noted leakage. Multiple 
ERCPs elsewhere with repeated balloon dilation and bilateral single 10 fr stent place-
ment did not lead to resolution of the stricture. We placed a 10 fr plastic stent into the, 
less severely affected, right system and a 12 cm 10 mm fcSEMS in the left. The procedure 
went uncomplicated and after 5 months both stents were removed and cholangiogra-
phy demonstrated complete resolution of the stricture towards both left and right sided 
biliary system. Follow up of now over 2 years did not reveal signs of recurrent stricture.
Our second patient was a 29 year old woman who developed an anastomotic 
stricture of the duct-to-duct anastomosis two years after OLT for acute liver failure. She 
underwent progressive stenting for this stricture with initially good response. Three 
months later however she developed recurrent cholestasis and at ERCP a recurrent 
stricture, partially extending into the liver hilum, was seen. She was treated with a 12 cm 
10 fr plastic stent into the left system and a 12 cm 10 mm fcSEMS into the right system. 
At removal after 4 months cholangiography revealed complete stricture resolution and 
after now more than 1 year follow up no signs of recurrent stricture are seen.
These cases nicely demonstrate that this new approach to benign hilar strictures 
is technically feasible and potentially efficacious. Some concerns remain however. Es-
pecially placement of a relatively large, compared to the diameter of the duct, fcSEMS 
intrahepatically could potentially lead to secondary strictures. Of course to answer the 
question whether this approach is more efficacious and at least as safe as progressive 
plastic stenting, ideally a randomized controlled trial should be performed. Due to the 
relative rareness of these strictures such a trial will very likely never be performed. Care-
ful registry of treated patients is therefore very important. We have started a prospective 
multicenter cohort study where we will treat patients with hilar benign biliary strictures 
with bilateral fcSEMS placement with a diameter of 7 mm.
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In het eerste deel van dit proefschrift, Endoechografie in screening en diagnose 
van alvleesklierziekten, worden enkele aspecten van de diagnostische waarde van 
endoechografie (EUS) onderzocht. EUS is een techniek waarbij door middel van een 
echoapparaatje op de tip van een flexibele endoscoop heel nauwkeurig vanuit de slok-
darm, maag, 12-vingerige darm en endeldarm omliggende organen bekeken kunnen 
worden. Ook kan op deze manier relatief eenvoudig, weinig belastend en veilig weefsel 
of vocht worden afgenomen voor verder onderzoek. Vooral de alvleesklier kan op deze 
manier heel nauwkeurig onderzocht worden.
In hoofdstuk 2 beschrijven we een onderzoek waarbij EUS gebruikt wordt om men-
sen met een sterk verhoogd risico op het krijgen van alvleesklierkanker te onderzoeken 
op afwijkingen voordat klachten aanwezig zijn. De prognose van alvleesklierkanker is 
dermate slecht als de aandoening ontdekt wordt op het moment dat er symptomen 
zijn, dat vroege opsporing van alvleesklierkanker, of één van de voorstadia hiervan ,één 
van de weinige manieren is waarmee potentieel de prognose van deze vreselijke ziekte 
verbeterd zou kunnen worden. Op dit moment komen alleen mensen en families voor 
een dergelijke screening in aanmerking als er sprake is van een erfelijke aanleg. Geschat 
wordt dat in ongeveer 10% tot 15% van alle gevallen van alvleesklierkanker er sprake is 
van een vorm van erfelijkheid.
Met EUS kan vanuit maag en 12-vingerige darm de alvleesklier zeer nauwkeurig 
geïnspecteerd worden; vandaar dat wij deze methode gekozen hebben als basis van 
ons screeningsprogramma. In deze studie beschrijven wij de resultaten van het eerste 
onderzoek met EUS in 44 individuen met een verhoogd risico op het krijgen van al-
vleesklierkanker als gevolg van een erfelijke aanleg. In drie individuen (6.8%) werden op 
dat moment nog asymptomatische gevallen van alvleesklierkanker gevonden met een 
grootte van 10, 27 en 50 mm. Ondanks een operatie waarbij de tumor in alle gevallen 
succesvol verwijderd kon worden, zijn al deze patiënten uiteindelijk toch aan de ziekte 
overleden als gevolg van uitzaaiingen in de lever die later ontdekt werden. Bij 7 patiënten 
(15.9%) werden cysteuze afwijkingen gevonden met afmetingen tussen de 4 en 15 mm. 
Al deze cysten waren enkelvoudig zonder intramurale nodules of solide componenten. 
Omdat bij EUS communicatie met de ductus pancreaticus, de afvoergang van de al-
vleesklier, ofwel aangetoond kon worden danwel zeer waarschijnlijk gemaakt, zijn deze 
cysteuze afwijkingen zeer waarschijnlijk intraductale papillaire mucineuze neoplasieën 
(IPMN). IPMNs zijn bekende voorstadia van alvleesklierkanker en het lijkt waarschijnlijk 
dat de veel hogere frequentie van voorkomen dan verwacht in onze serie, maar ook in 
andere, gerelateerd is aan de ontwikkeling van alvleesklierkanker in deze families.
Hoewel wij duidelijk aantonen dat EUS inderdaad in staat is om zowel vroege, nog 
asymptomatische, gevallen van alvleesklierkanker maar ook voorloperstadia daarvan, 
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op te sporen bij individuen met een verhoogd risico hierop, is hiermee natuurlijk niet 
aangetoond dat de uitkomst voor deze patiënten ook verbeterd. Het lijkt in elk geval 
wel duidelijk dat een screeningsprogramma voor alvleesklierkanker zich zal moeten 
concentreren op het detecteren en vervolgen van premaligne aandoeningen. Dit wordt 
mede onderstreept doordat alle drie de patiënten bij wie er reeds sprake was van kanker 
uiteindelijk aan de ziekte overleden zijn en in feite alleen maar eerder patiënt geworden 
zijn.
Vanwege het toenemend aantal CT-scans en MRI’s die gemaakt worden, soms zelfs voor 
een zogenaamde, commerciële check-up, worden steeds vaker cysten in de alvleesklier 
gevonden. De prevalentie in de algemene bevolking wordt geschat op circa 2.5%. Deze 
cysten kunnen volkomen onschuldig zijn, zonder dat verdere analyse of follow-up 
noodzakelijk is, kunnen kwaadaardig worden of kunnen zelfs al kwaadaardig zijn. Met 
EUS kan niet alleen heel goed gekeken worden, het is ook mogelijk om vloeistof uit de 
cyste te halen voor verdere analyse, EUS – FNA. In hoofdstuk 3 hebben wij in een pros-
pectieve studie de technische uitvoerbaarheid, veiligheid en opbrengst van EUS – FNA 
onderzocht naast de bekende morfologische criteria. Het verkregen cystevocht werd 
primair voor pathologisch onderzocht gebruikt en bij voldoende opbrengst werden ook 
biochemische tests gedaan naar tumormarkers en amylase.
Bij 128 van de 143 patiënten werd EUS – FNA verricht. In de andere gevallen werd van 
EUS – FNA afgezien, meestal doordat de afstand die de naald door normaal alvleesklier-
weefsel moest gaan als te groot werd ingeschat aangezien daarmee de kans op acute 
alvleesklierontsteking toeneemt. Complicaties werden gezien in 3 patiënten (2.4%). 
Uiteindelijk werd bij 124 patiënten daadwerkelijk vocht verkregen voor analyse door de 
patholoog. Helaas kon slechts in 44 patiënten (31%) een classificerende diagnose op de 
cytopathologie gesteld worden. In 80 van de 143 patiënten was vocht beschikbaar voor 
biochemische analyse al kon deze in slechts 70 patiënten (49%) verricht worden. In deze 
studie laten we zien dat zelfs in ervaren handen de diagnostische opbrengst van EUS – 
FNA bij cysteuze alvleesklierafwijkingen laag is hoewel technisch vrijwel altijd mogelijk. 
Deze opbrengst zou mogelijk verhoogd kunnen worden als gekozen zou worden om 
voorrang te geven aan de biochemische analyse in plaats van die door de patholoog en 
als het verkregen vocht voor de patholoog op een andere manier verwerkt zou worden.
Een ander aspect van de diagnostische waarde van EUS wordt besproken in hoofdstuk 4. 
Patiënten die zich presenteren met obstructie icterus en waarbij de klinische verdenking 
op een pancreaskopcarcinoom groot is, ondergaan over het algemeen in eerste instan-
tie een CT scan. Hoewel de sensitiviteit en accuratesse van CT wat betreft de detectie 
van de primaire tumor en het bepalen van afstandsmetastasen en resectabiliteit goed 
is en met de verdergaande technologische ontwikkeling ook steeds beter wordt, komt 
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het desondanks regelmatig voor dat op de CT scan de oorzaak van de obstructie icterus 
niet vastgesteld kan worden. Wij hebben de waarde van EUS onderzocht in deze setting 
in een multicenter retrospectieve cohort studie waarbij gedurende een periode van 2 
jaar alle patiënten die vanwege obstructie icterus en/of cholestase, gewichtsverlies en 
buikpijn een CT scan ondergingen volgens pancreasprotocol geanalyseerd werden.
Hierbij werden uiteindelijk 290 patiënten geïncludeerd. In 258 werd een tumor in de 
pancreas gevonden; derhalve kon bij 32 patiënten geen oorzaak worden aangetoond 
middels CT-scan. Bij deze patiënten werd EUS verricht waarbij deze in 31 compleet was. 
In 23 patiënten (74%) kon de oorzaak correct worden vastgesteld middels EUS: in 15 leek 
er sprake te zijn van een maligne tumor; dit bleek correct in 13 van de 15. In 3 gevallen 
werd vastgesteld dat er sprake was van een papiladenoom hetgeen correct was in 2 
patiënten en in 8 gevallen werd terecht geconcludeerd bij EUS dat er sprake was van een 
benigne oorzaak van de obstructie. EUS is echter niet perfect: in 5 patiënten (16%) kon 
geen oorzaak worden gevonden en bleek er uiteindelijk toch sprake van een maligne 
oorzaak van de obstructie icterus. In 3 van deze 5 patiënten werd de EUS verricht met 
een galwegstent in situ, een bekende oorzaak van verminderde accuratesse van EUS.
In hoofdstuk 5 werd de waarde en bruikbaarheid van een nieuw type EUS naald onder-
zocht. Hoewel EUS – FNA een techniek is die al meer dan 20 jaar bestaat en bewezen 
heeft veilig, accuraat, specifiek en sensitief te zijn, worden hierbij cytologische samples 
verkregen. Met cytologie kunnen losse cellen of celgroepjes bekeken worden. Voor de 
patholoog is met name cytologisch materiaal van de alvleesklier soms lastig te beoor-
delen. Bij histologisch materiaal kan de differentiatiegraad van een kwaadaardige tumor 
beoordeeld worden evenals de relatie met basaalmembraan, bloedvaten, zenuwen en 
bindweefsel. Hierdoor is er op zijn minst een potentiële meerwaarde voor het verkrijgen 
van histologisch materiaal. Er bestond echter geen betrouwbare manier om histolo-
gisch materiaal te verkrijgen, vooral niet onder moeilijker omstandigheden vanuit 
bijvoorbeeld de 12-vingerige darm. Wij onderzochten de bruikbaarheid en opbrengst 
van een nieuw type naald, ontwikkeld in samenwerking met een internationale groep 
gebruikers en Cook Endoscopy, die later tot ProCore omgedoopt zou worden en gericht 
is op het verrichten van een fine needle biopsy (FNB). Deze roestvrijstalen naald heeft 
een diameter van 19G en een snijrand 4 mm van de tip waarmee, door de naald heen 
en weer te bewegen in de laesie, histologisch materiaal verkregen zou moeten worden.
In totaal werd in 114 laesies bij 109 patiënten FNB gepoogd. De belangrijkste uit-
komstmaat van deze studie was het percentage waarin het ook lukte om een histolo-
gisch biopt te verkrijgen, beoordeeld door de patholoog. Het bleek technisch mogelijk 
om in 112 van 114 laesies (98.2%) de FNB te verrichten waarbij in 102 gevallen (89.5%) 
er daadwerkelijk een volledige histologische analyse verricht kon worden. Deze analyse 
bleek correct in 98 gevallen (86.0%) uitgaande van ofwel definitieve chirurgisch verkre-
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gen pathologie of klinische follow-up. De uiteindelijke accuratesse met betrekking tot 
het diagnosticeren van een maligniteit was 92.9%.
De indicaties voor EUS waren verschillend al betrof het in het grootste deel patiën-
ten met een pancreastumor (n = 47). De twee gevallen waarin EUS – FNB niet mogelijk 
bleek, betrof het puncties door het duodenum (33 / 35 succes). In beide gevallen bleek 
het onmogelijk om de stylet te verwijderen na puncteren van de laesie. In alle overige 
gevallen was EUS – FNB technisch mogelijk door slokdarm, maag of rectum. Complica-
ties werden niet gezien. Bij univariate analyse bleek alleen beoordeling door patholoog 
met specifieke gastrointestinale interesse van invloed op de uitkomst wanneer verge-
leken met algemene pathologen (Odds ratio 5.55; p = 0.004). Samenvattend bleek het 
met deze nieuwe naald goed mogelijk en veilig om onder vrijwel alle omstandigheden 
histologisch materiaal te verkrijgen, ook onder moeilijke omstandigheden als door het 
duodenum heen gebiopteerd moet worden.
In zekere zin zijn endoscopisten en endosonografisten slechts instrumenten van de 
patholoog als het gaat om het stellen van een definitieve diagnose van tumoren van de 
tractus digestivus. Er is echter weinig bekend over de interobserver variabiliteit en de 
reproduceerbaarheid van oordelen door de patholoog. Wij hebben daarom in hoofd-
stuk 6 hiernaar gekeken door ervaren gastrointestinale pathologen 50 histologische 
preparaten verkregen middels EUS – FNB te laten beoordelen op de aanwezigheid van 
een weefselbiopt, representabiliteit en beoordeelbaarheid van het preparaat en de 
mogelijkheid om aanvullende kleuringen te doen op het preparaat. Zowel biopten van 
de alvleesklier alsook andere tumoren en lymfklieren werden met elkaar vergeleken.
De preparaten werden als adequaat beschouwd in 91.2% met een kappa waarde van 
0.73 (uitstekende overeenstemming). De interpretatie van het preparaat werd als mak-
kelijk ingeschat in 87% van de gevallen; kappa van 0.44, gemiddelde overeenstemming. 
Additionele analyses waren mogelijk in 91% van de preparaten met wederom goede 
overeenstemming; kappa waarde van 0.66.
Wij konden derhalve aantonen dat voor ervaren gastrointestinale pathologen het 
materiaal dat verkregen wordt middels EUS – FNB goed te beoordelen is en dat er tussen 
hen een uitstekende overeenstemming bestaat voor wat betreft de beoordeling op een 
aantal essentiële punten.
Net als bij de meeste andere endoscopische technieken ontwikkelt ook EUS zich van een 
puur diagnostische techniek, inclusief EUS – FNA en EUS – FNB, naar een vorm van endo-
scopie waarmee ook therapeutische interventies verricht kunnen worden. In hoofdstuk 
7 wordt een uitgebreide review gegeven van therapeutische EUS waarbij onder andere 
plexus coeliacus blokkade, EUS fine needle injectie, EUS geleid plaatsen van markers 
voor radiotherapie, drainage van vochtcollecties en abcessen, toegang, drainage en 
Nederlandse Samenvatting 207
rendez-vous technieken van de galwegen en alvleesklier en vasculaire interventies. 
Naast een beschrijving van technieken inclusief praktische tips wordt ook uitgebreid 
stilgestaan bij indicaties, contra-indicaties, complicaties en lange-termijn resultaten.
In het derde deel van dit proefschrift, nieuwe ontwikkelingen in de endoscopische 
behandeling van benigne galweg- en alvleesklieraandoeningen, ligt de nadruk op 
de behandeling van benigne galwegstricturen. Deze kunnen onder andere ontstaan als 
gevolg van chronische pancreatitis maar ook door iatrogene schade, bijvoorbeeld als 
complicatie na cholecystectomie of levertransplantatie.
In hoofdstuk 8 wordt een uitgebreide review gegeven van de endoscopische 
behandelmogelijkheden bij chronische alvleesklierontsteking met de nadruk op de 
complicaties van deze aandoening: transpapillaire drainage van de ductus pancreaticus 
en de behandeling van stenen en stricturen, drainage van pseudocysten en behande-
ling van galwegobstructie. Er wordt tevens uitgebreid stilgestaan bij patiëntenselectie, 
technieken en duur van drainage in het licht van het beschikbare bewijs met betrekking 
tot morbiditeit, mortaliteit en lange termijn uitkomsten.
Galwegcomplicaties komen frequent voor na orthotope levertransplantatie (OLT). Tot 
30% van de getransplanteerde patiënten heeft last van lekkage, stricturen of stenen van 
de galwegen na de transplantatie. Het grootste deel van de stricturen bevindt zich op de 
anastomose tussen donor- en acceptorgalweg indien er een duct-to-duct anastomose 
wordt aangelegd. Deze zijn over het algemeen goed toegankelijk voor endoscopische 
therapie; de alternatieven zoals percutane of chirurgische behandeling zijn ofwel min-
der effectief ofwel veel meer invasief.
Tegenwoordig wordt meestal gekozen voor een progressief stenten protocol waarbij 
met tussenpozen van 3 maanden een toenemend aantal stents door de anastomose 
wordt geplaatst gedurende 1 jaar. In de studies die hierover tot nu toe gepubliceerd 
zijn, worden wisselende succespercentages gemeld waarbij de interpretatie van de 
gepubliceerde data ook moeilijk is doordat niet altijd duidelijk is in hoeverre ook zo-
genaamde vroege stricturen geïncludeerd zijn; deze zijn tijdelijk en behoeven slechts 
kortdurend endoscopische therapie. Mede omdat nieuwe therapieën, met name het 
tijdelijk plaatsen van volledig gecoverde metalen stents (fcSEMS), in opkomst zijn, is het 
extra belangrijk om de resultaten van de standaardbehandeling goed te kennen. Wij 
hebben daarom de uitkomst van progressief stenten onderzocht in ons eigen cohort 
van OLT patiënten in hoofdstuk 9.
Tussen 2000 en 2009 werden in totaal 375 OLTs uitgevoerd. Hiervan werd bij 304 een 
duct-to-duct anastomose uitgevoerd. Van hen ontwikkelde 63 (21%) een anastomoti-
sche strictuur; 28 van hen werden niet geïncludeerd in het progressief stenten protocol 
om verschillende redenen maar vooral omdat er sprake was van een goed resultaat op 
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1 stent bij vroege stricturen. Vier patiënten maakten het protocol niet af: twee van hen 
vanwege een re-transplantatie en twee overleden. Bij de 31 patiënten die het proto-
col afmaakten, werden mediaan 5 (range 4 – 11) ERCP’s verricht waarbij een mediaan 
maximaal aantal 10 french stents van 4 (range 2 – 8) werden geplaatst. Complicaties 
werden regelmatig gezien; 21 patiënten (67.7%) ontwikkelden 1 of meer complicaties 
gedurende de behandelperiode. Per procedure bedroeg het complicatiepercentage 
14.2% (22 / 155). De behandeling was uiteindelijk succesvol in 25 van de 31 patiënten 
(80.6%) met een mediane follow-up van 28 maanden.
De endoscopische behandeling van anastomotische stricturen na OLT middels pro-
gressief stenten met plastic stents is derhalve effectief; ruim 80% van de patiënten kan 
succesvol behandeld worden zonder dat uitgebreide chirurgie of zelfs re-transplantatie 
noodzakelijk is. Echter deze behandeling is belastend voor de patiënten maar ook voor 
ziekenhuizen en de endoscopie afdeling aangezien een groot aantal ERCP’s noodzake-
lijk is en het complicatierisico niet te verwaarlozen is.
In hoofdstuk 10 hebben wij een analyse gedaan van de kosteneffectiviteit van progres-
sief stenten vergeleken met een behandeling met een tijdelijke, verwijderbare, geco-
verde metalen stent (fcSEMS). Zoals we in hoofdstuk 9 hebben laten zien is de eerste 
behandeling weliswaar effectief maar ook potentieel kostbaar gezien het grote aantal 
benodigde ERCP’s. In de laatste jaren zijn meerdere studies verschenen die het gebruik 
van tijdelijke fcSEMS voor benigne galwegstricturen, waaronder die na OLT, onderzoeken 
waarbij complicatierisico en succespercentages ongeveer hetzelfde lijken te zijn. Er zijn 
echter geen directe vergelijkende studies gepubliceerd. Wij hebben daarom een analyse 
verricht op ons cohort dat met progressief stenten werd behandeld en deze vergeleken 
in verschillende scenario’s waarbij met fcSEMS werd behandeld. Voor de progressief 
stenten methode zijn mediaan 5 ERCP’s benodigd. Behandelkosten werden berekend 
op basis van bedragen afkomstig uit de financiële administratie van het ziekenhuis en 
voor deze analyse zijn we er vanuit gegaan dat succespercentage en complicatierisico 
gelijk was voor beide behandelingen.
Een behandeling met progressief stenten kost gemiddeld €4196. Het meest opti-
mistische scenario bij het gebruik van fcSEMS ging uit van 2 ERCP’s en een prijs van 
de fcSEMS van €1000. Meer realistisch berekenden wij ook dat 30% van de patiënten 
een tweede fcSEMS nodig zou hebben en 10% een derde. In alle scenarios leidde het 
gebruik van fcSEMS tot een reductie van kosten variërend van €296 tot €1696. Het 
gemiddelde aantal fcSEMS dat geplaatst zou kunnen worden per patiënt waarbij de 
kosten gelijk zouden blijven was 1.97, bij een fcSEMS prijs van €1000, en 1.53 bij een 
prijs van €1500.
De behandeling van anastomotische stricturen na OLT met fcSEMS is derhalve 
potentieel kosteneffectief in alle onderzochte scenario’s en vooral afhankelijk van de 
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prijs van fcSEMS. Voordat deze strategie als voorkeursbehandeling gekozen kan worden, 
zijn prospectieve gerandomiseerde trials echter noodzakelijk aangezien wij in onze 
analyse uitgegaan zijn van verschillende veronderstellingen die alle gebaseerd zijn op 
retrospectieve studies of case series.
Zoals we in hoofdstukken 9 en 10 hebben laten zien, is het gebruik van fcSEMS voor 
benigne galwegstricturen (BBS) veelbelovend. Een groot potentieel probleem is echter 
de verwijderbaarheid van deze stents. Bij het gebruik van niet gecoverde, en niet verwij-
derbare, stents voor BBS is gebleken dat deze uiteindelijk vrijwel zonder uitzondering 
weer dicht gaan zitten en derhalve moeten voor benigne indicaties gecoverde, partieel 
danwel volledig, metalen stents gebruikt worden.
Bij het verwijderen van deze stents wordt gebruik gemaakt van een distale lasso of 
verwijderlus of de gehele stent wordt in één keer omvat met een snaar waarna deze 
verwijderd wordt. Al deze methoden hebben als nadeel dat veel kracht moet worden 
uitgeoefend omdat het gehele intraductale oppervlak van de stent in één keer los moet 
laten van de wand van de ductus choledochus. Hierbij zijn bloedingen en perforaties 
van de galweg beschreven.
Wij hebben in hoofdstuk 11 onze ervaringen beschreven met een nieuw type fc-
SEMS. Deze heeft niet alleen een distale lasso maar ook een proximale lasso. Tractie aan 
deze lasso zorgt ervoor dat de stent gradueel binnenstebuiten gekeerd wordt waardoor 
de kracht geleidelijk aan leidt tot verwijdering. Onze studie was dan ook primair gericht 
op verwijderbaarheid. Hiertoe werden 24 patiënten met BBS geïncludeerd in een niet 
gerandomiseerde prospectieve studie met een sequentieel groep design. Groep A on-
derging stentplaatsing gedurende 2 maanden, indien nodig gevolgd door nog eens 3 
maanden. Voor groep B en C waren deze periodes 3 +4 en 4 + 4 respectievelijk.
Bij 1 patiënt bleek er helaas tijdens de behandeling toch sprake te zijn van een onder-
liggende maligniteit waardoor hij uit het protocol viel. Bij de overblijvende 23 patiënten 
waren de BBS als gevolg van chronische pancreatitis (n=13), OLT (n=6), laparoscopische 
cholecystectomie (n=3) en papilfibrose (n=1). In totaal 39 fcSEMS werden geplaatst en 
verwijderd zonder complicaties. In één patiënt met chronische pancreatitis en een zeer 
nauwe strictuur bleek er sprake te zijn van een stentbreuk, desondanks kon de stent 
zonder veel problemen verwijderd worden. In alle andere gevallen was de verwijdering 
eenvoudig volgens de endoscopist. De proximale lasso hing in het duodenum in 37 van 
de 39 gevallen; in de overige twee gevallen kon deze met ballon makkelijk tot in het 
duodenum gemobiliseerd worden.
Wij zagen meerdere complicaties: één patiënt ontwikkelde in aansluiting op de 
stentplaatsing cholecystitis, bij twee zagen we een verergering van de onderliggende 
chronische pancreatitis en er waren drie gevallen van cholangitis. Eén hiervan door 
migratie en bij de andere twee door verstopping van de stent. Tevens zagen we frequent 
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de eerste dagen na de stentplaatsing passagère pijn optreden als gevolg van uitzetting 
van de stent. Dit was in het algemeen goed te behandelen met pijnstillers.
Voor de gehele groep was het succespercentage na een mediane follow-up van 15 
maanden (11 – 25) 65% (15 van de 23). Het percentage was met 46% (6 / 13) duidelijk 
lager in de chronische pancreatitisgroep dan in de groep met andere oorzaken: 80% (8 / 
10) hoewel dit verschil niet statistisch significant was (p = 0.11). Tevens leek het zo te zijn 
dat bij de patiënten bij wie een tweede stent noodzakelijk was de kans op uiteindelijk 
succes (50%; 8 / 16) ook lager was vergeleken met hen bij wie slechts 1 stent geplaatst 
werd (86%; 6 / 7) hoewel ook dit verschil niet statistisch significant was (p = 0.12).
Vanzelfsprekend was onze studie niet gepowerd op het aantonen van verschillen 
in uitkomst. Desalniettemin zijn onze resultaten min of meer in overeenkomst met de 
resultaten zoals bekend uit de literatuur. Het is denkbaar dat bij langer in situ blijven 
van de stents de uitkomst nog verder verbetert. Het primaire eindpunt van deze studie 
was veilige verwijderbaarheid en het blijkt duidelijk het geval te zijn dat deze stent met 
behulp van de proximale lasso makkelijk en veilig verwijderd kan worden. Tevens blijkt 
dat, hoewel het gebruik van fcSEMS bij BBS conceptueel heel aantrekkelijk is, dit een 
behandeling is die niet zonder complicaties verloopt. Daarom is het ons inziens nog 
te vroeg om deze behandeling als de standaard behandeling te zien; idealiter dient 
hiervoor een adequaat gepowerde gerandomiseerde studie verricht te worden.
Wij en anderen hebben laten zien dat de behandeling van BBS met fcSEMS een effec-
tieve en redelijk veilige behandeling is met mogelijk voordelen boven de behandeling 
met meerdere plastic stents. Tot nu toe was de ervaring beperkt tot stricturen waarbij 
de afstand ten opzichte van de bifurcatie van de galwegen, de leverhilus, tenminste 2 
cm was. Deze grens werd gehanteerd vanwege het risico op afsluiten van contralate-
rale galwegen. Hoewel de meeste BBS inderdaad tenminste enkele centimeters onder 
de hilus zijn, strekt de strictuur zich in tot 14% van de gevallen uit tot in de hilus. De 
endoscopische behandeling van deze stricturen is traditioneel lastig omdat de prog-
nose vooral bepaald wordt door de agressiviteit van de behandeling; in dit geval het 
maximaal aantal stents dat door de strictuur ingebracht kan worden aan beide zijden en 
dit is technisch veel lastiger dan bij stricturen die zich niet in het hilusgebied bevinden.
Wij onderzochten in hoofdstuk 12 bij twee patiënten met benigne hilaire galweg-
stricturen of de combinatie van een fcSEMS en een beschermende contralaterale plastic 
stent technisch haalbaar was, veilig en mogelijk effectie. Hiertoe gebruikten wij een 
stent als beschreven in hoofdstuk 11, echter nu van 12 cm lengte.
De eerste patiënte betrof een 36-jarige vrouw die gezien werd met een hilaire stric-
tuur na een gecompliceerd verlopende cholecystectomie (lekkage en stricturen). Meer-
dere ERCP’s met stentplaatsing en ballondilatatie leidde niet tot adequate behandeling 
en patiënte bleef stent-afhankelijk. Wij plaatsten een 10 fr plastic stent in het minder 
aangedane rechter systeem en een 10 mm 12 cm fcSEMS in het linkergalwegsysteem. 
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Plaatsing en verwijdering na 5 maanden verliepen ongecompliceerd en op het cholan-
giogram was de hilaire strictuur verdwenen. Na meer dan 2 jaar follow-up zijn er geen 
aanwijzingen voor recidief strictuur.
De tweede patiënte was een 29-jarige vrouw die een anastomotische strictuur ont-
wikkelde van haar duct-to-duct anastomose 2 jaar na OLT. Zij werd hiervoor behandeld 
middels progressief plastic stenten met aanvankelijk goed resultaat. Drie maanden later 
was er echter sprake van een recidief strictuur, zich nu uitbreidend tot in de leverhilus. 
Zij werd vervolgens behandeld met een 10 fr 12 cm plastic stent in het linkersysteem 
en 12 cm 10 mm fcSEMS naar rechts. Na 4 maanden werden de stents verwijderd en bij 
cholangiografie was er geen strictuur meer zichtbaar. Ook na meer dan 12 maanden 
follow-up waren er geen aanwijzingen voor een recidief.
Hoewel deze 2 casus laten zien dat deze nieuwe behandeling van benigne hilaire 
galwegstricturen technisch haalbaar is, veilig lijkt en mogelijk effectief is, zijn er nog 
een aantal potentiële nadelen. Met name het plaatsen van een 10 mm stent in een 
intrahepatische galgang kan soms een te forse diameter zijn en mogelijk leiden tot 
secundaire stricturen. Wij zijn daarom een prospectieve multicenter registratie gestart 
waarbij patiënten met benigne hilaire galwegstricturen behandeld zullen worden met 
bilaterale 7 mm fcSEMS met proximale lasso.
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lIST OF abbREVIaTIONS (lOa)
AS Anastomotic Strictures
BBS Benigne Biliary Strictures
BRCA1/2 Breast Cancer gene 1/2
CA Carbohydrate Antigen
CDKN2A Cyclin Dependent Kinase inhibitor 2A
CEA Carcinoembryonic Antigen
CI Confidence Intervals
CP Chronic Pancreatitis
CPN Celiac Plexus Neurolysis
CRP C-Reactive Proteine
CT Computed Tomography
ERCP Endoscopic Retrograde Cholangio Pancreaticography
EUS Endoscopic Ultrasonography
EUS-FNA Endoscopic Ultrasonography Fine Needle Aspiration
ESWL Extracorporeal Shock Wave Lithotripsy
FAMMM Familial Atypical Multiple-Mole Melanoma
fcSEMS fully covered Self Expandable Metal Stents
FNA Fine Needle Aspiration
FNB Fine Needle Biopsy
FNI Fine Needle Injection
FPC Familial Pancreatic Cancer
GI Gastro Intestinal
HBOC Hereditary Breast and Ovarian Cancer
IPMN Intraductal Papillary Mucinous Neoplasia
IPMT Intraductal Papillary Mucinous Tumour
LCx Laparoscopic Cholecystectomy
LOA List of abbreviations
MCNs Mucinous Cystic Neoplasms
MDCT Helical Multidetector Computer Tomography
MRCP Magnetic Retrograde Cholangio Pancreaticography
MRI Magnetic Resonance Imaging
NOTES Natural Orifice Transluminal Endoscopic Surgery
NPV Negative Predictive Value
OLT Orthotopic Liver Transplantation
OR Odds Ratio
Pan-IN Pancreatic Intraepithelial Neoplasia
PBC Primary Biliary Cirrhosis
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PCs Pancreatic Cancer
pcSEMS partially covered Self Expandable Metal Stents
PET Positron Emission Tomography
PF Papillary Stenosis
PPPD Pylorus Preserving Pancreaticoduodenectomies
PPS Progressive Plastic Stenting
PPV Positive Predictive Value
PRSS1 Protease Serine 1 (trypsin 1)
PTT Partical Thromboplastin Time
Pt-INR Prothrombin time International Normalized Ratio
SEMS Self Expandable Metal Stents
SOC Standard of Care
SPSS Statistical Package for the Social Sciences
WOPN Walled Off Pancreatic Necrosis
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DaNKWOORD
De afgelopen jaren heb ik vele tientallen proefschriften mogen ontvangen waarvan ik 
toch op zijn minst de dankwoorden gelezen heb. Elk dankwoord is weer anders maar 
er zijn globaal twee categorieën: zij die kort, to-the-point en zakelijk blijven en de el-
lenlange uitgesponnen verhalen die er toe leiden dat zelfs het dankwoord slechts deels 
gelezen wordt. Het zal de lezer niet verbazen dat ik tot de laatste categorie behoor.
Zoals iedereen begin ook ik met mijn promotor: prof. Dr. M.J. Bruno. Beste Marco, 
hoewel ik je natuurlijk al kende, begon onze samenwerking in zekere zin tijdens de DDW 
in Washington DC in 2007 op het terras met een biertje. Je was druk in onderhandeling 
met mijn co-promotor om naar Rotterdam te komen maar, typerend voor jou, wilde je 
ook met mij praten voordat je toe wilde zeggen. Ik was, toen nog, het jongste staflid 
maar, net als jij, behept met grote interesse en belangstelling voor pancreaticobiliaire 
aandoeningen. Het gaat te ver om te zeggen dat je om mijn toestemming vroeg maar 
je wou wel zeker weten dat ook ik achter je aanstaande benoeming stond. Vanzelf-
sprekend was ik daar, ook toen, ontzettend blij mee en die blijdschap is alleen maar 
toegenomen. Ik heb heel veel van je geleerd als wetenschapper maar ook en vooral van 
jou als endoscopist en clinicus. In het theoretische geval dat we ook daadwerkelijk al-
lebei in Nederland zijn, spreken we elkaar vrijwel dagelijks en ik verheug me op nog vele 
jaren samenwerking om de zorg voor de complexe patiënten die wij zien nog verder 
te optimaliseren, de endoscopieafdeling te verbeteren, nieuwe behandelmethodes te 
onderzoeken en in te voeren en vooral bij elkaar binnen te lopen op de ERCP of de EUS 
kamer om elkaar te helpen, adviseren of om gewoon even te kijken wat de ander nu 
weer aan het uitspoken is.
Dan mijn co-promotor, prof. Dr. E.J. Kuipers. Beste Ernst, alweer ruim 10 jaar geleden 
heb je mij, ondanks (of misschien wel dankzij) de kortste sollicitatiebrief in de geschie-
denis, aangenomen voor de opleiding tot MDL-arts. Hoewel ik er toen nog rotsvast 
van overtuigd was dat ik zo snel als mogelijk aan het eind van mijn opleiding terug 
zou keren naar de periferie, is het anders gelopen. Dat is voor een heel belangrijk deel 
jouw verdienste. Hoewel je het drukker en drukker kreeg met het uitbouwen van de 
kleinste MDL-afdeling van het land tot de grootste, was er altijd tijd voor een gesprek 
of gesprekje en heb je mij, aan het eind van mijn opleiding en aan het begin als staflid, 
altijd ondersteund met het ontwikkelen van de technieken en procedures zoals die voor 
een deel in dit proefschrift beschreven zijn. Dat dit niet altijd van een leien dakje en 
zonder complicaties ging, moge duidelijk zijn en die bijna onvoorwaardelijke steun is 
heel belangrijk voor mij geweest. Hoewel ik de afgelopen jaren vaak tegen je gezegd 
hebt dat jij toch echt wel de verschrikkelijkste baan moest hebben die er bestond (en ik 
de leukste), is er niemand die het beter kan dan jij en ongetwijfeld ga je het fantastisch 
doen als voorzitter van de Raad van Bestuur.
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Ook wil ik graag de leescommissie bedanken: prof. Dr. C.H.J. van Eijck, prof. Dr. H.J. 
Metselaar en prof. Dr. H.J. de Koning. Beste Casper, mede dankzij jou heb ik mijn eerste 
schreden kunnen zetten op het pad van de endoscopische behandeling en diagnostiek 
van patiënten met chronische en acute pancreatitis en pancreascarcinoom. Ik heb veel 
geleerd van jou als chirurg maar vooral ook als clinicus en ik hoop nog jaren met je te 
kunnen blijven samenwerken (met af en toe een wedstrijdje in de Kuip als extra bonus). 
Ik ben er trots op dat je in mijn commissie plaats hebt willen nemen. Beste Herold, als 
hepatoloog met een gezonde weerzin tegen alle vormen van flexibele zwarte slangen, 
maar met een groot hart voor levertransplantie en leverfalen en daarnaast een aan-
genaam gevoel voor humor, is het soms vast zwaar voor je om samen te werken met 
mensen die denken dat je alles op kan lossen met die slangen. Ik ben blij en vereerd dat 
je in mijn commissie plaats hebt willen nemen. Beste Harry, ik ben blij dat jij, als expert 
op het gebied van screening, in mijn commissie plaats hebt willen nemen.
Ook de overige leden van mijn promotiecommissie wil ik hartelijk danken. Prof. Dr. L. 
Aabakken, dear Lars, what a pleasure it is to have you as a guest and in my PhD commit-
tee. I deeply admire you as an endoscopist but even more so as my friend. It is amazing 
how you are able to find the time and work as an ambassador of endoscopy all over the 
world and are able to handle most, if not all, highly complex cases in Norway. Although 
we run into each other all over the world, completely unexpected at a temple in Kyoto 
for example, the yearly course in Oslo is one of my favourite trips and I sincerely hope 
that I have the chance to visit you and your unit many more times in the future. Jeg synes 
det er veldig fint at du kan være der, og er stolt over at du er min venn.
Prof. Dr. S. Veldhuizen van Zanten, beste Sander, ik ben zeer vereerd dat je in mijn 
commissie plaats hebt willen nemen all the way from Edmonton, Canada.
Dr. H.M. van Dullemen, beste Hendrik, ook jou ben ik zeer erkentelijk dat je uit het, 
iets mindere verre, noorden hebt willen komen om in mijn commissie plaats te nemen. 
Jij als zeer ervaren endoechografist en endoscopist hebt mij al veel geleerd tijdens de 
jaren dat we samen de basiscursus EUS in Rotterdam gegeven hebben.
Dr. K. Biermann, beste Katharina, ik ben heel blij dat ook jij in mijn promotiecommis-
sie zit. Daarnaast ben ik ook heel blij dat jij als ervaren, enthousiaste en gezellige collega 
zo nauw betrokken bent bij het onderzoek naar het verbeteren van de kwaliteit van het 
materiaal dat wij als endoscopisten via EUS kunnen verkrijgen.
Daarnaast wil ik al mijn andere mede-auteurs, voor zover nog niet eerder vermeld, 
bedanken voor al het werk dat zij in de in dit proefschrift verschenen publicaties hebben 
gestoken. Irma Kluijt, Dirk Gouma, Femme Harinck (succes met de laatste loodjes), Anja 
Wagner, Cora Aalfs, Annemieke Cats, Yung Nio en Paul Fockens (jammer dat je er niet bij 
kan zijn) voor het werk op het gebied van screening op pancreascarcinoom. Daarnaast 
Koen de Jong en Jeanin van Hooft voor het onderzoek naar de waarde van EUS – FNA 
van pancreascysten. Eva Deerenberg, John Hermans, Sham Ganesh en Erwin van der 
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Harst voor de studie naar CT negatieve patiënten. My fellow members of the EUS core 
group Julio Iglesias, Alberto Larghi, Marc Giovannini, Mara Petrone, Ihab Abdulkader, 
Genevieve Monges, Guido Costamagna, Paolo Arcidiacono, Guido Rindi, Erwan Bories, 
Claudio Dogloni and Enrique Dominguez. All good friends and a fantastic group of 
people to do research together.
Djuna Cahen, lieve Djuna, kijk toch ’s wat je allemaal al weet te bereiken met 1 dagje 
in de week in Rotterdam! Kom toch gewoon gezellig bij ons werken! (en anders verkoop 
je toch de boot!). Marius Lekkerkerker, beste Marius, heel veel dank voor al het werk 
dat je verricht hebt in de studies over progressief plastic stenten bij lever trans plan tatie-
patiënten.
Henk van Buuren, Geert Kazemier (wanneer kom je nou terug?) en Jelle Haringsma 
voor de samenwerking bij de studie naar het gebruik van volledig gecoverde metalen 
stents bij benigne galwegstricturen. En last, but not least, Antonie van Tilburg. Ook jij 
hartelijk dank voor de buitengewoon prettige samenwerking en dan bedoel ik niet al-
leen bij de patiënten met benigne hilaire galwegstricturen.
Geen endoscopie afdeling en geen endoscopie onderzoek zonder endoscopie ver-
pleegkundigen. Complexe endoscopische verrichtingen doe je niet alleen maar in een 
team en de meiden (en 1 jongen) van de endoscopie afdeling zijn niet alleen onmisbaar 
maar ook essentieel voor het slagen van welke procedure dan ook, maar zeker voor 
de verrichtingen zoals beschreven in dit onderzoek. Voor Sandra en haar team is geen 
moeite teveel, er kan altijd nog wel wat bij en er mag altijd iets nieuws uitgeprobeerd 
worden. Wij als endoscopisten mogen ons gelukkig prijzen met een dergelijk enthousi-
ast en bevlogen team.
Lieve Andrea, Bernadette, Carla en ook Monica (als een soort privé secretaresse op 
afstand), ontzettend bedankt voor al jullie hulp. Niet alleen bij de totstandkoming van 
dit proefschrift maar vooral ook voor al jullie steun en gezelligheid daarbuiten (al weet ik 
zeker dat de proefschrift productie van de afdeling MDL gehalveerd zou worden zonder 
Bernadette).
Ook dank aan alle arts-assistenten van nu, maar ook in de afgelopen jaren. Hoewel 
ik weet dat mijn ERCP programma’s niet de populairste zijn onder de arts-assistenten, is 
jullie hulp tijdens de procedures maar zeker ook daarbuiten onmisbaar.
Dank aan Eric Wesdorp, Annekatrien Depla en Juup van Meyel voor hun geduld, hulp 
en begeleiding tijdens mijn eerste wankele schreden op het endoscopie pad. Zonder 
jullie was ik vast en zeker iets heel anders gaan doen; en dat was vast en zeker niet zo 
leuk geweest!
Veel dank ook aan mijn overige collega stafleden Joep Bartelsman, Henri Braat, Paul 
Didden, Bettina Hansen, Rob de Knegt, Arjun Koch, Wilco Lesterhuis, Rob de Man, Maikel 
Peppelenbosch, Manon Spaander, Dave Sprengers, Pavel Taimr, Eric Tjwa, Thomas van 
Wolleghem en Janneke van der Woude. Mede dankzij de bereidheid om voor elkaar in 
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te vallen, over te nemen en op te vangen, kunnen we als groep mooie en nog mooiere 
dingen doen.
Mijn erkentelijkheid en dank gaat ook uit naar alle patiënten die hebben meegedaan 
aan de onderzoeken en behandelingen in dit proefschrift. De ziektes die ervoor zorgen 
dat zij hiervoor in aanmerking komen, zijn zonder uitzondering belastend, levensbe-
dreigend en vaak pijnlijk. Ik heb ontzettend veel respect voor de vaak optimistische en 
dappere manier waarop zij hiermee omgegaan .
Christopher Teshima, dear Chris, although you were with us for only one year, it was 
and is amazing to see what you have achieved during this year culminating in defending 
your PhD thesis on the same day as myself. You are a talented and gifted endoscopist but 
more importantly a great guy and I’m proud to call you my friend. It is such a pleasure 
to celebrate this together and reminisce our time together in the Erasmus MC. Not only 
were you able to learn EUS and enteroscopy but somehow you also managed to see 
Europe almost in its entirety, keep the relationship with your future wife afloat, have lots 
of fun and bring 40 ties in one suitcase to Rotterdam.
Dan mijn paranimfen, onmisbaar voor de totstandkoming van het proefschrift maar 
vooral voor het feest. Simon Brouwers, ik ben ontzettend blij dat je mijn paranimf wil 
zijn. Van sales rep (onder andere) tot senior product manager met het grootste netwerk 
binnen de endoscopie dat ik ken. Letterlijk iedereen kent jou en iedereen vindt jou een 
aardige kerel. Het is bijzonder hoe we vrienden zijn geworden maar niet dát we vrienden 
zijn geworden. Ik verheug me er altijd op om met jou onderweg te zijn en te kletsen over 
werk maar vooral ook over de echt belangrijke dingen in het leven. Godfried Metz, mijn 
beste en langste (qua tijd dan) vriend. Ik zeg altijd, half voor de grap, dat je mij beter 
kent dan dat ik mijzelf ken. Het is toch een klein wondertje dat we vanaf de middelbare 
school altijd, min of meer door toeval gedreven, bij elkaar in de buurt zijn gebleven 
en de mogelijkheid hebben om op een terras in de buurt van de Witte de With onze 
beslommeringen met elkaar kunnen bespreken. Hopelijk de komende tijd weer wat 
vaker en langer dan de afgelopen maanden.
Lieve Wolanda, dit proefschrift was er niet geweest zonder jou. Je bent met me mee-
gegaan van Amsterdam naar Rotterdam en hoewel het daarna niet gegaan is zoals we 
gehoopt en gedacht hadden, ben ik heel erg blij met de manier waarop we met elkaar 
omgaan en minstens net zo blij dat jij de moeder bent van Emma, Wick en Raf.
Lieve Willeke en lieve Jack, ook al kan mama dit niet meer meemaken, ik ben wel heel 
blij dat wij dit samen kunnen delen. Ik ben ontzettend trots op jullie. Trots op de manier 
hoe jullie samen in het leven staan en er in makkelijke, maar vooral ook in moeilijke 
tijden, samen zijn voor elkaar.
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Dear Sanne and Nick, even though we get together infrequently for obvious reasons, 
I am very happy to have become part of your family as well. We are really looking forward 
to coming over to Perth next year and teach the boys the first principles of surfing.
Lieve John en Hanna, lieve opa en oma, lieve extra opa en oma. Natuurlijk ben ik heel 
blij met jullie dochter maar het is vooral ook zo mooi om te zien hoe jullie genieten van 
het leven, van elkaar en van Joost en Oscar. Zij hadden zich geen betere opa en oma 
kunnen wensen en ik geen betere schoonouders.
Lieve Emma, Wick, Raf en Joost, jullie weten bijna niet beter dan dat papa weg is, 
weg gaat (voor een spreekbeurt) of net terug is en zelfs op vakantie nog gebeld wordt 
door “het ziekenhuis”. En dan ook nog eens iets doet wat toch echt wel ontzettend 
vies is. Daarom is dit een mooie gelegenheid om niet alleen te zeggen maar ook eens 
te schrijven dat ik jullie alle vier even liefheb en ontzettend trots ben op jullie. Het is 
geweldig om jullie groot te zien worden, om te zien hoe jullie op elkaar lijken maar ook 
van elkaar verschillen. Samen koken, samen klap ’s in je handjes zingen of samen naar 
een film kijken. Soms slaande ruzie maar toch altijd in de eerste en laatste plaats broers 
en zus en er voor elkaar zijn. Ik hou van jullie.
Lieve Lotte, wie had dat gedacht alweer ruim 4 jaar geleden? Ik ben zo ontzettend blij 
dat je toch min of meer bij toeval mijn leven en mijn armen in bent gestruikeld. Eigenlijk 
is alles daarna heel natuurlijk en vanzelf gegaan en zijn we nu ontzettend gelukkig met 
z’n drieën (of met z’n zessen). Ik vind het zo knap om te zien hoe je om weet te gaan met 
een overvol en soms veel te druk leven dat geregeerd lijkt te worden door agenda’s en 
schema’s maar tegelijkertijd ook je eigen carrière hebt en ontzettend goed en bevlogen 
bent in wat je doet.
Je bent er voor mij maar ook voor Emma, Wick en Raf (ook al eten ze niet meer zo 
vaak bij de McD) en natuurlijk ook voor Joost. Het is altijd fijn om bij jou te zijn en samen 
thuis te komen of samen op reis te gaan. Ik hoop dat we dat de komende jaren en de rest 
van ons leven steeds meer kunnen gaan doen en blijven genieten van ons leven samen.
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CURRICUlUm VITaE
Na zijn geboorte op 31 januari 1968 in Hamburg en omzwervingen via Rotterdam 
en Hoogezand groeide Jan-Werner Poley op in Delfzijl. In 1987 deed hij eindexamen 
atheneum op het Fivelcollege aldaar. Na een jaartje rechten te hebben gestudeerd, 
begon hij in 1988 met de studie geneeskunde aan de Rijksuniversiteit Groningen. Na 
het afronden van zijn doctoraal in 1994 verhuisde hij naar Amsterdam om daar, na 
een wetenschappelijke stage op de afdeling kinderendocrinologie van het AMC, zijn 
co-schappen te lopen aan de Vrije Universiteit. In 1997 behaalde hij het artsexamen 
(cum laude) en begon als arts – assistent niet in opleiding in het toenmalige Sint Lucas 
ziekenhuis (nu Sint Lucas Andreas ziekenhuis) te Amsterdam. In 1999 begon hij, ook in 
het Sint Lucas Andreasziekenhuis, aan de opleiding Interne Geneeskunde (opleider dr. 
J.J.M. van Meyel) in de vaste overtuiging uiteindelijk internist – intensivist te worden. 
Tijdens zijn gastroenterologie stage en na de eerste schreden op het endoscopiepad 
gezet te hebben, besloot hij een carrière in de Maag-, Darm- en Leverziekten na te stre-
ven. Als zij – instromer begon hij in 2002 met de vervolgopleiding tot maag-, darm- en 
leverarts in het Erasmus MC (opleiders prof. dr. E.J. Kuipers en dr. R.A. de Man) die hij op 1 
januari 2005 afrondde. Sindsdien is hij werkzaam als MDL-arts in het Erasmus MC met als 
aandachtsgebied pancreaticobiliaire aandoeningen en interventie – endoscopie. Sinds 
1 december 2012 is hij hoofd en medisch coördinator van de MDL – endoscopie in het 
Erasmus MC.
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